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Acquired drug resistance is a multifactorial process that is one of the major 
causes for cancer treatment failure.  The anticancer drug, mitoxantrone, was recently 
determined to inhibit ribosome biogenesis.  Changes in ribosomal protein 
composition and efficiency with which the ribosomes incorporate 
35
S-methionine has 
been noted in a mitoxantrone resistant MCF7 cell line when compared with a drug-
susceptible parental cell line.  This dissertation evaluated three proteomic workflows 
in order to successfully characterize the changes in the primary structures of 
cytoplasmic ribosomal proteins isolated from a mitoxantrone resistant breast cancer 
cell line that could serve some functional significance to the resistance when 
compared with a parental drug-susceptible cell line. 
A combination of the data from the three workflows allowed for the 
identification of 76 of the 79 human ribosomal proteins with an average sequence 
coverage of 76%.  The N-terminal ends of 52 of the ribosomal proteins were 
  
identified using bottom-up and middle-down mass spectrometric approaches.  An 
additional 7 N-terminal fragments were identified by top-down high resolution mass 
spectrometric analysis.  Forty of the 52 N-terminal peptides were observed to have 
lost their N-terminal methionine and 19 were acetylated.  Identification of the N-
terminal peptides was most successful using the middle-down approach. Internal 
acetylations (on lysine) and phosphorylations were only noted with trypsin in-gel 
digestion and HPLC fraction analysis.   
Gel arrays of the two ribosomal populations illustrated differences in the 
protein compositions.  Comparative densitometry imaging software indicated the 
presence of two novel protein spots in the drug resistant cell line as well six 
additional spots with increased and decreased abundances.  High coverage bottom-up 
mass spectrometric analysis allowed for these protein spots to be assigned as isoform 
pairs of RPS3, RPS10, RPL11 and RPL23A.  Molecular masses and top-down 
analyses were used to define the alterations in the ribosomal proteins in conjunction 
with high coverage bottom up and middle-down analyses.  The change in the primary 
structures of these four ribosomal proteins is believed to alter access to the mRNA 
tunnel in the ribosome.  This suggests that these ribosomes may participate in 
differential selective translation to allow for the cell to produce the necessary proteins 
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Chapter 1: Background & Introduction 
Structure and function of the ribosome 
Understanding the ability of a single cell, whether prokaryotic or eukaryotic, 
to manufacture all the proteins necessary to sustain the life of that cell has been the 
focus of intense scrutiny in the life sciences for decades.  Collaborative efforts from 
researchers around the world have determined that an organelle referred to as the 
ribosome is central to the execution of this task in the cell.  In 2009, Venkatraman 
Ramakrishnan, Thomas A. Steitz and Ada E. Yonath were awarded the Nobel Prize in 




 The ribosome is a large ribonucleoprotein complex that catalyzes the 
peptidyltransferase reaction in polypeptide synthesis.  It is often referred to as a 
“molecular machine” which plays a fundamental role in the generation of the cellular 
proteome 
4
.  The human ribosome is composed of one molecule each of 79 different 
proteins and four different ribosomal RNAs (rRNA).  Coordinated expression of the 
ribosomal protein genes is necessary to ensure equimolar accumulation of ribosomal 
proteins 
5
.   Deficiencies in any of the ribosomal protein mRNAs or ribosomal rRNAs 
have been associated with cellular abnormalities in human cell lines
6
.  In fact, 
investigations using live cell imaging and quantitative mass spectrometry have shown 
that healthy eukaryotic cells import more ribosomal proteins into the nucleus than 
export ribosomal subunits, suggesting that an excess of ribosomal proteins are 




with human cervical cancer cells where the transcription of rRNA was prevented, 
ribosomal protein synthesis did not immediately end however the ribosomal proteins 




Although the active site of the ribosome is comprised of rRNA, classifying 
this organelle as a “ribozyme”, ribosomal proteins play a crucial function in providing 
the structure for the rRNA 
9
.  In addition, multiple ribosomal proteins have been 
implicated in playing a regulatory role in cell differentiation and apoptosis.  For 
example, ribosomal protein RPS5 has been shown to play a role in cell cycle arrest 
10
.  
Certain ribosomal proteins, like Escherichia coli ribosomal protein RPL4, have also 
been shown to function as repressors of their own transcription 
11
.   
Ribosomes are critical for the survival of the cell since they are responsible 
for the translation of transcripts encoded in the cellular genome.  The ribosome is 
comprised of two subunits referred to as the large and the small subunit.  However, 
the composition and size of these subunits differ between bacteria, animals, fungi and 
plants.  Both of these subunits have rRNA and protein components.  The intact and 
subunit components have been characterized by their sedimentation coefficients.  In 
the case of the eukaryotic ribosome, the intact cytosolic ribosome sediments at 80S 
while its large and small subunit sediment at 60S and 40S respectively.  The 
prokaryotic ribosome is referred to as the 70S ribosome and its respective large and 
small subunits the 50S and 30S subunits 
4
.  The larger sedimentation coefficient of 
the eukaryotic ribosome is due to its mass of ~4MDa compared with the 2.3MDa 
mass of the prokaryotic Escherichia coli ribosome
12; 13




eukaryotic ribosome is the result of it containing a larger number of proteins 
(approximately 2 dozen more), an additional rRNA molecule, and longer rRNA 
chains known as expansion segments 
14
.  Cell growth is closely coupled to ribosome 
accessibility since ribosomes are responsible for the production of all the proteins in 
the cell, and thus ribosomes are very abundant in multiplying cells.  In a typical 
human cell there are on average 4 x 10
6
 ribosomes with approximately 5 to 10% of 
cellular protein and roughly 80% of all cellular RNA being ribosomal 
15
.  It is 




The structural differences between the ribosomes of different animal 
kingdoms relates back to differences in their protein and RNA molecular 
composition.  On average, there are a total of 79 ribosomal proteins of the eukaryotic 
ribosome (79 in the human; not counting sex linked RPS4 individually) in 
comparison with the 57 proteins of the prokaryotic ribosome and 68 proteins of the 
archaeal ribosome.  The large subunit of the eukaryotic human ribosome contains 47 
proteins versus 40 for archaea and 34 for prokaryotes.  The small subunit of human 
ribosomes possess 32 proteins compared to the 28 seen in archaea and 23 seen in 
prokaryotes 
17
.  Despite the discrepancy in the number of proteins each of these 
evolutionary domain possess, many of the ribosomal proteins are homologous 
between species.  Orthologous counterparts exist between roughly 30% of 
prokaryotic ribosomal proteins and the proteins of eukaryotes and archaeal 
ribosomes.  An additional 30% of the ribosomal proteins of archaea have shared 






As previously mentioned, the rRNA components of the ribosomes of the three 
evolutionary domains also differ.  The large subunit in prokaryotes is composed of 
two rRNA molecules, the 23S and the 5S, while the large subunit in eukaryotes 
consists of three rRNA molecules, 25S (yeast)/28S (humans), 5.8S and 5S
12; 19; 20
.  
The additional eukaryotic rRNA of the large subunit, 5.8S, is similar in sequence to 
the 5’ end of the prokaryotic 23S rRNA and contains about 160  nucleotides 
21
.  The 
28S rRNA is about 2300 nucleotides longer in humans than the 23S of prokaryotes 
(E. coli) 
20
.  The small subunit in all species contains only one rRNA molecule 
however in eukaryotes it sediments at 18S versus 16S in prokaryotes (~1550 
nucleotides) due to an additional 300+ nucleotides for a total of ~1900 nucleotides 
12; 
20
.  The eukaryotic ribosome with its additional proteins and rRNA molecules is 
considerably larger than its prokaryotic counterpart. 
Ribosomal proteins were originally named (and numbered) by their respective 
position on a two dimensional polyacrylamide gel starting from the number one at the 
top of the gel and counting down to the bottom.  As a result, a small basic protein will 
be assigned a large number while a large acidic protein is appointed a small number 
18
.  Given the differences among the ribosome of various species, the respective 
nomenclature assigned to a ribosomal protein from one organism does not always 
correspond with the protein of the same number in another organism.  The average 
human ribosomal protein is relatively small containing 164 amino acid residues 
(range from 25 to 421) and having a molecular weight around 18.5 kDa (range from 
3.5 kDa for RPL41 to 47.7 kDa for RPL4) 
22




Human ribosomal proteins (and ribosomal proteins in general) are very basic.  
Rat ribosomal proteins which are similar in sequence to humans were determined by 
Wool and colleagues to have an average isoelectric point (pI) of 11.05 with a pI range 
from 4.07 for RPLP1 to 13.46 for RPL41 (12.96 theoretical pI for human RPL41).  
The basic amino acids that contribute to this pI are often found in clusters of 3 or 4 
consecutive residues.  Additionally, a very small number of ribosomal proteins have 
clusters of acidic amino acid residues often at or near the carboxyl terminus.  Repeats 
of 3 to 8 residue sequences is a common structural feature of ribosomal proteins 
although the reasons for these repeats are not well understood 
22
.  Zinc finger motifs 
coordinated with zinc have been found in numerous ribosomal proteins in many 
species including eukaryotes and archaea suggesting that they may contribute in the 
interaction between the rRNA and the proteins 
22; 23; 24
.  A leucine zipper-like motif 
has also been found in several ribosomal proteins, presumably to mediate nucleic acid 
binding
22; 25; 26
.  These protein structural motifs most likely help ribosomal proteins to 
play their role in ribosome biogenesis (docking them in the correct position on the 
forming ribosome).   
Human ribosomal proteins additionally contain nuclear localization signals to 
facilitate their entry into the nucleolus where they associate with pre-rRNA during 
ribosome biogenesis 
22
.  It is in the nucleolus where RNA polymerase I (Pol I) 
generates the primary precursors of 5.8S, 18S and 25S/28S rRNA.  It is believed that 
these pre-rRNA precursors along with a large subset of the ribosomal proteins, non-
ribosomal proteins and small nucleolar ribonucleoprotein particles (snoRNPs) amass 




undergo extensive modifications carried out by the snoRNPs, the majority of which 
are 2’ O methylations and pseudouridylation.  These rRNA modifications 
cumulatively have been shown to optimize the rRNA structure to generate ribosomes 
that undergo translation with improved accuracy and efficiency
19; 27; 28
.  The 90S 
particles undergo nucleolytic cleavages to produce the pre-40S and pre-60S particles 
which are processed separately prior to export from the nucleoplasm into the 





The ribosomal subunits are found independent of one another in the cell 
except during active translation of an mRNA transcript.  The ribosome contains three 
specialized binding sites which are involved in the translation process; the A site 
which binds the aminoacyl-tRNAs, the P site that binds peptidyl-tRNA and the E site 
which binds the deacylated tRNA before it exits the ribosome.  The process of 
translation is commonly described as occurring in three phases; initiation, elongation, 
and termination 
13
.  An increased level of complexity, with the requirement for 
additional protein cofactors, distinguishes eukaryotic translation from the simpler 
archaeal and prokaryotic processes 
29
. 
Translation initiation in eukaryotes requires the involvement of more than 25 
polypeptides.  As part of the initiation process, a ternary complex must be formed 
consisting of a GTP-coupled eukaryotic initiation factor 2 (eIF2) and the methionine-
loaded initiator tRNA which is responsible for the recognition of the AUG codon on 
the mRNA 
30




assembly which also includes the 40S subunit and eIF3, eIF1, eIF1A and eIF5.  
Binding of this assembly to the mRNA requires the formation of a scaffold which 
first involves the ATP dependent unwinding of structures in the 5’-untranslated 
region (UTR) by the eIF4F complex which has assembled on the 5’ 7-
methylguanosine cap of the mRNA.  A poly(A) binding protein bound to the 3’-
poly(A) tail of the mRNA then interacts with components of the eIF4F complex in 
conjunction with eIF3 to load the mRNA onto the 43S complex.  Bound to the 5’ end 
of the mRNA, the 43S pre-initiation complex first scans the mRNA in a 5’  3’ 
direction until the AUG initiation codon is found.  eIF1 is required for the selection of 
the correct initiation codon 
29; 31
.   
When this AUG codon is encountered, embedded in the Kozak sequence or a 
variant thereof, codon-anticodon base pairing takes place between the initiator tRNA 
in the ternary complex and the initiation codon, forming the 48S complex.  This event 
prompts the hydrolysis of GTP by eIF2 with the assistance of the GTPase-activating 
protein (GAP) eIF5, which allows for the deposit of the Met-tRNA into the P-site of 
the 40S subunit and dissociation of eIF2*GDP, eIF1, eIF1A, eIF3 and eIF5 from the 
complex.  The last step in eukaryotic translation initiation requires the recruitment of 
the 60S subunit to the 40S pre-initiation complex.  eIF5B*GTP, another GTPase in 
the initiation pathway, is required for coupling of the 60S subunit with the 40S*Met-
tRNA*mRNA complex.  Although GTP hydrolysis by eIF5B is not required for the 
subunit coupling, it is necessary for ribosomal peptide bond catalysis to occur.  






Peptide chain elongation has been highly conserved across the three 
evolutionary kingdoms with each set of protein cofactors in eukaryotes having 
analogous sets in prokaryotes and archaea.  Elongation begins with the delivery of the 
cognate aminoacyl tRNA to the vacant A site by the ternary complex 
eEF1A*GTP*aa-tRNA where conformational changes within the decoding center of 
the small ribosomal subunit and GTP hydrolysis help to ensure only the cognate aa-
tRNA is selected 
32
.  The formation of the peptide bond between the incoming amino 
acid on the cognate aa-tRNA and the methionine on the peptidyl-tRNA is then 
catalyzed via a transfer reaction by the ribosomal peptidyl transferase center (PTC). 
This involves a nucleophilic attack of the carboxyl group of the methionine by the 
amino group of the amino acid bound to the aa-tRNA.  The forming polypeptide 
chain is placed on the tRNA that was in the A site and as a result of this reaction this 
tRNA assumes a hybrid state where the acceptor end is now in the P site of the large 
subunit while the anticodon end remains in the A site of the small subunit. The 
deacylated tRNA which carried the methionine is also in a hybrid state with its 
acceptor end in the E site of the large subunit while the anticodon end remains in the 
P site of the small subunit.  eEF2*GTP allows for the complete translocation of these 
tRNAs to open up the A site for another aa-tRNA and to move the mRNA three 
nucleotides to place the next codon into the A site.  GTP is hydrolyzed by eEF2 
during the translocation process.  This elongation cycle repeats until a stop codon in 
the mRNA moves into the A site which initiates termination 
31
.  Recent studies with 
bacteria, yeast, and rabbit liver-derived ribosomes have illustrated that in addition to 




between the A site and E site where the affinity for the one site is decreased by the 
occupation of the other 
33
. 
Termination is also catalyzed by the PTC but in this case since the stop codon 
(UAA, UAG, or UGA) does not have a cognate aa-tRNA, a release factor referred to 
as eRF1 is recruited to the ribosome.  eRF1 promotes the nucleophilic attack by water 
of the carboxyl group on the polypeptide linked to the peptidyl-tRNA leading to the 
release of the polypeptide chain.  eRF3 is another eukaryotic release factor believed 
to aide in the ejection of eRF1 from the ribosome after the hydrolysis reaction 
31
.  The 
recycling of the ribosomal subunits for another round of translation is promoted by a 





 The chemotherapeutic agent referred to as mitoxantrone is an anthracenedione 
shown in Figure 1.1.  Its intended mechanism of action is to intercalate DNA which 
has been found to lead to the inhibition of topoisomerase II and DNA strand breaks
35
.  
Additional effects of mitoxantrone have been determined.  Mitoxantrone along with 
many other chemotherapeutic drugs has been discovered to inhibit ribosome 
biogenesis by interfering in the transcription of 47S rRNA at concentrations below 
clinical relevance
36
.  Mitoxantrone and related quinones have also been discovered to 
undergo metabolism by cytochromes-P450 to form oxidized products
37
.  The 
formation of these metabolites also produces reactive oxygen species (ROS) that 
contribute to the cytotoxicity of the drug.  The oxidized metabolites of mitoxantrone 




strong interaction with glutathione to form thioether conjugates
37
.  Two other known 
interactions/actions of mitoxantrone have recently been reported.  Mitoxantrone binds 
to nucleolar and coiled body phosphoprotein 1 (NOLC1) also known as Nopp140.  
Phosphorylated Nopp140 interacts with casein kinase 2 (CK2) to inhibit the catalytic 
activity of CK2.  Mitoxantrone enhances the interaction between these two proteins.  
CK2 is known to play a role in the regulation of rDNA transcription and apoptosis 
and the inhibition of its activity is thought to suppress cancer cell survival.  A final 
interaction that mitoxantrone is known to have is with two specific vault RNAs 
(vRNAs)
38
.  A recent study of three human cell lines resistant to mitoxantrone has 
found that vRNAs were overexpressed in all three cell lines.  In addition, the 
interaction between mitoxantrone and the vRNAs was found to assist in the 
detoxification of the cell as the vRNAs allow for the export of toxic compounds from 
the cell.  When the vRNAs were suppressed with RNA interference, the resistance 
progressively decreased
39
.      
 




Drug Resistance and Ribosomal Proteins 
Although the active role of translation is catalyzed by rRNA, ribosomal 
proteins have been shown to play an integral role in the transfer of information during 
the translation process.  In particular, RPL2 (RPL8 in higher eukaryotes) and RPL3 
have been demonstrated through mutant screenings in Escherichia coli to play critical 
roles in ribosomal function
40; 41
.  Point mutations in either RPL2 or RPL3 in 
Saccharomyces cerevisiae have been shown to convey resistance to anisomycin, an 
A-site specific translational inhibitor
40; 41
.     
Changes in other ribosomal proteins have also been connected with drug 
resistance.  Ribosomal protein RPL41 has been shown to convey resistance to 
cyclohexamide, which inhibits peptidyl elongation in various strains of yeast when 
Proline 56 is converted to Glutamine
42
.  Point mutations discovered in RPS12, RPS5, 
and RPL22 have been shown to convey resistance in E. coli to streptomycin, 
spectinomycin and erythromycin respectively
43
.  Changes of amino acids at position 
37, 42, or 90 in ribosomal protein RPS12 in Thermus thermophilus led to various 
drug resistant or drug dependent phenotypes
44
.  Carr et al. investigated further the 
link between streptomycin resistance and a β-methylthiolation modification found in 
this resistant bacterium at D88.  Although they found the resistant phenotype in 
RPS12 could be retained in the absence of the β-methylthio-aspartic acid, it appeared 
to be under the condition that the modified residue at position 90 be a bulky residue
44; 
45
.    
Multiple ribosomal proteins have been shown to have extra-ribosomal 




biogenesis or after being incorporated into the ribosomal machine.  Some studies 
have even shown ribosomal proteins leaving the ribosome to perform these 
functions
25; 46
.   Drug resistance, particularly multi-drug resistance (MDR), in humans 
has recently been shown to be associated with the interactions these ribosomal 
proteins have with non-ribosomal proteins/factors.  A recent study of MDR in gastric 
cancer cells showed that over expression of RPS13 and RPL23 were associated with 
resistance to the anti-cancer drugs vincristine, adriamycin, 5-fluorouracil and in the 
case of RPL23 also resistance to cisplatin.  This MDR was linked to suppression of 
drug-induced apoptosis and in the case of overexpression of RPL23, through the 
control of the glutathione-S-transferase-mediated drug-detoxifying system 
47
.  Drug 





Proteomics and the use of mass spectrometry 
The use of proteomic strategies is the most practical approach to examine and 
compare a large set of proteins such as those from the ribosome complex.  The term 
“proteome” was first used in print in 1995 by Wasinger et al. 
49
.  Proteome refers to the 
protein complement expressed by a given tissue type or genome under known environmental 
conditions or in a disease state 
50
.  The field of proteomics was defined by N. Leigh 
Anderson and Norman G. Anderson as “the use of quantitative protein-level measurements of 
gene expression to characterize biological processes (e.g., disease processes and drug 
effects) and decipher the mechanisms of gene expression control” 
51
.  According to Chhabil 




proteomics, which investigates the identity of a group of proteins involved in a specific 
function, (2) characterization proteomics, which evaluates the proteins present in a tissue, 
cell or biofluid, and (3) differential proteomics, which distinguishes proteins that are 




The human genome is reported to consist of approximately 20,000 genes, 
however due to alternative splicing, one of the most conservative estimates of the 
number of human proteins is around 35,000 according to the UniProtKB/Swiss-Prot 
database
53
 .  The complexity of this set of proteins and the dynamic range of the 
concentrations in which these proteins exist poses major technical challenges in 
proteomics.  This is further complicated by new research which suggests that the 
amino acid sequence of many human proteins do not match their underlying DNA 
sequence
54
.  There are four basic stages incorporated into proteomic analysis to help 
overcome these seemingly insurmountable obstacles
52
.    
The first step for overcoming the large dynamic range of a sample, for 
example a human cell sample, is in the sample preparation.  Subcellular fractionation 
as a part of sample preparation can drastically reduce sample complexity and allow 
for deeper proteome coverage.  Sample preparation may also include depletion of 
highly abundant proteins to enrich low abundance proteins 
52
.  This strategy is often 
utilized in the analysis of blood serum by the depletion of albumin 
55
.   In the case of 
the ribosome, proteins are kept in approximately equimolar concentration, thus the 






The second step involves the separation and purification of proteins from the 
subcellular fraction(s) into individual proteins 
52
.  In the current study, the use of 
liquid chromatography and gel electrophoresis were essential for this purpose 
allowing for the enrichment of each protein in a respective fraction or gel spot.  
The third stage of a proteomic workflow involves the end point analysis of the 
sample, which in most proteomic studies utilizes mass spectrometry, i.e. analysis of 
peptides 
52
. Mass spectrometry is most often used because it provides sequence tags 
or peptide mass maps that form the basis for searches of the protein databases.  It 




The fourth stage of a proteomic workflow involves the database search of the 
mass spectra.  There are multiple publically available search engines that can be used 
to perform this task.  The choice of an appropriate database depends on the nature of 
the sample analyzed (i.e. protein, DNA) and the type of mass spectrometric analysis 
used. 
Mass spectrometric analysis can be approached using one of three strategies.  
The first approach is referred to as bottom-up proteomics.  In this strategy, the 
protein(s) of interest is/are first digested using enzymatic or chemical cleavage.  
These peptides are then analyzed by one of several mass spectrometric platforms.  
One of the two most common workflows is peptide mass fingerprinting where the 
proteins are traditionally first separated by 2-D gel electrophoresis and then each 
individual gel spot is subjected to tryptic digestion and analyzed by mass 




fingerprint” that can be used to identify the corresponding protein in the database.  
Another more comprehensive workflow requires digestion of the entire protein 
mixture, fractionation of the peptides via multi-step chromatography and analysis 
using tandem mass spectrometry.  This step produces MS/MS spectra, which can be 
searched against a given database
52; 57
.  Search algorithms have been developed to 
identify peptides on the basis of tandem mass spectra data in search engines such as 
MASCOT, SEQUEST, OMSSA, X!Tandem, and Myrimatch.  The algorithms are 
used to match the arrangement of fragment ions detected in the spectrum with those 
calculated theoretically from the database entries.  The most commonly used search 
engines are MASCOT and SEQUEST 
52
 
An alternative strategy being developed for proteomic analysis is the top-
down approach.  This approach uses mass spectrometry to weigh intact protein ions 
and multi-stage tandem mass spectrometry to produce sequence tags from large 
protein fragments.  Post-translational modifications which play a crucial role in cell 
signaling can be more readily identified and quantified using top-down techniques 
due to the fact that intact proteins are less susceptible to the instrumental biases of 
small peptides (i.e. differences in ionization efficiency).  Until recently however, this 
has been less widely used.  This is in part due to the fact that larger sample quantities 
are required by current instrumentation.  In addition, the analysis time has not, until 
recently been compatible with the chromatographic timescale
58; 59
.   ProSight is 
currently the only commercially available algorithm for identifying protein forms 
from the tandem mass spectra of intact proteins
58; 60
.  As the public database of 




identities and PTMs become more robust, the top-down proteomic approach is 
becoming the method of choice for investigating combinatorial PTMs 
58; 61
.  The most 
robust characterizations will include a combination of both top-down and bottom-up 
proteomics.  
In lieu of top-down or in combination with it, another approach that has been 
widely favored in proteomics research in recent years is referred to as the middle-
down approach.  The middle-down approach typically takes advantage of enzymatic 
or chemical cleavage with selectivity for a single amino acid residue.  The resulting 
proteolytic products produced from the protein(s) of interest are large, with 
polypeptides typically observed between 3kDa to 10kDa in size.  Larger polypeptides 
have been observed to fractionate with improved resolution by HPLC.  These 
peptides can be analyzed using a variety of mass spectrometric platforms, often 
through a combination of methods used in top-down and bottom-up proteomics based 
on the nature and complexity of the sample being investigated.  A common approach 
is fractionation of the peptides via nanoLC interfaced with a high resolution 
instrument, such as a Thermo LTQ-Orbitrap, for high resolution (survey scans 
acquired at 30K resolution) tandem mass spectrometry of both precursor and product 
ions. Large polypeptides carry a higher number of charges when electrosprayed 
which enhances CID and ETD.  The middle-down approach is especially favored in 
the investigation of proteins containing multiple PTMs or proteomes which contain 
multiple protein isoforms
2; 62; 63; 64; 65; 66
.  The interpretation of the mass spectra is 




several search engines including ProSightPC, Mascot and SEQUEST to interrogate 
the data 
2; 64; 66
.    
 
Application to the study of ribosomal proteins 
Since the inception of proteomics, the characterization of the ribosomal 
proteome of both prokaryotic and eukaryotic organisms has been the focus of many 
research laboratories.  The ribosome as a research focus posed an opportunity for 
scientists to develop experimental approaches for the study of non-covalent protein 
complexes.  Interest in the ribosomal proteome was also facilitated by the fact that an 
equimolar contribution of each protein was expected in the ribosomal machine.  As a 
result, concerns regarding dynamic range were thought to be negligible.  Although 
researchers were aware that the ribosomal proteins could be modified, it was not until 
these studies were underway that researchers became aware of the extensive number 
and, on occasion, combination of PTMs found on the ribosomal proteins. 
 Research on the ribosome using proteomics tools and techniques has often 
used a combination of top-down and bottom-up mass spectrometry to identify 
ribosomal proteins and their associated PTMs with a more complete characterization 
than one technique alone can provide.  The bottom-up strategy has frequently 
involved the use of two-dimensional gel electrophoresis for visualization of ribosomal 
protein spots or 1 or 2-D fractionation of the proteins with liquid chromatography 
(usually strong cation exchange followed by reverse phase) prior to proteolysis.  
Occasionally the whole ribosomal protein mixture has been digested without 




researcher to distinguish between protein isoforms.  Proteolysis of the ribosomal 
proteome has been reported with trypsin, Lys-C, Glu-C or acid digestion among 
others.  Proteolytic products are analyzed with peptide mass fingerprinting or tandem 
mass spectrometry (usually ESI/MS/MS) to identify protein components and 
associated PTMs on a particular peptide.  The top-down strategy has either involved 
MS or MS/MS of intact ribosomal proteins.  The use of more sensitive and/or high 
resolution mass spectrometers for these measurements such as an FT-ICR mass 
spectrometer, hybrid ion trap mass spectrometer (for example LTQ-Orbitrap) or 
hybrid Quadrupole mass spectrometer (Quadrupole-FT or the Q-TOF) has become 
standard in ribosomal proteome studies.  Bioinformatic tools have also been advanced 
which was necessary for the identification of whole ribosomal proteins measured with 
these instruments (i.e. Thrash algorithm and ProSightPC) 
64; 67; 68; 69; 70; 71; 72
.  These 
practices enabled the discovery of many co- and post-translational modifications on 
both eukaryotic and prokaryotic ribosomal proteins and ribosome associated proteins 
such as RACK1.  Several examples of proteomic research focused on the ribosome 
follow. 
One of the earliest successful studies to characterize the ribosomal proteome 
using proteomic techniques was published by the Ahn lab in 1996
73
.  This study used 
a combination of top-down and bottom-up mass spectrometry and focused on 
ribosomal proteins of the small subunit from Rat-1 fibroblasts.  The ribosomal protein 
mixture was simultaneously fractionated for collection via RPLC monitored via UV 
detector and a portion of the HPLC effluent was directed to a triple quadrupole mass 




for intact protein mass measurements (determined from ion series across multiple 
scans).   LC/MS/MS analysis of intact proteins was also achieved where further 
analysis was determined necessary for protein identification.  Corresponding HPLC 
fractions were digested with Lys-C for protein identification using tandem mass 
spectrometry with a triple quadrupole instrument.  Forty one proteins were observed 
in total, 36 of which corresponded with the 32 expected small ribosomal subunit 
proteins.  Four ribosomal proteins were discovered to have two forms (isoforms); 
RPS3, RPS5, RPS7 and RPS24.  Of the 32 ribosomal proteins observed, twelve had 
molecular masses identical to the predicted mass of the proteins; RPS4, RPS6, RPS7, 
RPS8, RPS13, RPS15a, RPS16, RPS17, RPS19, RPS27a, RPS29, and RPS30.  An 
internal hydroxylation or methylation was proposed for mass changes observed in 
RPS23.  A loss of the N-terminal methionine and/or acetylation was observed or 
proposed in thirteen of the remaining proteins; RPSa, RPS3a, RPS5, RPS11, RPS15, 
RPS18, RPS20, RPS21, RPS24, RPS26, RPS27, RPS28, and one RPS7 isoform. 
Additional modifications were found on two of these proteins, RPS5 and RPS27 
which were proposed to be internally formylated or acetylated respectively.  The 
remaining ribosomal proteins; RPS2 (+ 220Da), RPS3 (Isoform 1;-75Da; Isoform 2; -
362Da), RPS9 (+86Da), RPS10 (+57Da), RPS12 (-100Da), RPS14 (-117Da), RPS25 
(-103Da) showed changes in their molecular mass which were sometimes localized to 
portions of the sequence but could not be explained 
73
.  This study indicated that the 
majority of ribosomal proteins are co- or post-translationally modified, illustrating the 




 In 2005, the Leary lab examined and compared the ribosomal proteome of the 
human 40S subunit with the proteome of a human 40S subunit complexed with 
Hepatitis C Virus (HCV) IRES (Internal Ribosome Entry Site) using a combination of 
top-down and bottom-up methods
74
.  The isolated ribosomal protein mixture was 
fractionated via RP-HPLC into 120 fractions.  HPLC effluent was lyophilized and 
resolubilized in 79:20:1 Acetonitrile:Water:Formic acid.  Molecular mass 
measurements were obtained by infusion of the samples at 1µL/min into an FT-ICR 
mass spectrometer equipped with an ESI source.  Bottom-up analysis was achieved 
by reducing, alkylating and digesting the entire ribosomal protein mixture with 
trypsin.  The polypeptide mixture was then subjected to LC/MS/MS using a Q-TOF 
mass spectrometer.  Of the expected thirty two proteins found in the small subunit, 
thirty one were observed between all observations.  All of the proteins identified 
using top-down methods were found to contain PTMs which included; N-terminal 
Met loss, acetylation, methylation, dimethylation, and disulfide bond formation.  
Between the two proteomes, the native 40S proteome and the HCV IRES-complexed 
ribosomal proteome, two proteins were observed to contain differences in their 
PTMs, RPS25 and RPS29.  In the case of RPS25, the native 40S protein was always 
observed to be dimethylated while the IRES-complexed RPS25 was observed to exist 
in both a mono- and dimethylated form.  The native 40S RPS29 protein was observed 
to contain 2 disulfide bonds while the IRES-complexed version of the protein did not 
contain any disulfide bonds.  Six proteins from the native 40S proteome, RPS11, 
RPS4, RPS6, RPS8, RPS26, and RPS3a, were not found using the top-down method 




proteins also differ between the two proteomes (since 100% sequence coverage was 
not achieved with polypeptide analysis).  Proteins associated with the ribosomes were 
also observed. RACK1 was detected with both proteomes however nucleolin was 
only witnessed in association with the IRES-complexed proteome 
74
.  This study 
suggested that PTMs on the ribosomal proteins that are part of native 40S complex 
versus those involved in a HCV-IRES complex may be useful in distinguishing 
healthy from diseased state.  
 In 2007, James P. Reilly and colleagues used a top-down/bottom-up approach 
to study the ribosomal protein components in the Caulobacter crescentes bacterium
72
.  
Ribosomal proteins isolated from these organisms were fractionated using an intricate 
two-dimensional liquid chromatography (2D-LC) system that contained a strong 
cation-exchange column which fed into 20 reversed phase trap columns followed by 2 
reversed phase analytical columns.  Eluent from the second analytical column was 
split with a portion of the flow directed to an ESI source coupled with a Q-TOF mass 
spectrometer for intact protein measurements.  Protein identification was confirmed 
by proteolysis of protein fractions collected from the 2D-LC.  Three methods of 
proteolysis were used to increase sequence coverage.  To determine the sequence at 
the C-terminal end of the protein, Carboxypeptidase Y and Carboxypeptidase P were 
used and proteolytic products analyzed using a Q-TOF mass spectrometer.  Protein 
fractions were in certain cases selectively digested with Glu-C and analyzed with 
MALDI/MS peptide mass mapping.  Additionally, trypsin digestion was used for 
peptide analysis on each protein fraction.  Proteolytic products of the trypsin digests 




mass spectrometer. Fifty three of the fifty four ribosomal proteins found in C. 
cresecentes were identified and their intact masses determined.  The masses of 
approximately one half of the ribosomal proteins matched the theoretical mass with 
the loss of the N-terminal methionine, while one quarter matched the theoretical mass 
without Met loss.  The remaining ribosomal proteins possessed various PTMs 
including combinations of Met loss, acetylation, methylation, and oxidation in the 
case of one protein.  There were also discrepancies between the observed protein 
masses and the theoretical protein masses, supported at the peptide level, which could 
be explained by truncations of 13 and 11 residues at the N-termini of RPL3 and 
RPS21 respectively and termination of the sequence in RPL27 prior to the final C-
terminal residue, Glu.  Reilly and his colleagues argued that since random proteolysis 
of the proteins was not observed in any other cases, this was strong argument for an 
error in the interpretation of the genome sequencing data for those 3 proteins 
72
.  Not 
only did this study illustrate the great extent to which prokaryotic ribosomal proteins 
may be modified but it also suggested that for certain prokaryotic organisms in 
particular, the gene annotation may have been misinterpreted. 
 In 2008, Carroll et al. studied the ribosomal proteins of Arabidopsis thaliana 
using a multifaceted bottom-up approach
75
.  Ribosomal proteins were isolated and 
100µg of protein was run in parallel in three lanes of a large format gel.  Protein 
bands were divided into 30 gel regions, individually excised and subjected to in-gel 
protease digestion with trypsin.  Using duplicate gels, low molecular mass protein 
bands (≤ 20kDa) were also digested separately with chymotrypsin and pepsin.  




stain in order to detect proteins which were phosphorylated.  Protein bands containing 
these phosphorylated proteins were excised and subjected to in-gel proteolysis 
followed by phosphopeptide enrichment with TiO2 microcolumns.  Extracted peptides 
were subjected to LC/MS/MS using a Q-TOF mass spectrometer fitted with an ESI 
source. More detailed analyses were conducted using a nanospray source (also with 
the Q-TOF instrument) to identify PTMs.  In-silico approaches in addition to custom 
software for the filtering of peptide match information led to the identification of 87 
individual proteins and 79 of the 80 predicted protein families of the Arabidopsis 
ribosome.  Five of these ribosomal protein gene families had never previously been 
observed experimentally for Arabidopsis; RPS29, RPS30, RPL29, RPL36a and 
RPL39.  Theoretical approaches suggested that 63 of the ribosomal protein gene 
families should have distinguishable peptide products.  Of these, the authors found 
good specific gene matches in the following protein families; RPS3, RPS3a, RPS6, 
RPS24,RP L7, RPL13a,RP L35, RPL4, RPL5, RPL7a, RPL14, RPL17, RPL23a, 
RPL26,RP L28, RPL32 and RPLP3.  Four non-ribosomal proteins were identified as 
being associated with the ribosomes; 2 guanine nucleotide-binding family proteins, a 
ferritin-like protein and a eukaryotic translation initiation factor.  Strong MS/MS 
evidence was found for 30 unique covalently modified peptides with a total of 41 
covalent modification events.  These modifications included 15 instances of Met loss, 
12 cases of N-terminal acetylation, 1 occurrence of N-terminal dimethylation, 9 
instances of phosphorylation and 3 cases of N-methylation of Lys side chains.  
Conservation of modifications across eukaryotes is suggested based on the fact that, 




homologous proteins in yeast.  Additionally patterns of Met removal and N-terminal 
acetylation and phosphorylation are also reported as being widely conserved across 
eukaryotic ribosomal proteins 
75
.  This study reinforced the fact that with the 
heterogeneity in ribosomal protein gene families and possible PTMs, considerable 
forethought must be put into the acquisition and filtering of MS/MS data in order to 
identify specific members of a ribosomal protein family (which by the authors’ own 
account sometimes only vary by one residue).  The suggestion that there may be 
conservation of modifications found on homologous ribosomal proteins requires 
further investigation.     
The Ribosome is not Static 
Ribosomal proteins and disease 
Over the last few decades, researchers have uncovered a link between 
ribosomal protein expression levels and/or gene mutations of ribosomal proteins with 
human diseases.  Certain inherited conditions are linked with ribosomal protein 
dysfunction and mutation including Diamond Black-fan Anemia syndrome (RPS19), 
Turner syndrome (RPS4X), Camurati-Engelmann disease (RPS18), Noonan 
syndrome (RPL6), and Bardet-Beidl syndrome (RPS30) to name a few
76
.  In addition, 
numerous studies have cited an increase in ribosomal protein expression levels in 
association with cancer.  This includes (but is not limited to); esophageal cancer 
(RPL15), gastrointestinal cancer (RPL13), cervical cancer (RPS12), prostate cancer 
(RPL37 and RPL7a), colorectal cancer (RPS3, RPS6, RPS8, RPS12, RPL5, RPL22, 
RPL35, RPL36) and hepatocellular cancer (RPL13, RPL36a, RPS8, RPL12, RPL23a, 
RPL27 and RPL30) 
76




homoplasmic mutation in a mitochondrial rRNA gene confirmed a coordinated over-
expression of most cytoplasmic ribosomal protein genes with microarray, flow-
cytometry and quantitative RT-PRC, believed to be a compensatory mechanism for 
this mutation 
77
.  Comparative studies of different colorectal carcinomas suggested 
that the expression of certain ribosomal proteins could be correlated with the stage of 
tumor and the malignancy potential of the cancer 
78
. 
There are generally two theories regarding the reason/role that ribosomal 
proteins are differentially expressed in disease states such as cancer. One; a disruption 
in the distribution of ribosomal proteins in the cell affects their function in the 
ribosome in protein biosynthesis which either precedes, follows, or is the cause of 
tumorigenesis or two; the extra-ribosomal functions of these ribosomal proteins 
directly leads to a signal pathway(s) causing tumor formation and/or growth 
78; 79; 80; 
81
.  Both theories are supported in the literature, however at this time only select 
ribosomal proteins have known extra-ribosomal functions.  Research in the laboratory 
of Paul Fox (among others) has shown that not all ribosomal proteins are essential for 
the ribosomal machine to perform its function in protein biosynthesis and in certain 
circumstances modification of a ribosomal protein may lead to its departure from the 
ribosomal complex to perform an extra-ribosomal function.  For example, a study 
investigating the extra-ribosomal function of human RPL13a illustrated that 
phosphorylation of RPL13a allowed for its release from the ribosome and subsequent 
function as a transcript-selective, translational silencer of ceruloplasmin.  This 
suggested that the ribosome may act as a “storage depot” for translational control 
proteins 
25




behind the differential expression of ribosomal proteins, ribosomal proteins which are 
not easily able to “leave” the ribosomal complex to perform extra-ribosomal 
functions would be excluded.    
Currently there is a hypothesis referred to as the “ribosome filter hypothesis” 
which provides an explanation for how ribosomal proteins embedded in the complex 
may perform a function in the translational control of other proteins
82
.  The ribosome 
filter hypothesis proposes that mechanisms involving differential mRNA capture 
allow for the ribosomal subunits to affect the translation of particular mRNAs.  This 
hypothesis was originally rooted in the observation that most mRNAs have regions of 
their sequence which are complementary to sequences in the 28S or 18S rRNAs 
suggesting a potential mechanism by which mRNA-rRNA pairing might occur 
82; 83
.  
Support for this hypothesis has come not only from the fact that the literature 
documents differential expression of ribosomal proteins (in diseased states for 
example) but also from the discovery that PTMs on the ribosomal proteins (within the 
confines of the ribosome) differ during different stages of the cell cycle.  For 
example, a study by Haselbacher et al in 1979 found that phosphorylation of RPS6 
was influenced by insulin-growth factor in the transition from G0 to G1.  A similar 
discovery was made by Spence et al in 2000 when they discovered that ribosome-
associated RPL29 (RPL27a in humans) was multi-ubiquitinated in both yeast and 
human cells as a functional cell-cycle dependent modification.  Porras-Yakushi et al 
illustrated in 2006 the role that methylation plays in the ribosomal proteins, 
particularly at different times in the complex
84; 85; 86
.  Four interrelated views which 




ribosome structure allow for the preferential translation of subsets of the mRNA 
population, 2) ribosomal interactions allow for regulatory effects on mRNA, 3) 
binding site competition in the ribosomal subunits may affect the rate of translation of 
different mRNAs and 4) ribosomal heterogeneity may allow for masking or altering 
of particular binding sites on the ribosome 
82
.    
Testing by Mauro and Edelman of the hypothesis that complementarity 
between rRNA and mRNA leads to preferential translation examined a 9 nucleotide 
(9-nt) element in the mRNA sequence of the Gtx homeodomain protein.  Functional 
and biochemical studies showed that translation was maximally enhanced with a 
specific 7-nt sequence in the 9-nt element.  In experiments where there was poor 
complementarity between the Gtx element and rRNA (such as in Saccharomyces 
cerevisiae), translation of the protein was not enhanced however when the nucleotide 
sequence was altered to complement the rRNA, a dramatic increase in translation 
efficiency was observed 
82
. 
Additional work by Mauro and Edelman which supports the ribosome filter 
hypothesis illustrated that ribosomes are heterogeneous as previous studies have 
supported.  Ribosome protein composition/expression in disease states and during 
stages of the cell cycle has been observed with different ribosomal protein expression 
patterns.  Duplicate genes for ribosomal proteins found in S. cerevisiae have been 
observed to serve functionally distinct roles 
87
.  In light of the fact that some studies 
have suggested that a select number of ribosomal proteins are unnecessary for the 
protein biosynthesis function of the ribosome, there exists a possibility that ribosomes 






Modifications of rRNA have been observed to play a role in IRES-dependent 
translation control and deficiencies in these modifications are linked with human X-
linked Dyskeratosis Congenital syndrome and pituitary tumor formation 
88
. 
Perhaps one of the greatest strides taken in ribosomal research in recent years 
has been the discovery that the ribosome plays a regulatory rather than a constitutive 
role in the coordination of gene expression during embryonic development.  This 
should not be surprising considering that all other molecular machinery such as 
chromatin associated histones and the spliceosome involved in gene expression 
confer specialized functions in gene regulation.  Kondrashov et al have recently 
found that RPL38 plays a critical function in the axial skeletal patterning during 
embryonic development of mice.  Mutations in RPL38 manifest themselves by 
skeletal patterning defects and shorter kinky tails.  When transgenic mice were 
created which rescued the RPL38 mutation, normal phenotypes and typical RPL38 
expression levels were observed.  Axial skeletal morphology is regulated in mammals 
with HOX genes.  Kondrashov et al examined the expression boundaries and 
transcript levels of the HOX genes in the mutant mice and found that they were 
unchanged in the mutants suggesting the mutant phenotypes were attributable to 
RPL38 and not due to transcript levels and/or expression boundaries of the HOX 
genes.  Differences in the amount of general cap-dependent vs. IRES-dependent 
translational control were measured as well as the global protein synthesis assessed 
and both found to be unchanged from the WT embryo.  Microscale polysome analysis 
revealed that the number of small to large subunits and the polysome distribution was 




no change in global protein synthesis.  Quantitative PCR analysis of the HOX 
mRNAs found that there was no evidence of a perturbation in transcriptional control 
of the HOX genes.  Despite this fact, the association of certain HOX mRNAs with 
both the light and heavy polysomes was decreased in the mutants.  The corresponding 
proteins for the HOX mRNAs which were found to associate at a lower level with the 
polysomes were also found in lower abundance.  This suggested that the control of 
the HOX mRNA by RPL38 was at a translational level.  Protein expression levels of 
the translationally deregulated HOX mRNAs in mutants was restored to normal levels 
in transgenic mice and was also able to be controlled by an in-vitro translation 











) were examined and it was found that no changes in 
HOX mRNA expression/translation or axial skeletal morphology were observed even 
in cases when global protein synthesis was markedly affected.  Several experiments 
were conducted to determine the role which RPL38 played in the translational control 
of certain HOX mRNAs and perceived that RPL38 is involved in the formation of the 
80S ribosome on these mRNAs (perhaps a form of ribosomal “recruitment”).  
Ribosomal protein expression patterns in tissues throughout the mice revealed 
specific patterns which are believed to be relevant to the role these ribosomal proteins 
play in their translational control.  The question remains to be answered whether 
“specialized ribosomes” such as these exist as a result of the role that specific 
ribosomal proteins play in transcript-specific translational-control or simply by 
ribosomal protein heterogeneity.  There also exists the possibility that PTMs 
contribute to the properties of “specialized ribosomes” 
89




All of the studies discussed above illustrate that the ribosome is a complex, 
malleable organelle whose protein isoforms/modifications and sometimes 
composition vary with tissue type, stage in cell cycle, health of the organism and 
developmental state.  Ribosomal research has shown that despite the plasticity of the 
ribosome, certain mutations can lead to disease and death.  Answering the questions 
posed by the Kondrashov study regarding “specialized ribosomes” will help scientists 
to better understand the role which the ribosome and ribosomal proteins can play in 
translational regulation and disease.  Modifications of ribosomal proteins such as 
truncation and PTMs were distinguishing features of certain ribosomal proteins in 
disease and studies of the cell cycle 
25; 73; 74; 75; 79; 87; 90
.  Given the role the ribosome 
plays in the regulation of the cell cycle and the link it has to some forms of drug 
resistance in prokaryotic organisms, it is experimentally relevant to investigate and 
compare the ribosomal proteome in chemotherapeutic resistant human cell lines with 













Objective & Specific Aims  
Based on the aforementioned evidence illustrating the plasticity of the ribosome, it is 
our objective to develop an effective means by which modified ribosomal proteins 
may be isolated and identified.  These methods will be applied to characterize 
modifications in the ribosome of a drug resistant cancer cell line compared to the drug 
susceptible precursor.  With this goal, we have the following specific aims; 
1  Develop methods that allow the rapid analysis of ribosomal proteins 
with high sequence coverage. 
2  Characterize the primary structure of altered ribosomal proteins in 
MCF 7 human cancer cells selected for resistance to mitoxantrone. 
3 Consider the possible impact on function of the ribosome played by 




Chapter 2: Materials and Methods 
 
Materials 
Mitoxantrone resistant cells and drug susceptible cells were provided by Dr. 
Takeo Nakanishi and Professor Peter L. Gutierrez of the University of Maryland 
Greenebaum Cancer Center. Canted neck T-150cm
2
 cell culture flasks were 
purchased from Corning, Inc. (Lowell, MA).  Improved Minimal Essential Media 
(IMEM) supplemented with L-glutamine, fetal bovine serum and phosphate buffered 
saline (PBS) were purchased from Mediatech, Inc. (Manassas, Virginia).  Acetic acid, 
ammonium bicarbonate, 3-[(3-cholamidopropyl) dimethylamonio] -1-
propanesulfonate (CHAPS), glycerol, magnesium acetate, magnesium chloride, 
penicillin streptomycin antibiotic solution, potassium chloride, sodium dodecyl 
sulfate (SDS), sucrose, thiourea, trifluoroacetic acid (TFA), Trizma base, cell culture 
grade trypsin (.025%), and urea were obtained from Sigma Aldrich (St. Louis, 
Missouri).   LCMS grade Acetonitrile (Optima), formic acid and HPLC-grade water 
was purchased from Fisher Scientific (Fairlawn, New Jersey).  The Immobilized pH 
gradient (IPG) strips, pH 7-11 NL (non-linear gradient), and corresponding 
ampholytes (IPG buffer) were purchased from GE Healthcare (Piscataway, New 
Jersey).  The ultra-clear ultracentrifuge tubes were obtained from Beckman-Coulter 
(Fullerton, California).  Molecular weight cut-off filters (MWCO, 3 kDa) were 
purchased from Millipore (Microcon Ultracel YM-3, Billerica, MA). The RC/DC 
protein assay kit, bromophenol blue, cup-loading sample cups, Protean II precast gels 




Coomassie Blue were purchased from Bio-Rad (Hercules, California).  Sequencing 
grade trypsin was purchased from Promega Corporation (Madison, Wisconsin).  




The mechanical homogenizer was purchased from Kinematica (Littau, 
Lucerne; Switzerland).  The DU-530 UV-Vis spectrophotometer and Optima LE-80K 
preparative ultracentrifuge are from Beckman Coulter (Fullerton, CA).  The Orbital 
shaker was purchased from Fisher Scientific (Pittsburgh, PA).  The lyophilizer was 
purchased from Labconco (Freezone 2.5 Liter Benchtop Freeze Dry system, 
Labconco Corp., Kansas City, MO).  Isoelectric focusing device, second dimension 
gel apparatus, and GS-800 densitometer were purchased from Bio-Rad (Hercules, 
CA).   An Accela HPLC, electrospray ionization source, nanospray ionization source 
and LTQ-Orbitrap XL were obtained from Thermo Fisher Scientific (San Jose, CA).  
An additional ionization source, the Advance CaptiveSpray Plug-and-Play source was 
acquired from Michrom Bioresources (Auburn, CA).  Two HPLCs (microflow and 
nanoflow) and a MALDI-TOF instrument were all purchased from Shimadzu 
Scientific Instruments (Columbia MD).  The Discoverer Benchmate microwave 
system with a fiber-optic temperature probe and a 45mL digestion vessel capable of 







Mitoxantrone susceptible (henceforth referred to as MXS) and mitoxantrone 
resistant breast cancer cells (henceforth referred to as MXR) were grown until 
confluency in 150 cm
2
 flasks (Corning, New York) in Improved Minimal Essential 
Media (IMEM) with L-glutamine supplemented with 1% penicillin-streptomycin 
antibiotic solution and 10% heat inactivated fetal bovine serum.  To retain the 
mitoxantrone resistant phenotype, cells were grown with media that contains 250nM 
mitoxantrone as described by Nakagawa et al, 1992
35
.  Cells were maintained at a 
temperature of 37°C in a water jacketed CO2 incubator with 5% carbon dioxide.  




To isolate the ribosomes, a modification of a method previously developed in 
the Fenselau lab was used 
1
.  MCF7 cells were released from the flask bed by 
washing with 15mL of cell culture grade 10mM phosphate buffered saline (PBS) 
followed by a 5 minute incubation with 3mL cell culture grade trypsin.  Tryptic 
activity was stopped by the addition of 10 mL IMEM after the incubation.  Cells were 
suspended in solution and transferred to a pre-weighed centrifuge tube for 
centrifugation at 500g for 5 minutes at 4°C in a benchtop centrifuge (Allegra 21R 
centrifuge, Beckman, Fullerton, CA).  The cell pellet was resuspended in PBS and 




  Homogenization of the cell pellet on ice with a Kinematica mechanical 
homogenizer (Littau, Lucerne; Switzerland) in two volumes homogenization buffer 
(50mM Tris-HCL, pH 7.5; 5mM MgCl2, 25mM KCl, 200mM Sucrose) was followed 
by centrifugation at 10,000g for 10 minutes at 4°C in the benchtop centrifuge.  The 
supernatant was collected and the remaining pellet re-homogenized on ice and 
centrifuged.  The supernatant was layered 1:1 over a sucrose cushion buffer (50mM 
Tris-HCl, pH 7.5; 5mM MgCl2, 25mM KCl, 2M Sucrose) and the ribosomal pellet 
isolated by centrifugation (Optima LE-80K preparative ultracentrifuge, Beckman 
Coulter, Fullerton, CA) at 260,000g at 4°C for 2 hours in a swinging bucket rotor 
(SW60Ti).  At this time point the samples were stored in 1mL homogenization buffer 
at -80°C until protein extraction.  
 
Extraction/Isolation of Ribosomal Proteins 
   All procedures were carried out on ice unless otherwise indicated.  Prior to 
protein extraction, the ribosomes were first precipitated by the addition of 0.7 
volumes ice cold ethanol and this suspension centrifuged for ten minutes at 7000rpm.  
The pellet was then resuspended in 250µL homogenization buffer without sucrose.  
Ribosomal proteins were separated from the rRNA using a variation of the acid 
extraction procedure described by Hardy et al, 1969 
91
.  In brief, one volume of the 
ribosomal suspension was mixed with 0.25 volumes of 1M Mg(OAc)2 followed by 
the addition of 1 volume glacial acetic acid.  Each solution was incubated for 1 hour.  
The precipitated rRNA was pelleted by centrifugation at 10,000rpm at 4°C for 10 min 




collected for each ribosomal type. Solution digestion was carried out with both 




Figure 2.1 Experimental workflows used to evaluate the primary structure of the 
altered ribosomal proteins 
 
Processing of the extracted ribosomal proteins depended on whether they were 
intended for use with an HPLC, gel electrophoresis or immediate cleavage of the 
whole ribosomal proteome with chemical digestion.  In the case of both HPLC and 
cleavage of the whole ribosomal proteome, lyophilization and/or 3kDa MWCO filters 
were used to concentrate the samples and reduce the acid content. After desalting and 
concentrating the samples, the protein concentrations were determined using the Bio-
Rad RC/DC protein assay (Bio-Rad, Hercules, CA).  For samples intended for 2-D 




1976 was used 
92
.  The proteins in the acetic acid extraction are mixed with 4 volumes 
ice cold acetone and incubated at -20°C for between 2 to 4 hours.  The precipitated 
ribosomal proteins are then centrifuged in a benchtop centrifuge for 20 minutes at 
10,500 g.  The supernatant is quickly poured into another tube and the protein pellet 
washed with 1mL of acetone for two additional spins of 20 minutes at 10,500g.  The 
supernatant from the original wash was also centrifuged to collect additional protein 
that did not pellet in the first run.  This is washed with acetone as described for the 
main pellet.  The acetone washed protein pellet was resuspended in a rehydration 
buffer, the volume and composition of which varied depending on the sample loading 
method for the first dimension. In the case of rehydration loading (both active and 
passive) the rehydration buffer consisted of 7M urea, 2M thiourea, 2% CHAPS, 0.5% 
IPG buffer, .05% bromophenol blue and 50mM DTT with a sample volume of 
approximately 240µL.  In the case of cup-loading, the rehydration buffer consisted of; 
7M urea, 2M thiourea, 15% isopropanol, 2.5% glycerol, 2% CHAPS, 0.5% IPG 
buffer, 0.05% bromophenol blue and 50mM DTT with a sample volume of 
approximately 100µL.  Samples were incubated for a minimum of an hour in the 
rehydration buffer before an aliquot of 25uL was taken for a protein assay using the 
Bio-Rad RC/DC kit. 
HPLC Fractionation of Ribosome Protein Mixture  
(See Fig. 2.1) 
  Two methods were evaluated for pre-fractionation of the ribosomal proteome 
prior to bottom-up and molecular mass measurement.  These were the use of 2-D gel 




methods fractionate based on different chemical characteristics of the proteins.  In the 
case of the first stage of 2DGE, proteins are fractionated based on their isoelectric 
point while in the case of RP-HPLC, they are grouped based on their hydrophobic 
character. 
Fractionation of the ribosomal proteome using HPLC first required the 
buffering of the protein mixture for reduction of the proteins.  This was achieved by 
the addition of 2 volumes of 100mM ammonium bicarbonate.  The sample was then 
reduced with 2mM DTT for 1 hour at 56° C.  In some experiments, this was followed 
by alkylation with 4mM IAA in the dark at room temperature for 45 minutes. Since 
the injection loop on the HPLC used in these experiments holds 500µL, an 
appropriate volume of mobile phase A (10% acetonitrile/90% water/ 0.1% TFA), 
typically around 150µL, was added to each sample to aid with sample mixing upon 
injection. 
The HPLC system used for these experiments was equipped with two 
Shimadzu LC-10 reciprocating pumps with a variable SPD-10 AVP UV-VIS detector 
and a Rheodyne 500µL stainless steel sample loop and manual injection valve (Idex 
Health and Science, Rohnert Park, CA).  A Phenomenex (Torrance, California) 
Jupiter 5µm particle size C-18 300Å 250 x 4.6mm i.d. column was used for these 
experiments.  The column was run with a Phenomenex Security guard column 
equipped with a C-18 cartridge.  The UV detector recorded chromatograms at 215nm.  
Solvents A and B were originally prepared as documented in earlier literature for the 
HPLC of ribosomal proteins with Solvent A consisting of 0.1% TFA in water and 
Solvent B, 0.1% TFA in acetonitrile 
74




instrument was not observed, different concentrations of acetonitrile (ACN) were 
evaluated for solvent A.  Ten percent ACN containing 0.1%TFA was determined to 
generate the most reproducible results. 
A set of four standard proteins chosen for their molecular weight and 
isoelectric points; hen egg white lysozyme (MW=14,307 Da, pI=11.35), horse heart 
cytochrome C (MW=12,384 Da, pI=10.5), bovine pancreas ribonuclease A 
(MW=13,690 Da, pI=9.6), and horse heart myoglobin (MW=17,641 Da, pI~7.2), was 
used to determine what HPLC conditions would generate reproducible separations.  
Stock solutions of each of these proteins were prepared as 0.5mg/mL in solvent A and 
kept frozen in between uses.  Experiments determined that low nanomolar 
concentrations were the lower limit of protein concentration necessary for detection.  
A typical standard protein injection contained ~5 nanomoles of each protein.  An 
average human ribosomal protein injection contained approximately 1.3mg/mL of 
protein.  Taking into consideration that the average ribosomal protein weighs 
approximately 18.5kDa, there was approximately 70pmol/uL of each protein in these 
samples, meaning that for each 500µL injection in the sample loop there was ~10.5 
nanomoles of each protein injected. 
Several gradients were tested for the enriched ribosomal protein samples. 
Yeast ribosomal proteins were used initially as standards for testing HPLC 
conditions.  The initial gradient tested was that reported by Yu et al. in 2005 for their 
work with the human 40S ribosomal subunit 
74
.  This gradient proceeded as follows; 
(1) 0 – 3 min 10% ACN, (2) 3 – 33 min 10 – 30% ACN, (3) 33 – 37 min 30 – 37% 




113 – 123 min 80 – 95% ACN.  The aforementioned gradient resulted in solvent 
mixing issues which led to poor resolution and peak capacity.  Eleven additional 
gradients were tested before the following gradient was decided upon; (1) 0 – 83 min 
15 – 95% ACN, (2) 83 – 93 min 95% ACN, (3) 93 – 94 min 95 – 15% ACN, (4) 94 – 
113 min 15% ACN.  Although different flow rates were attempted, 0.55mL/min 
produced the best results with the Phenomenex columns. 
Fractions were manually collected every minute beginning at 5 minutes until 
60 minutes.  At 60 minutes, fractions were subsequently collected every 5 minutes 
until 80 minutes at which point one fraction was collected every ten minutes.  Each 
fraction was split into two aliquots for bottom-up analysis and molecular mass 
analysis.  Inspection of the whole proteins in each fraction using the MALDI-TOF 
revealed which fractions contained proteins.  Molecular mass measurements were 
made with ESI-LTQ-Orbitrap on the whole protein fraction aliquots to determine the 
mass of individual proteins.  Fractions containing proteins were digested in solution 
with trypsin to identify protein components.  
Enzymatic digestion of these HPLC aliquots with trypsin was accomplished 
by first reducing the fractions with 2mM DTT for 1 hour at 56° C.  Samples were 
then incubated in the dark with 4mM IAA at room temperature for 45 minutes.  Each 
fraction was then incubated overnight with 0.6µg trypsin at 37° C.  Peptides were 
dried down and redissolved in 60µL of 0.1% formic acid solution to stop the 
digestion and to prepare the samples for injection on the Thermo Accela HPLC 





Whole Ribosome Protein Digestion Methods 
Acid Digestion of Whole Ribosomal Protein Mixture  
In cases where the ribosomal protein mixture was not fractionated prior to 
enzymatic or chemical cleavage, microwave accelerated acid digestion was evaluated.  
For the acid digestion 12.5% acetic acid and 5mM dithiothreitol were added to each 
sample.  The Discover Benchmate microwave system was used.  Microwave-
accelerated acid cleavage on six 50µL aliquots of the ribosomal protein suspensions 
was carried out using methods previously described by this laboratory 
64
.  In brief, the 
digestion was carried out at a constant temperature of 140 ± 5°C with 300W for 20 
minutes.  Samples were allowed to cool before removal and combining them for mass 
spectrometric analysis. 
 
Two-Dimensional Gel Electrophoresis 
Isoelectric Focusing 
 Alkaline proteins are renowned for being difficult to focus in the first 
dimension of two-dimensional gel electrophoresis
93; 94; 95; 96
.  This is due in part to the 
fact that the common reducing agent, DTT, is a weak acid with pka values of the thiol 
groups being 9.2 and 10.1 respectively.  Dithiothreitol will thus ionize at basic pH 
and migrate towards the anode during IEF.  This poses a problem for the focusing of 
the cysteine containing alkaline ribosomal proteins.  In order to overcome this 
obstacle, researchers have taken many approaches including trying different sample 
loading methods, altering the composition of the rehydration buffer, and using a 








Several methods of sample loading were tested for isoelectric focusing.  
Rehydration loading involves the loading of the sample onto the strip at the same time 
that the strip is rehydrated.  Two versions of rehydration loading were tested.  These 
are referred to as passive and active rehydration loading 
99
.  For each, 18cm IPG 
strips (7-11 NL, GE Healthcare) were used.  In this procedure, 320µL rehydration 
solution containing 100µg sample was pipetted across a lane in the focusing tray.  For 
passive rehydration, the IPG was laid face-down over this sample containing solution, 
covered with mineral oil to prevent the strip from drying out and incubated overnight 
before proceeding with the focusing.  For the active rehydration tested in these 
experiments, the IPG strip was laid face down over the sample containing solution, 
the wetted strip covered with mineral oil and the focusing tray placed in the Bio-Rad 
Protean IEF cell at 50V overnight at 20° C to aide with sample entering the IPG strip.  
In both cases, rehydrated strips were then drained of mineral oil and placed in a clean 
focusing tray face-down.  An electrode wick dipped in 15mM DTT is placed under 
the strip at the electrode on the cathode end while an electrode wick dipped in water 
is placed on the anode end.  The strip is covered in mineral oil and the tray is placed 
in the apparatus for focusing.  The best method for focusing with these forms of 
sample loading involved the following method; 500V for 2 hours with rapid ramping, 
8000V for 30 min with linear ramping, and finally 8000V for 50kVhr with rapid 
ramping.  
 Neither form of rehydration loading resulted in reproducible and well resolved 
protein spots despite trying several focusing methods.  Different rehydration buffer 




isopropanol and glycerol to suppress the reverse endoosmotic flow effect observed 
with each run 
94; 100
.  Though these changes to the buffer composition did improve the 
spot resolution on the gel, there were still problems with distinguishing individual 
spots.   
As a result, a form of sample loading often recommended for basic proteins, 
referred to as cup-loading, was used 
96
.  Prior to cup-loading of the samples, the IPG 
strips needed to be rehydrated.  This was done by incubating the IPG strips face down 
in 340µL rehydration buffer (7M urea, 2M thiourea, 2% CHAPS, 15% isopropanol, 
2.5% glycerol, 0.5% IPG buffer, 0.05% bromophenol blue, 50mM DTT) overnight at 
20° C covered with mineral oil.  Rehydrated IPG strips were then picked-up with 
forceps to drain mineral oil, rinsed briefly (5 seconds) in Millipore water to remove 
any urea crystals, patted dry with filter paper (Bio-Rad) and placed face-up in the 
cup-loading isoelectric focusing tray.  An electrode wick dampened with 15mM DTT 
was placed on the IPG strip at the cathode end while an electrode wick dampened 
with water was placed at the anode end.  The platinum electrodes were placed over 
each end of the strip and 100µL sample cups placed firmly over the strip at the anode 
end.  Rehydration buffer was used to test for a possible sample leakage from the cup.  
For each 18cm strip, 100µg of protein in approximately 50µL was added to each cup.  
Sample in each cup and strip were covered with mineral oil to prevent drying out and 
sample loss.  The optimized method for focusing these proteins with cup-loading was 
found to be; 150V 1hr, 300V 2hr, 600V 1hr, 8000V 30min (linear ramping), 8000V 
48kVhr.  The total run averaged 60kVhr for 2 IPG strips.  At least once during the 




After optimization, the Destreak™ reagent (GE Healthcare, Piscataway, NJ) 
was tested as an alternative to DTT to simplify and possibly improve the method.  
The Destreak™ reagent is thought to be superior to DTT as instead of reducing the 
cysteine residues on the proteins, it oxidizes them resulting in “mixed disulfides” 
allowing the proteins to move into the basic region of the strip that posed a problem 
with DTT 
96; 97
.  For each 100µg sample, 1.2% Destreak™ reagent was added.  The 
gels were run as above except that Destreak™ was used in place of DTT in the 
rehydration buffer, sample buffer and cathode wick solution.  These gels were found 
to be of similar quality or poorer quality (more combined spots resulting in fewer 
spots in addition to sample loss) to the gels from the original method so it was 
determined that Destreak™ was not an improvement for this study. 
 
Equilibration and Gel Electrophoresis 
After isoelectric focusing it is necessary to equilibrate the IPG strips in 
equilibration buffer to allow the proteins to fully interact with SDS prior to 
electrophoresis.  This is done in two steps in order to fully reduce and alkylate the 
proteins as well.  However, since that is a slow process, the equilibration for each step 
must also be extended for at least 15min each 
99
.  Equilibration was performed using 
methods previously described by our lab with minor adjustments to account for the 
difference in sample loading 
1
. In short, the IPG strip was removed from the cup-
loading tray and drained of the mineral oil and placed in an equilibration tray (Bio 
Rad) containing Equilibration Buffer I (50Mm Tris-HCl (pH8.8), 6M Urea, 20% 




from this solution and incubated for 30 minutes in fresh equilibration buffer with 4% 
IAA replacing the DTT.  The strip was removed, and quickly (5 seconds) rinsed in 
the electrophoresis running buffer (25mM Tris, 192mM glycine, 0.1% SDS) 
purchased from Bio Rad.  It was then placed on top of an 8-16% Tris-HCl SDS-
PAGE precast gel (Bio-Rad or Jule Inc.) and run using the same method previously 
used in our lab 
1
.  The strip was then covered with warm agarose solution purchased 
from Bio Rad and allowed to dry.  Running buffer was added to the electrophoresis 
unit (Bio Rad) and the method used was; 16mA/gel for 30 minutes followed by 
24mA/gel for 5 hours or until the Coomassie blue has reached the bottom of the 
resolving gel. 
After the electrophoresis was completed the gel was removed and placed in a 
gel box (Corning) in fixing solution (45% Methanol/5%Acetic Acid/50% water) and 
left overnight on a shaker (Thermo Fisher).  After fixing the gel was washed with 
water a minimum of 3 times for 15 minutes.  The gel was then incubated on the 
shaker in the Bio Rad Bio-safe™ Coomassie blue staining solution for a period of at 
least 1 hour.  Gels were then destained by soaking in water numerous times to remove 
background staining. 
The gel image was obtained using a GS-800 Densitometer along with the 
associated Bio Rad software known as PDQuest™.  PDQuest™ allows for 
comparison of individual gels as well as the composite of gels within that group 
(referred to as “automatching”).  This is obtained by the software manually aligning 
gel spots (referred to as “landmark spots”) from individual gels with one another.  




not aligned properly by the software.  The user may also remove areas of background 
noise that are mistakenly identified as spots by the automatching process.  A total of 
four gels for each harvest were combined for these analyses. Proteins from the two 
cell lines (MXR and MXS) were both harvested and separated by 2DGE on the same 
day in three of the four pairs.  These gels were compared to one another as well as 
used in the composite gel for the MXR and MXS cell line comparison.  Another 
software package called CompugenZ3™ (Compugen Limited, Tel Aviv, Israel) was 
used to analyze the gels in much the same way with a more automated system.  The 
TIFF image of each gel obtained from the GS-800 densitometer was exported.  The 
intensity of each spot in the gels was measured and background level values 
subtracted.  Pairing of the gel spots between images was inspected manually using 
“zoomed” images.  Spots whose abundances differed more than two fold from their 
matching spot in both software programs were selected for further investigation. 
 
In-Gel Digestion 
In order to identify the proteins of interest, a trypsin digestion of the gel spot 
was utilized. The protocol outlined by Shevchenko et al. in 2007 was used for this 
101
.  
Gel spots of interest were excised from the gel under a laminar flow hood, cut into 1 x 
1mm pieces and placed into a clean microcentrifuge tube.  These gel spots were 
rinsed in 500µL milliQ water to remove any particulates. They were then spun down 
in a benchtop microcentrifuge for 30 seconds. Water was removed and gel pieces 




Reduction and alkylation was accomplished by first removing the acetonitrile.  
Spots were then incubated at 56° with a fresh solution of 10mM dithiothreitol in 
100mM ammonium bicarbonate (NH4HCO3) for 30 minutes. After the tubes had 
cooled down to room temperature, 100µL of neat acetonitrile was added to the 
solution and they were incubated for 10 minutes.  All of the solution was removed 
and a fresh solution of 55mM iodoacetamide in 100mM NH4HCO3 was added and 
tubes incubated in the dark at room temperature for 20 minutes.  As with the 
reduction step, 100µL of neat acetonitrile was added and tubes incubated for 10 
minutes.  After the gel pieces had shrunken, all of the liquid was removed and they 
were destained. 
Destaining involved incubating the gel pieces with occasional vortexing in a 
100 µL 1:1 (vol:vol) solution of 100mM NH4HCO3/neat acetonitrile for 30 minutes 
or longer.  Five hundred microliters of neat acetonitrile was then added to this 
solution and the gels incubated with occasional vortexing until the gel pieces were 
almost entirely white/clear/opaque.  This took between 10 minutes to 1 hour 
depending on the original intensity of the staining.  The solution was removed and 
after assuring that the gel pieces were dry (from the acetonitrile), they were digested 
with trypsin. 
Trypsin digestion was achieved by first adding sufficient trypsin buffer 
(13ng/µL trypsin in 10mM NH4HCO3 with 10% (vol/vol) neat acetonitrile) on the gel 
spot pieces to cover them (usually around 75µL buffer).  They were incubated in this 
buffer in an ice bucket for 30 minutes.  At this time, if there was area of the gel spot 




The gel spot pieces were incubated an additional 90 minutes on ice.  At this time, 
15µL of NH4HCO3 buffer was added and the gel spots placed in an incubator at 37° 
overnight. To extract the peptides, a 1:2 (vol/vol) of extraction buffer (usually 150µL 
extraction buffer, which consists of 1:2 (vol/vol) 5% formic acid/acetonitrile) was 
added to the digest.  This mixture was then incubated at 37° on a shaker for 15 
minutes.  The microcentrifuge tubes containing the gel pieces were then spun briefly 
(30 seconds) in a benchtop microcentrifuge at 7000rpm.   The extracted digest was 
removed with a fine gel-loader pipette tip and placed in a clean labeled tube and 
stored at -20°C until analysis on the LTQ-Orbitrap. 
    
Extraction of Whole Proteins from Gels 
Duplicate gels of each harvest and cell line were initially developed in order 
to have a gel available for protein extraction as well as one for trypsin digestion.  
Proteins were extracted following the protocol previously described by our 
laboratory
1
 and originally developed by Mirza et al 
1; 102
.  This protocol involves first 
cutting the gel spots of interest from the gel with a clean razor blade and placing them 
in a labeled microcentrifuge tube.  The spots are first washed for a minimum of one 
minute with 500µL HPLC grade water in order to remove any debris from the gel.  
Water was then removed and the excised gel pieces vortexed for 10 minutes in 10% 
acetic acid.  The volume of this solution depended on the size of the gel spot however 
as a rule enough solution was used to cover the spot.  After the removal of the acetic 
acid solution, the gel spots were washed 3 times with 500µL water for approximately 




vortexing in neat acetonitrile for 20 minutes.  The volume was again dependent on the 
size of the gel spot, but averaged 200µL per spot.  The acetonitrile was removed after 
20 minutes and the gel spots washed in 500µL water for approximately 1 minute 
each.  The gel spots were then washed with HPLC grade methanol for 20 minutes 
with occasional vortexing.  The solvent was again removed and the gel piece washed 
with HPLC grade water for 1 minute.  The gel pieces were then each dipped into a 
solution of formic acid:water:isopropanol (FWI) (1:3:2, v/v/v) for between 30 
minutes to 4 hours depending on the staining intensity of the spot.  This final 
destaining solution was retained in clean labeled tubes for each spot to verify if there 
was protein loss in this step as this solution has also been shown to extract protein 
from gels.  After the gel pieces were colorless, the gel spots were washed in water 
again and moved to clean labeled microcentrifuge tubes.  They were then allowed to 
partially dry either on the bench top or under a laminar flow hood.  The gel spots 
were crushed into small pieces and the proteins extracted by adding 30µL of 
extraction solution, 0.1% trifluoroacetic acid: acetonitrile (1:1, v/v) to each tube and 
vortexing them overnight (or a minimum of 5 hours).  The following morning, the 
microcentrifuge tubes containing the extracted proteins were centrifuged in the 
benchtop microcentrifuge at 10,000rpm for 30 seconds to ensure the extraction 
solution could be collected at the bottom of the tube.  A clean gel-loader pipette tip 
was used to collect the extracted protein solution from each spot and they were stored 
in a clean labeled Lo-bind™ Eppendorf tube at -20° until further analysis.  The 
crushed gel spot material was also stored at -20° for each gel spot for further 




When it became apparent that more material (protein) would be required for 
molecular mass determination with the ESI-Orbitrap, not only were additional 2-D 
gels prepared to collect replicate spots but also stored crushed gel spots were re-
extracted with the extraction solution (no destaining or washing prior to additional 
extraction).  Small amounts (2 to 3µL) of the material from each extraction were 
evaluated with MALDI to compare the new extraction to the older extractions.  
Extractions/re-extractions from a total of seven gels was combined for analysis on the 
ESI-Orbitrap. 
Detection 
MALDI (Intact Protein) 
 Intact proteins were evaluated with the Shimadzu-Axima CFR + MALDI-
TOF instrument equipped with a nitrogen laser at a wavelength of 337nm to ensure 
that protein was in fact present.  The methods described by this laboratory previously 
were used 
1
.  A MALDI matrix was prepared with 10mg/mL sinapinic acid in 50% 
acetonitrile/1% trifluoroacetic acid (matrix solution).  Solutions were also prepared 
with 5% Triton-X 100.  For each sample, 1µL protein extract was mixed with 1µL of 
either the standard matrix solution or the detergent-containing matrix solution in a 
clean, labeled tube.  A method known as the sandwich method was used to spot these 
samples on a clean MALDI plate.  This was achieved by first spotting the plate for 
each sample with 0.5µL of the MALDI matrix.  After allowing this to dry, 1µL of the 
sample was spotted on top and allowed to dry and then followed by 0.5µL of the 
MALDI matrix.  The same methods were used to calibrate the instrument prior to 




calibration kit which included protein standards which ranged in mass from 
approximately6kDa to 66kDa.  The settings for the instrument were as follows; laser 
power: 100-115, over 200 profiles averaged; instrument method: linear mode, m/z 
range: 10,000 – 70,000. 
 
Electrospray Ionization (ESI) 
 All ESI samples were transferred into HPLC sample vials and placed in the 
autosampler of either a Shimadzu Prominence HPLC or an Accela HPLC.  Peptides 
from a preliminary investigation of the acid digested ribosomal proteins were 
analyzed by online ESI-MS/MS using a 1mm i.d. x 150mm column packed with 
reversed phase material (Biobasic-C-18, 300Å pore size, 5µ particle size) on the 
Accela HPLC running at a column flow rate of 40µL/min.  The HPLC solvent 
gradient (solvent A 0.1% formic acid/2.5%ACN versus solvent B 0.1% formic 
acid/2.5% HPLC-grade water/97.5%ACN) was linear and began at 10% Solvent B 
and rose to 85% over 65 min.  The HPLC solvent gradient was controlled by the 
XCalibur data system.   
  The LC-MSMS spectra were recorded on an LTQ-Orbitrap equipped with a 
Thermo electrospray ion source.  The following ESI parameters were used: capillary 
temperature, 275°C; spray voltage, 4kV; capillary voltage, 21V; sheath gas flow, 35 
arbitrary units; auxiliary gas flow, 8 arbitrary units.  The Automated Gain Control 
(AGC) target and maximum injection time for precursor ions were set at 5x10
5
 and 
250ms respectively for precursor scans, while for MS/MS they were set at 5x10
4
 and 




ion trap and MS/MS analysis for every precursor scan.  Precursor ions were scanned 
between m/z 350 and 2000.  Precursor ions were isolated with a 3Da window and 
fragmented by low energy collisions with He gas for 30ms with normalized collision 
energy of 35 arbitrary units.  Selected ions were excluded for the subsequent 10s for 
the S. cerevisiae sample and between 10-90s for the MCF7 samples (MXR and 
MXS).  High resolution analysis (30,000 at m/z 400) of both precursor and product 
ions were determined using the Orbitrap. 
  Analysis of trypsin digests of the ribosomal proteome and the HPLC fractions 
were optimized under electrospray conditions of 50µL/min using the Shimadzu 
Prominence HPLC interfaced with the LTQ-Orbitrap via a Thermo ESI source.  
Samples were loaded onto a PepTrap 300Å C-18 pre-column at 5% solvent B for 10 
minutes for desalting.  Peptides were then eluted into an Agilent 5µ 300Å 15cm x 
1mm ID C-18 column.  ESI parameters used for the trypsin digested samples were: 
capillary temperature, 275°C; spray voltage, 4kV; capillary voltage, 35V; sheath gas 
flow, 35 arbitrary units; auxiliary gas flow, 10 arbitrary units.  The AGC target and 
maximum injection time for precursor ions were set at 5x10
5
 and 500ms respectively. 
The five most abundant ions were selected for CID in the linear ion trap and MS/MS 
analysis for every precursor scan.  Precursor ions were scanned between m/z 350 and 
2000 for one full set of HPLC fractions and between m/z 400 and 2000 for the second 
full set.  Precursor ions were isolated with a 2Da window and fragmented by low 
energy collision with He gas for 30ms with normalized collision energy of 35 




with high resolution analysis (60,000 at m/z 400) using the Orbitrap, while the linear 
ion trap was used for MS/MS analysis. 
 Intact protein analysis of the whole ribosomal proteome utilized the Accela 
HPLC system with a Waters X-Bridge C-18 (3.5µM particle size 300Å 4.6 x 250mm) 
column to separate the protein mixture over 130 minutes increasing acetonitrile from 
15% to 80%, while a portion of the HPLC effluent was diverted to the LTQ-Orbitrap 
equipped with a Thermo ESI source.  The remainder of the effluent was collected 
throughout the chromatographic separation for future analysis.  When ion activation 
was used (for top-down analysis), the five most abundant ions in each precursor scan 
were automatically selected for CID in the linear ion trap and MS/MS analysis.  
Precursor ions were scanned between m/z 400 and 2000.  Precursor ions were isolated 
with a 3Da window and fragmented by low energy collisions with He gas for 60ms 
with a normalized collision energy of 35 arbitrary units.  Selected ions were excluded 
for 30s.  High resolution analysis of both precursor (60,000 at m/z 400) and product 
(30,000 at m/z 400) ions were determined using the Orbitrap.  ESI parameters were: 
capillary temperature, 275°C; spray voltage, 4kV; capillary voltage, 15V; sheath gas 
flow, 35 arbitrary units; auxiliary gas flow, 8 arbitrary units; sweep gas flow, 5 
arbitrary units.  The AGC target and maximum injection time for precursor ions were 
set at 5x10
5








Nanospray Ionization (NSI) 
 All NSI samples were transferred into HPLC sample vials and placed in the 
autosampler of the Shimadzu Prominence HPLC.  Injections were made into the 
NanoLC interfaced with the LTQ Orbitrap mass spectrometer via either an Advance 
CaptiveSpray Plug-and-Play source or the ThermoFisher NSI Source. 
Analyses of in-gel trypsin digests of gel spots were optimized for NSI 
conditions of 400nL/min.  Samples were loaded onto a 0.3 x 5 mm
2
 PepTrap 300Å C-
18 precolumn in 5% solvent B (solvent A: 0.1% formic acid/2.5%ACN vs. solvent B: 
0.1% formic acid/2.5% HPLC-grade water/97.5%ACN) for 10 minutes for desalting.  
Peptides were then eluted into an Agilent (5µ 100Å 15cm x 0.075mm ID) C-18 
analytical column and separated with a linear gradient of solvent B (97.5% 
ACN/2.5%H2O/0.1% formic acid) over 35 minutes.  The HPLC gradient was 
controlled by the Thermo Fisher Scientific XCalibur® 2.0.7 data system.  Precursor 
ions were scanned between m/z 400-2000.  Survey scans were acquired in the 
Orbitrap with resolving power of 60,000 at m/z 400 and an AGC target level of 5x10
5
 
and a maximum injection time into the Orbitrap of 500ms.  The 5 most abundant ions 
were selected for CID in the ion trap.  Precursor ions were isolated with a 2Da 
window and fragmented by low collision energy with He gas for 30ms with 
normalized collision energy of 35 (arbitrary units).  NSI parameters used for the 
trypsin digested samples were: capillary temperature, 300°C; spray voltage, 1.8kV; 
capillary voltage, 35 arbitrary units.  Selected ions repeated 4 times over 45s were 




Automated peptide analysis of acid digested ribosomal proteins was carried 
out by online NSI-MS/MS on the Shimadzu NanoLC interfaced with the LTQ-
Orbitrap via the Advance CaptiveSpray Plug-and-Play source running at a column 
flow rate of 500nL/min.  Sample injections were loaded onto a 0.3 x 5mm
2
 Peptrap 
300Å C-18 precolumn for 15min at 5% solvent B (0.1% formic acid/2.5% 
H2O/97.5%ACN) for desalting.  Peptides were eluted into a 150 x 0.1mm analytical 
column (Grace Vydac, Deerfield, IL) and separated with a linear gradient of solvent 
B; 5-15% in 5 minutes, 15-70%B in 115min.  Survey scans were acquired in the 
Orbitrap with resolving power of 30,000 at m/z 400 and an AGC target level of 5x10
5
.  
The three most abundant ions were selected for fragmentation using CID in the linear 
ion trap.  Precursor ions were isolated using a 3Da window and fragmented by low 
collision energy with He gas for 30ms with normalized collision energy of 35 
(arbitrary units).  The product ion AGC target level was set to 5x10
4
 and fragment ion 
scans were acquired in the Orbitrap with resolving power of 15,000 at m/z 400.  NSI 
parameters used for the acid digested samples were: capillary temperature, 200°C; 
spray voltage, 1.6kV; sheath gas flow rate, 2 arbitrary units; capillary voltage, 32 
arbitrary units.  Dynamic exclusion parameters were set to exclude ions previously 
selected for fragmentation for 3 min. 
 Intact proteins extracted from gels spots were analyzed under NSI conditions 
of 800nL/min using the Shimadzu Prominence HPLC interfaced with the LTQ-
Orbitrap via the Advance CaptiveSpray Plug-and-Play source.  Samples were loaded 
onto a 0.3 x 2.5 mm
2
 TARGA Piccolo 5µ C-18 precolumn (Higgins Analytical, 




eluted into a PLRP-S capillary column (150mm x 0.1mmID 5µ particle size, 1000Å 
pore size) and separated with a linear gradient of solvent B (solvent A: 0.1% formic 
acid/2.5%ACN vs. solvent B: 0.1% formic acid/2.5% HPLC-grade 
water/97.5%ACN) over 40 minutes.  The HPLC gradient was controlled by the 
Thermo Fisher Scientific XCalibur® 2.0.7 data system.  Ions were scanned between 
m/z 400-2000.  Survey scans (4 microscans/survey scan) were acquired in the 
Orbitrap with resolving power of 60,000 at m/z 400.  The 3 most abundant ions were 
selected for CID in the linear ion trap and fragment ion scans were acquired for each 
precursor ion in the Orbitrap with a resolving power of 30,000 at m/z 400.  Precursor 
ions were isolated using a 5Da window and fragmented by low energy collision with 
He gas for 60ms with normalized collision energy of 35 (arbitrary units).  NSI 
parameters used for the intact protein samples were: capillary temperature, 200°C; 
spray voltage, 1.6kV; sheath gas flow rate, 2 arbitrary units; capillary voltage, 32 
arbitrary units.  Reduced detection delay was used to improve protein detection.  An 
in-source voltage of 6V was used to knock off salt adducts or impurities from the 
protein samples.  Selected ions that were identified 3 times over 45s were excluded 
for the next 45s. 
 
Bioinformatics 
 Analyses of .RAW data files using Mascot© (Matrix Science Ltd., London 
UK) searches required files to be converted first to .mgf files.  This was accomplished 
in one of two ways; Thermo Proteome-Discoverer™ (ThermoFisher, San Jose CA) or 




Spectra obtained from the trypsin tandem mass spectral analysis of the 
ribosomal peptides were searched in collaboration with Professor Nathan Edwards at 
Georgetown University, on his network of computers using PepArML, a meta-search 
engine capable of machine learning which provides a single user interface to seven 
commonly used search engines.  This system allows for confident peptide assignment 
as well as the detection of peptides that would otherwise be missed when using only 
one search engine, as it combines the results of searches across Mascot, Tandem, 
Tandem with K-score and S-Score scoring plugins, OMSSA, Myrimatch and InsPecT 
103
. 
Mascot searches alone were also used for the bottom-up analyses of trypsin 
digests.  Searches were carried out specifying trypsin.  Up to 5 missed cleavages were 
allowed with precursor tolerance of 25 ppm and product ion tolerance of 0.6 Da.  
ESI-TRAP was selected for fragment specificity. Variable modifications were 
selected to include N-terminal acetylation, N,Q deamidation, M oxidation and S,T,Y 
phosphorylation.   
Peptides generated from acid digestion were analyzed as previously described 
2
.  Spectral files were processed using ProSightPC 2.0 provided by Professor Neil 
Kelleher, University of Illinois, which is now commercially available from 
ThermoFisher. Each .RAW file was processed in High Throughput mode.  Spectra 
were decharged with cRAWler using the THRASH algorithm. A FASTA format 
protein sequence database of 79 human ribosomal proteins was extracted from an in-
house Ribosomal Protein Gene Database and the IPI human database and configured 




Mass mode using a 2.5 Da precursor window based on the peptide monoisotopic 
mass.  An additional search, using a loose precursor window of 250 Da, was carried 
out to look for evidence of post-translationally modified peptide isoforms.  
ProSightPC’s Sequence Gazer tool allowed for manual investigations of significant 
identifications, when sufficient b and/or y ions were matched despite discrepancies 
between the predicted precursor mass and the observed mass. The sequence positions 
of the matched b and/or y ions helped to localize the mass-shift from putative PTM’s 
and single amino acid substitutions
104
.  Mass tolerance for fragment ions was set at 15 
ppm.  False discovery rates (FDR) were calculated using a randomly shuffled version 
of the ribosomal protein sequence database previously described 
64
.  
Mascot searches were also used to analyze the acid digest data.  Searches were 
carried out specifying “no enzyme”.  Up to 9 missed cleavages were allowed for acid 
digests with precursor tolerance of 10 ppm and product ion tolerance of 0.05 Da.  
ESI-TRAP was selected for fragment specificity. Variable modifications were 
selected to include N-terminal acetylation, N,Q deamidation, M and H oxidation and 
S,T,Y phosphorylation. 
Molecular ions and fragment data generated from top-down analyses of the 
ribosomal proteome were analyzed using similar methods as those used for acid 
polypeptides.  ProSightPC 2.0 was used to process spectral files.  Each .RAW file 
was processed in High Throughput mode.  Spectra were decharged with cRAWler 
using the THRASH algorithm. A FASTA format protein sequence database of 79 
human ribosomal proteins was extracted from an in-house Ribosomal Protein Gene 




using a 250 Da precursor window based on the protein monoisotopic mass to include 
the possibility of PTMs.  ProSightPC’s Sequence Gazer tool allowed for manual 
investigations of significant identifications, when sufficient b and/or y ions were 
matched despite discrepancies between the predicted precursor mass and the observed 
mass. The sequence positions of the matched b and/or y ions helped to localize the 
mass-shift from putative PTM’s and single amino acid substitutions.  Mass tolerance 
for fragment ions was set at 15 ppm. 
This information was coordinated with molecular masses determined from 
whole protein analyses to identify and locate modifications.  With analyses of the 
spectra produced from repeated injections, protein identification and high coverage 
was accomplished.  To provide additional verification of the protein isoform, the 
chemical formula of the protein (along with any proposed modifications) was used to 
create a theoretical isotope envelope with Thermo Qual Browser (part of the Thermo 
Fisher Scientific XCalibur® 2.0.7 Software package) and compared with the highly 
resolved deconvoluted (with Thermo Xtract®) isotope envelope of the observed 
protein isoform.  These efforts allowed us to characterize modifications of these 











Chapter 3: Results 
This research project successfully characterized the modifications in altered 
ribosomal proteins of drug resistant and drug susceptible precursor MCF7 breast 
cancer cell lines.  As will be discussed, the altered proteins characterized by this study 
play integral roles in the ribosome in protein synthesis.  We suggest based on our 
results and the research of other scientists that the plasticity observed in our cancer 
ribosomes/ribosomal proteins is possibly a natural mechanism in eukaryotic cell 
development and survival that is utilized by our ribosomes to survive exposure to 
chemotherapeutic drugs by altering their structure during translation. 
  
Ribosome Isolation 
Improvements in the protein yield observed from ribosome isolation and  
protein extraction from the whole ribosome was accomplished through modifications 
of protocols previously established in our laboratory 
1
.  Modifications to our original 
protocol occurred in the final centrifugation step where a swinging bucket rotor was 
observed to improve the quality and size of the ribosomal pellet when compared with 
that of the fixed angle rotor previously used (See Table 3.1).   
For each harvest of the cell lines, flasks were seeded at the same time and 
their growth monitored.  Harvests for MXR and MXS which were compared 1:1 with 
each other (either by gel array or HPLC) and were completed as close together as 
possible (in 3 of 4 cases they were harvested one day apart).  Protein concentrations 
for both cell lines in a set were determined using a Bio-Rad RC/DC protein assay.  




the commonly used bovine serum albumin (BSA).  This allowed for the standard 
protein in the assay to more closely mimic the amino acid composition of the 
ribosomal proteins. In general, a higher number of cells were harvested from the 
MXS cell line with each harvest when compared with the MXR cell line (see Fig 3.1).  
To compensate for this discrepancy, a larger number of flasks of the resistant cell line 
were seeded and harvested to ensure enough material from each was collected. 
 
 




Fixed Angle Rotor 1.406 0.46 
Swinging Bucket Rotor 1.543 1.52 
 
 
Table 3.1 Average cell pellet weight (wet weight in g) and MXR protein 
concentration before and after change in protocol illustrates that after the 







Figure 3.1 Protein concentrations of MXR and MXS as determined by Bio Rad 
RC/DC protein Assay.  
The cell pellet weight (shown in Table 3.1) and protein yield in rehydration buffer 
(for gel arrays) of the MXR cell line was initially low (as seen in A) and compensated 
for by an increase in the number of flasks seeded with MXR per harvest (B) and the 
use of a swinging bucket rotor for ribosomal pellet isolation 
 
HPLC fractionation of ribosomal proteins 
Consulting previous studies that involved the HPLC fractionation of 
ribosomal proteins 
72; 73; 91; 105; 106; 107; 108
 it was determined most prudent to test both 
C-4 and C-18 columns for their efficacy of resolving the MCF7 ribosomal proteins.  
In addition to different resins, acetonitrile gradients were tested with the standard 
protein mixture and yeast ribosomal proteins for their effectiveness.  An assessment 
of time of the gradient run versus the cost/benefit of protein resolution was 
considered.  Twelve gradients in total were tested before the following gradient was 
decided upon; (1) 0 – 83 min; 15 – 95% ACN, (2) 83 – 93 min; 95% ACN, (3) 93 – 
94 min; 95 – 15% ACN, (4) 94 – 113 min; 15% ACN.  Approximately 10.5nmol of 




Fractions were manually collected every minute beginning at 5 minutes until 
60 minutes.  At 60 minutes, fractions were subsequently collected every 5 minutes 
until 80 minutes at which point one fraction was collected every ten minutes.  Typical 
UV chromatograms for both standard proteins and ribosomal proteins are seen in 
Figures 3.2 and 3.3 respectively.  Each fraction was aliquoted for bottom-up analysis 
and molecular mass analysis. 
Inspection of the whole proteins in each fraction using the MALDI-TOF 
revealed which fractions contained proteins.  Fractions containing proteins were 
digested in solution with trypsin to identify protein components and molecular mass 
measurements were made with ESI-LTQ-Orbitrap on the whole protein fraction 





Figure 3.2 UV chromatogram of the mixture of four standard proteins 
The mixture consisted of lysozyme, ribonuclease A, cytochrome C and myoglobin 














Detection of Proteins in HPLC fractions  
HPLC fractions were first evaluated with the Shimadzu-Axima CFR + 
MALDI-TOF instrument to ensure the presence of protein.  Yeast ribosomal proteins 
were first assessed to determine the sample application methods and instrument 
parameters best suited to fractions from different regions of the acetonitrile gradient.  
The m/z range initially examined by MALDI was 7k – 70k and then later changed to 
10k - 70k to avoid signal interference from low molecular weight contaminants.  As 
was to be expected, samples that eluted late in the gradient and which thus had a high 
acetonitrile concentration produced better spectra for many proteins when the 
MALDI matrix was mixed with 5% Triton-X 100 (Fig 3.4 – Fig 3.5).  When these 
methods were applied to the human ribosomal protein HPLC fractions, of the 





Fig 3.4 MALDI spectra without detergent 
MALDI spectra of MXR ribosomal protein 36 minute HPLC fraction 
spotted on MALDI plate with MALDI matrix (10mg/mL sinapinic acid in 




Fig 3.5 MALDI spectra with detergent 
MALDI spectra of MXR ribosomal protein 36 minute HPLC fraction 
spotted on MALDI plate with MALDI matrix (10mg/mL sinapinic acid in 




ESI-MS analysis of HPLC fractions 
Trypsin digestion 
Peptides generated from an in-solution digestion of the individual HPLC 
fractions were fractionated and analyzed using the LC-LTQ-Orbitrap.  The 5 most 
abundant ions were selected from each precursor scan for tandem MS analysis and 
MS/MS spectra were searched against the IPI human database as described in the 
Experimental section.  Initial runs showed extended elution profiles for certain 
peptide hits.  Alterations in the sample injection volume, gradient and dynamic 
exclusion parameters were used to minimize this along with exclusion lists. 
Ribosomal proteins identified in these HPLC fraction digests from the 
database search were compared with their theoretical isoelectric point 
(http://expasy.org/tools/) and mapped over time in the protein gradient.  Frequently, 




In the first LC-MS/MS analysis of the ribosomal protein HPLC fractions, 
peptides from 71 of the 79 ribosomal proteins were observed in the 36 fractions (not 
observed; RPS27, RPL26, RPL32, RPL37, RPL37A, RPL39, RPL41) however the 
sequence coverage for each protein was low, frequently with only 2 peptides 
confidently identified for an individual protein (data not shown).  The second LC-
MS/MS analysis utilized a slightly different gradient (shorter; changed from 95min to 
48min) and a total of 404 (346 non-overlapping) ribosomal peptides were confidently 
identified in the 56 fractions, corresponding to 57 ribosomal proteins.  An example of 
a total ion chromatogram from one of the HPLC fractions is shown in Figure 3.6.  
Sequence coverage of these proteins averaged 36.2% and ranged from 14% to 95% 
(See Table 3.2).  In order to improve sequence coverage and discovery of post 
translational modifications, additional digestion methods were investigated. 
 
RT: 0.00 - 47.98




















































Figure 3.6 The Total Ion Chromatogram from the 28 minute HPLC fraction that 
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  Table 3.2 Ribosomal proteins identified by 2 or more peptides in a single LC-
MS/MS analysis of the HPLC fractions based on PepArML 
 
Whole Ribosomal Proteome 
Acid Digestion 
An alternative approach to digesting the ribosome and improving sequence 
coverage was utilized by the microwave accelerated acid digestion of the whole 
human ribosomal proteome.  Both ESI and NSI (NSI-Orbitrap analysis will be 
discussed later) were utilized in the automated peptide analysis of acid digested 
ribosomal proteins as described in the Experimental section.  For ESI-Orbitrap 
analysis, 5 injections of acid digested MXR ribosomal peptides were combined to 
confidently identify 217 distinct peptides corresponding to 63 of the 79 ribosomal 
proteins.  Seventy one peptides were identified as having masses above 3kDa, with 
charges as high as 11+.  An example of one such peptide, in this case from RPSA, 






Figure 3.7 Precursor spectrum of the 5604Da peptide confidently identified by 






Figure 3.8 Product ion spectrum and decharged product ion spectrum of the 




Intact Mass Measurements of Human Ribosomal Proteins 
Molecular ion measurements of intact ribosomal proteins were obtained using 




ribosomal proteins as described in the Experimental section.  Molecular mass 
measurements of the most abundant protein components in the HPLC fractions were 
matched with proteins confidently identified by in-solution digestion of the 
corresponding fraction (as determined by both PepArML and/or Scaffold).  Abundant 
molecular ions which did not match proteins identified in the in-solution digestion 
(with 2 or more peptides) were compared with those proteins identified in the fraction 
with one confidently identified peptide; if the molecular ion exactly matched the 
theoretical mass of the protein, it was accepted as identification.  For example; RPS29 
was identified in the 23 minute fraction by one peptide and the theoretical molecular 
mass of RPS29 is 6544.27 which is nearly identical to the observed mass of 6544.28. 
This technique allowed for the identification of 37 proteins not including 
isoforms of individual proteins.  Protein modifications were observed that have been 
confirmed by the investigations conducted in this lab, by the bottom-up data from the 
LC fractions and/or the in-gel digestions (see Table 3.3), or by other published 
research on human ribosomal proteins.  For example, a study of these MXR proteins 
conducted previously in this lab
1
 made the observation of a 47Da ± 5Da increase of 
RPL11 found in spot #25.  The bottom up research conducted in the current 
investigation of these ribosomes has revealed that this mass change can be attributed 
to an N-terminal acetylation.  Another protein, RPL31 was found in the previous 
study to lose several hundred Daltons from its theoretical mass.  This same protein 
was observed with the same loss of mass in an HPLC fraction of this investigation 
with 48.8% sequence coverage and 11 unique peptides at the 99.9% cut off criteria 






 or the current in solution digestion data were able to confidently detect the 
N-terminal end of this protein.  This suggests the possibility of an N-terminal 
truncation.  If the first 3 amino acid residues on the N-terminal end were truncated, a 
protein that would originally be expected to weigh 14459.95Da is now theoretically 
expected to weigh 14160.82Da.  The deconvoluted experimental mass observed in the 
LC fraction was 14162.78Da.  The gel extracted mass observed previously in this lab 
by MALDI-MS
1
 was 14183 ± 5 Da (Refer to Table 3.3).  The difference between the 
MALDI-MS and the experimental mass determined by LC-ESI-Orbitrap is evidence 
of a sodium adduct (+21), a common artifact observed with MALDI-MS.     
Protein isoforms were also noted in the HPLC fractions.  For example, RPS25 
was observed in two different fractions, once with its N-terminal methionine and once 
without.  Most of the protein isoforms of interest were identified in the HPLC 
fractions as well as the gel extracted protein.  For example, one of the RPS10 
isoforms was identified via the trypsin digestion in the fraction collected at 31 
minutes (See Fig 3.9, 3.10, and 3.11) and the molecular mass observed corresponded 









Figure 3.9 Mascot search results for the fraction collected at 31 minutes when 
searched against the IPI human database.  RPS10 was found to be the most 





Figure 3.10 RPS10 containing fraction TIC (inset) and ESI-Orbitrap MS 









Figure 3.11 Deconvoluted mass spectrum of the HPLC fraction collected at 31 
minutes.  Notice the abundant mass shown at 18952.91 which is one of the 
RPS10 isoforms found in the gel extracted experiment (spot 29; Refer to Figs 













RPL36A/RPL36a mass +oxidation 
(Met loss) 





20 RPL26 17255.56 17256.53 65.52 
21 RPL24 17775.92 17777.85 59.24 
22 RPL27 (Met loss) 15663.73 15665.67 43.38 
22, 23 RPL37a (Met loss) 10141.45 10142.41 38.04 
22 RPS29 (Met loss) 6544.27 6542.23 35.71 
22, 23 RPL38 (Met loss) 8084.7 8085.69 60 
23 RPL28 (Met loss + acetyl) 15655.66 15657.59 53.28 
24 RPL35A (Met loss + acetyl) 12445.76 12447.71 45.45 
24 RPSll (Met loss + acetyl) 18337.99 18339.94 56.33 
24 RPL31 (loss of 1st 3 N-terminal AA) 14160.82 14162.78 48.8 
25 RPS24 (+ acetyl) 15461.46 15464.33 30 
25 RPS23 (+ oxidation) 15689.69 15690.55 55.94 




26 RPL27A (Met loss + oxidation) 16443.02 16444.87 56 
26 RPL18A 20758.93 20760.72 48.86 
26,27 RPS19 (Met loss) 15926.52 15927.46 51.03 
27 RPL17 (Met loss) 21263.32 21265.24 45.11 
27 RPL23 (Met loss + acetyl) 14773.05 14775.01 58.57 
27 RPL22 (Met loss) 14653.79 14655.75 42.19 
27 RPL10 (Met loss) 24468.86 24470.82 28.26 
28 RPL23A (Met loss + acetyl) 17603.13 17604.10 46.84 
28 
RPL23A (Met loss + acetyl + 
phosphorylation +2 oxidation) 
17717.1 17719.10 46.84 
28 RPS25 (Met loss + formyl) 13636.67 13638.67 38.4 
28 RPS27 (Met loss + acetyl) 9369.82 9370.83 40.48 
28 RPL30 (Met loss) 12649.72 12651.69 59.13 
29 RPS16 (Met loss) 16311.02 16314.00 47.26 
29 RPL11 (Met loss + acetyl) 20162.61 20163.60 64.97 
29 RPS15 (Met loss + acetyl) 16948.17 16949.08 18.62 
30 RPL32 (Met loss) 15725.79 15727.72 52.29 
30 RPL18 (Met loss) 21501.06 21500.95 44.68 
31 RPS10 (2 dimethyl) 18952.97 18952.91 40 
31 RPS13 17089.64 17090.62 45.7 
33 RPL13A (Met loss + acetyl) 23485.68 23486.30 38.92 
34 RPS12 (Met loss + Acetyl) 14422.47 14423.45 65.91 
35 RPL9 21860.83 21862.80 60.42 
35 RPS25 (2 oxidations) 13771.71 13774.61 40 
36 RPSA (Met loss + Acetyl) 32760.45 32764.43 77.39 
37 RPS3 (Met loss + acetyl) 26598.46 26598.42 69.14 
37 
RPS3 (Met loss + acetyl + 
phospho+oxidation) 
26694.44 26698.46 69.14 
37 RPS3 (Met loss) 26556.44 26.00 69.14 
 
 Table 3.3 Proteins observed in HPLC fractions and their corresponding 





Fragmentation of Intact Ribosomal Proteins 
The examination of the whole ribosomal proteome also included additional 
analyses of high resolution mass measurements with fragmentation products of the 
proteins.  As described previously, ProSightPC 2.0 was used to decharge the spectra 
of the precursor and fragment ions and to search the MS/MS spectra.  A custom 
database of the 79 human ribosomal proteins was used for this search however the 
data was also searched against the IPI human protein database to ensure confidence in 
the ribosomal protein identifications.  One analysis of each cell line was conducted in 
this fashion and from these two sample runs, a total of 18 proteins were identified 
excluding isoforms of the individual proteins.  Variations of the observed proteins 
included loss of N-terminal methionine, acetylation and oxidation.  For example, 
RPS23 was observed with and without oxidation (with oxidation in the MXR cell 
line).  It should be noted that the analysis of rat fibroblast small subunit ribosomal 
proteins in the Ahn lab also indicated two forms of RPS23 which differed in mass by 
15.9 mass units (proposed as containing either an internal methylation or 
hydroxylation; oxidation considered less likely since corresponding sequence lacked 
methionine).  A table of the observed proteins is found in Table 3.4.  An example of 
one of the proteins identified with an N-terminal Met loss and an acetylation (N-





RT: 11.42 - 137.26































































Base Peak F: FTMS + p 
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Figure 3.12 Base peak chromatogram of the top-down analysis of the human 
MXR ribosomal proteome.  The RPS11 protein was observed in the peak seen at 
65.28 minutes 
 
Top_down_MCF7MXRP_protein_top5_msms_new_method #4268-4287 RT: 65.14-65.35 AV: 4 NL: 9.63E5
F: FTMS + p ESI Full ms [400.00-2000.00]
















































































Figure 3.13 Precursor spectrum of the confidently identified ribosomal protein 








Top_down_MCF7MXRP_protein_top5_msms_new_method #4193-4283 RT: 65.04-65.30 AV: 2 NL: 1.20E5
F: FTMS + p ESI d Full ms2 834.80@cid35.00 [215.00-2000.00]






































































Figure 13.14 MS/MS spectrum of the precursor ion at m/z 834.80 (22+ charge 
state, intact mass = 18341.01 Da) 
 
 
Top_down_MCF7MXRP_protein_top5_msms_new_method_XT_00001_M_ #1 RT: 1.00 AV: 1 NL: 1.95E4
F: FTMS + p ESI d Full ms2 834.80@cid35.00 [215.00-2000.00]







































Figure 13.15 Decharged MS/MS spectrum of Fig 3.14. ProSightPC 2.0 








Figure 13.16 Protein sequence of RPS11 showing the 15 fragmentation sites 












RPS11 8.36E-10 Met loss, N-acetyl-L-Ala 18337.99 18341.01 
RPS15A 1.30E-14 Met loss 14707.95 14708.00 
RPS16 4.00E-05 Met loss 16311.02 16313.04 
RPS19 7.60E-09 Met loss 15926.52 15928.48 
RPS20 3.00E-04 Met loss, N-acetyl-L-Ala 13281.30 13281.28 
RPS21 1.00E-04 N-acetyl-L-Met 9151.59 9154.59 
RPS23 4.90E-05 Met loss, oxidation 15689.69 15691.65 
RPS23 1.00E-04 Met loss 15673.70 15675.68 
RPS24 4.80E-07 Formylation 15449.46 15447.45 
RPS24 0.0009 N-acetyl-L-Met 15462.47 15464.43 
RPS27 7.60E-05 Met loss, Acetylation 9369.82 9371.80 
RPS28 1.10E-23 N-acetyl-L-Met 7882.22 7882.25 
RPL27 2.70E-12 Met loss 15663.73 15665.79 
RPL28 3.20E-05 Met loss, N-acetyl-L-Ser 15655.66 15656.66 
RPL30 3.50E-11 Met loss 12649.72 12652.69 
RPL32 1.10E-07 Met loss 15725.79 15728.72 




RPL35A 3.50E-08 Met loss, N-acetyl-L-Ser 12445.76 12447.68 
RPL35A 1.70E-08 
Met loss, N-acetyl-L-Ser, + 
18.08Da 
12445.76 12463.83 
RPL37A 1.10E-05 Met loss 10141.45 10140.44 
RPL38 3.50E-21 Met loss 8084.70 8086.71 
RPLP2 1.80E-07 +162.06Da 11662.86 11824.92 
           
Table 3.4 Proteins observed with top-down analysis of both cell lines (1 sample 
injection per cell line) 
 
nLC-Orbitrap Analysis of ribosomal proteins 
Acid digested Ribosomal Proteins 
As mentioned previously, automated peptide analyses of the acid digestion 
products of the ribosomal proteome were made using both ESI-MS and NSI-MS.  The 
nLC-Orbitrap analysis included 4 injections of the MXR peptides and 3 injections of 
the MXS peptides.  Data was processed using ProSightPC 2.0 and peptide 
identification accepted with an E-value of less than 1.0E-03.  There were similar 
retention times for shared peptides between the two cell lines however the MXS cell 
line contained approximately half as many matched spectra as the MXR cell line.  
The data was searched against a human ribosomal protein database as well as the IPI 
human database.  As there were no discernible differences in the non-ribosomal 
proteins discovered between the two cell lines, the difference in matched spectra is 
attributed to a probable error in determination of protein concentration in the MXS 
cell line.   
Ribosomal protein identifications overlapped between the cell lines with the 




unique to that cell line.  Across the seven injections, 366 distinct peptides were 
confidently identified including redundancies (where identified peptides differed only 
in the addition or removal of an N- or C-terminal Asp).  After removing redundant 
peptides, 276 peptide identifications remained.  Sixty five of the 79 human ribosomal 
proteins were identified by two or more peptides and 70 by one confidently identified 
peptide (See Appendix for a list of peptides).  Average sequence coverage was 46.2% 
for these 70 proteins.  Forty four percent of these peptides were identified as having 
masses above 3kDa, with charges as high as 12+.  An example of one such peptide, in 
this case from ribosomal protein RPL24, is found in Fig 3.17, 3.18 and 3.19.  This 
peptide was confidently identified by ProSightPC 2.0 with 15 fragments and an E-
value = 1.29E-21. 
 
 
Figure 3.17 Precursor spectrum of RPL24 peptide observed during nLC-
Orbitrap analysis of MXR ribosomal protein acid digest and theoretical vs. 










Figure 3.18 Product ion spectrum of precursor ion shown in Fig 3.17. The 
precursor ion chosen for this peptide was m/z = 736.74 and as a result, the mass 






Figure 3.19 Deconvoluted product ion spectrum of RPL24 peptide from AA 89-
156.  This peptide was confidently identified by ProSightPC 2.0 with 15 





  Gel Extracted Proteins 
Proteins were extracted from duplicate gel arrays and combined for LC-
Orbitrap analysis as described in the Experimental section.  HPLC columns packed 
with three different resins were tested for mass measurement/top-down analysis of the 
gel extracted proteins; C-18, C-4 and PLRP-S.  In addition to type of column, two 
sources and instrument parameters were tested.  The C-18 and C-4 columns were both 
manufactured by Agilent (0.1 x 150mm 5µ, 300Å pore size).  These columns were 
fitted to the Thermo NSI source with the dynamic NSI probe and an emitter 
purchased from New Objective, Inc.  The instrument was externally calibrated using 
the standard Thermo mixture (caffeine, MRFA, Ultramark 1600) and tuned with 
cytochrome C prior to sample analysis.   
The most effective combination which provided the data discussed henceforth 
used the Advance CaptiveSpray Plug-and-Play source.  Samples were loaded onto a 
0.3 x 2.5 mm
2
 TARGA Piccolo 5µ C-18 precolumn at 5% solvent B for 10 minutes 
for desalting.  Proteins were then eluted into a PLRP-S capillary column.  Not only 
was it found that this source/column and trap combination were an effective 
configuration but the specifications of the flow-rate and back-pressure for the loading 
of the sample onto the trap proved critical.  This was achieved by having the fused 
silica that loaded the trap (for desalting) of a larger inner diameter (0.025µm) than the 
fused silica on the other side of the trap (0.015µm).  In doing this, another advantage 
was that a small change in solvent concentration when the valve switched out of the 
trapping position (an intermittent increase in solvent B) would have less impact on 




A limitation of the Advance CaptiveSpray Plug-and-Play source is the fact 
that the capillary specific to that source is not to be used above 200˚C.  However with 
the ability to use the sheath gas (sheath gas flow rate set at 2.00 arbitrary units) and 
the tube lens voltage increased (175V), the capillary temperature was not an issue.  
The verification of this workflow came with the observation of identical masses of 
proteins seen in both the gel extracted proteins and the HPLC fraction molecular mass 
measurement of the same proteins.  An example of one such case is seen by 
comparing the spectra in Figure 3.20. 
 
 
Figure 3.20 Deconvoluted spectrum of the protein peak observed from the gel 
extracted protein identified as RPS10 (top) compared with the deconvoluted 




Two-Dimensional Gel Electrophoresis 
Sample Loading Methods 
Four different methods/conditions were tested for the loading of samples in 
the first dimension of the gel arrays.  All methods except the test of rehydration with 
Destreak
TM
 used an electrode wick dipped in 15mM DTT at the cathode end to 
provide a continuous influx of DTT which is a weak acid and as a result, migrates out 
of the basic part of the IEF gel.  The first method had previously been used in this lab 
for ribosomal protein visualization with gel array which involved in-gel rehydration 
of the sample (both passive and active loading) in standard rehydration buffer (7M 
urea, 2M thiourea, 2% CHAPS, 0.5% IPG buffer, 50mM DTT).  Both active and 
passive rehydration of the sample led to inconsistencies in the sample loading and 
streaking in the final gel image as seen in Fig 3.21.  The rehydration buffer was 
altered in subsequent gels to contain 15% IPA and 2.5% glycerol which further 
optimized the gel appearance but still resulted in some sample streaking (refer to Fig 
3.21).  A more traditional approach to working with basic proteins in IEF was then 
tested with cup loading of the sample at the cathode end of the IPG strip.  This proved 
to be the most effective method of sample loading with reproducible patterns seen in 
the gel arrays of the same cell line as seen in Fig 3.22.  All gels used in this 
comparative analysis were produced using cup-loading at the anode end with DTT, 





Figure 3.21 Image A shows an example of a gel produced with rehydration 
loading of the sample in standard rehydration buffer which led to streaking 
(both horizontal and vertical streaking were observed though vertical 
streaking is attributed to the second dimension). Image B shows an example 
of a gel produced with rehydration loading of the sample with modified 






Figure 3.22 Reproducibility of spot patterns in gel arrays of the same cell line 
(MXR in this case) when samples were loaded using cup-loading at the anode 




In-Gel Digestion and Protein Sequence Coverage 
Gel arrays of MXR ribosomes with proteins spots that had been annotated and 
identified previously in this lab
1
 were used as a reference for comparison to aid in the 
identification of protein spots (See Figure 3.23).  In-gel digestion was used to confirm 
the identities of the protein spots observed in the gels and to determine the 
modifications of the proteins in the spots of interest.  Spots chosen for in-gel 




lines (as determined by imaging software discussed in the next section) but also 




Figure 3.23 Annotated MXR gel of previous research
1
 compared with an 
annotated MXR gel from the current study.   
Gel (A.) on the left shows previously published work from this lab
1
 with spot 
annotation while gel (B.) on the right shows the current work using the same 
spot annotation 
 
Twenty three spots including spots found in differential abundance or unique 




peptides from more than one protein (spot 20; refer to Fig 3.23).  Identifications of 
proteins in nearby spots were considered to rule out the possibility of overlap from a 
neighboring spot.  When a neighboring spot could not assist in restricting the protein 
composition of a spot of interest, molecular masses of the extracted gel proteins were 
used in determining which protein was most abundant in the selected spot. 
Protein sequence coverage was ultimately determined by a combination of the 
information from the in-gel digestion, intact molecular mass of extracted proteins, 
and acid digestion data.  Modifications of the proteins were assigned exclusively by 
confidently identified peptides from the in-gel digestion of protein spots except for 
the non-acetylated form of the N-terminal end of RPS3 which was identified in the 
acid digestion data and confirmed by the intact molecular mass.  The twenty two 
spots have a combined digestion (acid and trypsin) sequence coverage which ranged 
from 50% to 99% shown in Table 3.5.  Peptides that were confidently identified by 
trypsin digestion only are shown in red, those confidently identified by acid digestion 
only are shown in blue and those confidently identified by both acid and trypsin 
digestion are identified by red with black outline text.  For the nine spots of interest 
(including one unchanging spot; spot #7) the sequence coverage ranged from 65% to 




































































































Table 3.5 Protein sequence coverage of twenty ribosomal proteins selected for in-
gel digestion in the MXR gel arrays is indicated above. Peptides that were 
confidently identified by trypsin digestion only are shown in red, those 
confidently identified by acid digestion only are shown in blue and those 




Table 3.6 Sequence coverage of the ribosomal proteins found in altered 
abundance between MXR and MXS using comparative densitometry 
 
Spot # Protein Name Percent Sequence Coverage 
6 RPS3 98 
7 RPS3 85 
8 RPS3 89 
25 RPL11 92 
26A RPL23A 65 
26B RPL11 81 
26C RPL23A 67 
29 RPS10 93 





Comparative Densitometry between MXR and MXS Cell Lines  
To provide confidence in the identification of altered proteins between the two 
cell lines, two imaging software programs were used concurrently to analyze the 
protein abundance profiles in the gel arrays, PDQuest™ from Bio-Rad and 
CompugenZ3™.  Both imaging programs controlled for normalization of the spot 
intensity between images to take into account differences between sample loadings.  
In addition, both programs allowed for the alignment of the gel arrays and the 
creation of a master image/registered image of averaged gels for each cell line.  Four 
gels of each cell line were used in order to create these master images for comparative 
densitometry.  Composite gel arrays were evaluated in this way between the cell lines 
indicating homologous spots that were increased or decreased in abundance greater 
than 2-fold or only observed in one cell line (on/off).  PDQuest™ also granted the 
additional option of a T-test comparison between the master images of the cell lines.  
Relative quantitation of the proteins was determined using the Compugen™ software.  
Figure 3.24 shows the composite 2-D gel maps of the MXS (left) and MXR (right) 
cell lines with Compugen™ spot assignment based on user defined parameters; 
Minimum spot area = 50, Minimum spot contrast = 20.     
All of these analyses were taken into account and both PDQuest™ and 
CompugenZ3™ agreed on 8 protein spots whose protein abundance was altered.  
Figures 3.25 and 3.26 each show the protein spots chosen as differentially abundant 
by CompugenZ3™ and PDQuest™ respectively.  Yellow circles in the Compugen™ 




cell line while blue circles indicate proteins found in higher abundance.  Red circles 
indicate protein spots which were only found in the MXR cell line.  Since PDQuest™ 
separated gel spots by on/off, >2-fold abundance and T-test results into different gel 
maps, one figure was created to show only those 8 protein spots shared with the 
Compugen™ analysis.  PDQuest™ spot notation in Fig 3.26 is as follows; yellow 
circles with no fill indicate proteins found in higher abundance in the MXR cell line 
while yellow circles with black fill indicate proteins found in lower abundance in the 
MXR cell line.  Red circles were added to indicate protein spots determined by 
PDQuest™ to be found only in the MXR gel arrays (those shared in common with 
CompugenZ3™ analysis).   
In-gel digestion allowed for the confident identification of these proteins as 
isoforms of RPS3, RPS10, RPL11 and RPL23A.  In-gel digestion also allowed the 
addition of a ninth spot, an additional isoform of RPS3, which served as a reference 
spot as it remained unchanged between the two cell lines.    In the case of the 
Compugen™ analysis, one of the differentially abundant RPS10 isoforms (spot #39) 
was considered to be unique to the MXR cell line while in the PDQuest™ analysis, 
this spot was classified as being greater than 2-fold more abundant in the MXR cell 
line.  As a result, this isoform was considered to be present in both cell lines however 
in significantly greater abundance in the MXR cell line.   A zoomed in image of each 
of these changes between the two cell lines is seen in Figures 3.27, 3.28, 3.29, and 
3.30.  Spots in these Figures are labeled following the color scheme used in the 
Compugen™ program.   Relative quantitation of the protein spots was determined by 





Figure 3.24 Composite gel maps of the MXS (left) and the MXR (right) gel 
arrays with Compugen™ assigned spots (maps were also manually inspected 













Figure 3.25 Overlaid gel image for comparative densitometry conducted by 
CompugenZ3™ and the sets of spots assigned which corresponded with proteins 
also found differentially abundant by PDQuest™ (Fig 3.26).  Blue circles 
represent proteins found in higher abundance in the MXR cell line, yellow 
circles represent those proteins found in lower abundance in the MXR cell line 





















Figure 3.26 Overlayed composite of MXR and MXS gels for comparison 
conducted by PDQuest™. Proteins that were in lower abundance in the MXR 
cell line are represented by yellow filled in circles, while those proteins in higher 
abundance are represented by yellow circles without fill.  Proteins found only in 
the MXR cell line are represented here by red circles.  The gel images on the 



























Figure 3.27 RPS3 protein abundance changes between the MXR and MXS cell 
lines. 
The yellow circle indicates a protein isoform that is found in lower abundance in the 
MXR cell line while the red circle indicates a spot which is novel to the MXR cell 
line (unmatched).  Spot number 7 indicated with the black circle is an RPS3 isoform 
















Figure 3.28 RPL11 protein abundance changes between the MXR and MXS cell 
lines. 
The yellow circle indicates a protein spot found in higher abundance in the MXS cell 









Figure 3.29 RPL23A protein abundance changes between the MXR and MXS 
cell lines. 
The yellow circle indicates a protein spot found in higher abundance in the MXS cell 
line while the blue circle indicates a protein which is found in higher abundance in 














Figure 3.30 RPS10 protein abundance changes between the MXR and MXS cell 
lines. 
The yellow circle indicates a protein isoform which was found in lower abundance in 
the MXR cell line while the blue circle indicates a protein isoform which was found 
in higher abundance in the MXR cell line. Spot 39 was considered to be unique 
(unmatched) to the MXR cell line by the CompugenZ3™ software program while it 
was considered to be in greater than 2-fold abundance in the MXR cell line based on 
the PDQuest™ software package 
 
 




Spot Name Protein Isoform MXS Cell  Line MXR Cell Line 
6 RPS3 1 0.45 ± 0.02 
7 RPS3 1 1 
8 RPS3 Not Present Present 
25 RPL11 1 0.23 ± 0.02 
26B RPL11 Not Present Present 
26A RPL23A 1 0.51 ± 0.02 
26C RPL23A 1 2.57 ± 0.10 
29 RPS10 1 0.53 ± 0.03 
39 RPS10 Not Present 
Present  
(> 2-fold PDQuest™) 
 
Table 3.7 CompugenZ3™ determined relative quantitation of protein isoforms 
with altered abundance between the two cell lines. Spot #39 was considered 
unique (unmatched) to the MXR cell line by CompugenZ3™ but labeled as a 






Protein Isoform Characterization 
Results of the gel-extracted molecular masses were integrated with in-gel 
digestion data, MXR acid digestion data, HPLC fraction molecular masses and HPLC 
fraction trypsin digestion data in order to fully characterize the protein isoforms found 
in the MXR cell line.  The initial step in the protein isoform characterization was 
determination of an approximate molecular mass with MALDI (this process also 
verified the presence of protein in the gel extraction solution).  An aliquot of the gel 
extraction solution consisted of MALDI matrix solvent (50%ACN/0.1% TFA) which 
was mixed 1:1 with MALDI matrix (10mg/mL sinapinic acid) in matrix solvent with 
5% Triton-100X (final concentration 2.5%) as described in the Experimental section 
and spotted on the MALDI plate using the sandwich method.  As was the case with 
the in-gel digestions, additional protein spots were selected for protein extraction for 
gel validation purposes.  Twenty three spots in all were examined with MALDI.  The 
change in mass from the theoretical mass was initially intended to be used as a rough 
guide for possible post translational modifications however it served as an early 
indication of what was later verified with the in-gel digestion analysis to be 
incomplete alkylation (with IAA) of many of the proteins.  Instrument settings were 
as described in the Experimental.  A table of the molecular masses observed with 

















MALDI Mass Delta Mass (Da) 
3 RPL6 1 32654 32792 138 
5 RPS3A 4 30042 28367 -1675 
6 RPS3 3 26728 26828 100 
7 RPS3 3 26728 26898 170 
8 RPS3 3 26728 26704 -24 
13 RPL8 4 28121 28095 -26 
15 RPS8 5 24359 24201 -158 
16B RPL13 1 24187 24335 148 
18 RPL10 8 24929 24954 25 
19 RPL13A 1 23503 23711 208 
20 RPS7 0 22126 22188 62 
20 RPL9 2 21977 21900 77 
24 RPL17 4 21494 21296 -198 
25 RPL11 iso1 4 20349 20385 36 
26A RPL23A 0 17563 17562 1 




40 (with Met) 
171 (without Met) 
26C RPL23A 0 17563 17671 108 
29 RPS10 0 18897 18991 93 
39 RPS10 0 18897 15922 -2975 




44 RPL23 2 14979 14954 -25 
45 RPL35A 1 12595 12559 -36 
46 RPL38 1 8144 8145 1 
53 RPL12 3 17990 18021 31 
 
Table 3.8 Whole proteins which were extracted from the gels were first 
evaluated with MALDI to verify the presence of sample.  The delta mass values 
were the first indication that there was incomplete alkylation of the proteins in 




Following MALDI analysis of the gel protein extracts, protein isoforms were 
characterized by comparison of their nLC-Orbitrap molecular mass measurements 
with information determined from the in-gel digestion data.  If it was determined that 
further information was required to determine the modifications of the protein in 
question, information gathered from the MXR acid digestion as well as digestion data 
and molecular masses observed during HPLC fraction analysis were also considered.  
One major issue which proved problematic with the molecular mass 
interpretation was the incomplete alkylation with IAA first observed with MALDI in 
cysteine containing proteins.  In RPS3 for example, more than one version of each 
protein isoform was observed containing between 0 – 3 carbamidomethylations.  
Depending on the modification(s) and number of artifactual methionine oxidations 
(from sample handling and storage), overlap between the protein isotopic envelopes 
on more than one occasion was observed.  Digestion data was found to support the 
incomplete alkylation of the proteins.  To simplify data interpretation, the most 




under the condition that this molecular mass agreed with earlier observations made 
regarding the protein in question (in-gel digestion, acid digestion, etc.).  As described 
previously, once a protein isoform with modifications was determined based on mass 
and digestion data, the high resolution deconvoluted isotope peaks of each protein 
was compared with the theoretical isotope envelope expected for the average mass of 
the amino acid composition of the given protein (along with any detected 
modifications; PTM or artifactual).  
In the instance of RPS3, three protein spots identified as numbers 6, 7 and 8 
were noted in the gel arrays corresponding to each protein isoform (See Figures 3.23 
and 3.37).  The sequence annotation of RPS3 has noted the loss of the initiator 
methionine and was observed to be the case with the digestion data analysis.  For spot 
#6, the most abundant experimental mass was 26598.45Da (the unalkylated form of 
the protein; supported by digestion data and HPLC fraction molecular mass), shown 
in the bottom of Figure 3.31.  The mass difference between the theoretical mass of 
RPS3 and the observed mass of spot #6 corresponded exactly with the addition of an 
acetylation/trimethylation.  Inspection of the digestion data revealed that the N-
terminal acetylated peptide of the protein had been detected in both the MXR acid 
digestion data and the trypsin digestion data as seen in Figures 3.32 and 3.33.  The 
theoretical spectrum corresponding to this protein with an acetylation is shown in the 
top panel of Fig 3.31.  The most abundant mass of the isoform of RPS3 observed in 
spot #7 was measured as 26897.52Da as seen in the bottom panel of Figure 3.35.  The 
presence of additional protein species in the sample resulted in some issues with 




oxidations (the result of sample handling and storage) as shown in Table 3.9, 
however, the most abundant mass contained three oxidations.  In-gel digestion data 
verified that the mass difference between the experimental mass and the theoretical 
mass was attributable to the addition of an N-terminal acetylation and one 
phosphorylation found on T221.  A comparison of the theoretical spectrum of all 
three oxidized species with the observed species is seen in Figure 3.34.  Figure 3.36 
illustrates the phosphopeptide observed for this protein.  The theoretical spectrum for 
the protein with the proposed modifications is shown in the top panel of Fig 3.35.  
Another isoform of RPS3 was detected in spot #8 at a mass of 26667.46Da as shown 
in the bottom panel of Figure 3.37.  This corresponded with the mass of the protein 
without any modifications except for 2 carbamidomethylations (without acetylation).  
This was further supported by examination of the acid digestion data which found the 
N-terminal peptide of RPS3 without an acetylation.  The theoretical spectrum for the 
protein with the proposed modifications is shown in the top panel of Fig 3.37.  The 
sequence coverage for all three isoforms is shown aligned in Figure 3.38.  A list of all 







Figure 3.31 Experimental spectrum of extracted RPS3 protein found in spot #6 
(bottom panel) compared with theoretical spectrum with the corresponding 




Figure 3.32 MS/MS spectrum of N-terminal acetylation of RPS3 identified from 
in-gel digestion.  Neutral water loss was noted in both this and the acid digestion 








Figure 3.33 Fragment ions identified during nLC-Orbitrap analysis of the MXR 
acid digest to confidently identify the N-terminal acetylation of RPS3 in spot 6 
and spot 7.  The A residue highlighted in red signifies the acetylation while the S 
residue highlighted in orange signifies that that fragment was dehydrated 





Figure 3.34 Theoretical (top panel) and observed (bottom panel) mass spectrum 
for RPS3 isoform found in spot #7 with 1, 2 and 3 methionine oxidations.  The 
lack of agreement is attributed to unidentified contaminating protein species 








Figure 3.35 Theoretical (top panel) and observed (bottom panel) mass spectrum 
for RPS3 isoform found in spot #7. Digestion data showed this isoform to contain 
an N-terminal acetylation (as seen in Figure 3.31 for spot 6), 3 oxidations (refer 
to Table 3.9), and a phosphorylation on T221 (refer to Fig 3.36) 
 
 
Table 3.9 As with many other gel extracted proteins, the molecular mass of spot 
#7 was observed with multiple oxidations.  The most abundant molecular mass 
for this RPS3 isoform contained 3 methionine oxidations.  These oxidations were 








Supporting peptides observed in bottom-up 
analyses w/ and without oxidation  
3  26897.52  26897.48  
K.-FVDGLMIHSGDPVNYYVDTAVR.-H, 
 K.-IMLPWDPTGK.-I,  
K.-GGKPEPPAMPQPVPTA-  
















Figure 3.36 MS/MS spectrum of the phosphopeptide found on T221 in the RPS3 
isoform found in spot 7 
 
 
Figure 3.37 Theoretical (top panel) and experimental (bottom panel) mass 





Figure 3.38 Sequence coverage observed for all three RPS3 isoforms. Underlined 
residues indicate a modification was observed 
 
 
Two spots in the gel arrays were identified as isoforms of RPL11 and labeled 
as spot #25 and #26B (see Fig 3.23 and 3.28).  There are two spliced variants of 
RPL11 noted in the currently accepted human ribosomal protein database 
(UniProtKB/Swiss-Prot; P62913-1, P62913-2) which differ in sequence by one amino 
acid (Q in position 3 in isoform 1 or the loss of Q in isoform 2).  Both of these 
variants of RPL11 were observed in the in-gel digestion data and the MS/MS spectra 
of the identifying peptides are shown in Figures 3.40 and 3.42. The initiator 
methionine is noted in the database sequence annotation as being removed and was 
observed as such in the digestion data.  Observations of a mass difference between 
the most abundant nLC-Orbitrap experimental molecular mass and the theoretical 




acetylation/trimethylation and were noted in spot #25 with a mass of 20161.61Da 
seen in Figure 3.39.  This mass change was supported with the in-gel digestion data 
by the discovery of the N-terminal end of the protein with an N-acetyl-L-alanine 
(shown in Figure 3.40).  Cysteine containing peptides were observed in the digestion 
data with and without carbamidomethylation (4 in total).  The other isoform of 
RPL11 was labeled as spot #26B.   The most abundant mass was observed as 
20410.62Da and is shown in Figure 3.41.  Inspection of the in-gel digestion data 
revealed that this variant of RPL11 is isoform 2 contained 4 acetylations, 1 
deamidation and 1 oxidation.  The deamidated peptide ion precursor was manually 
inspected to determine the validity of the assignment of this modification.  Although a 
possibility exists that the deamidation could be misassigned, the precursor ion was 
found to align more closely with the expected ion of the deamidated peptide versus 
the unmodified peptide.  This can be seen in Figure 3.42.  MS/MS spectra of two of 
these peptides are shown in Figures 3.43 and 3.44.  Sequence coverage of the two 
RPL11 isoforms aligned is shown in Figure 3.45.  All modified peptides of RPL11 





Figure 3.39 Theoretical (top panel) and experimental (bottom panel) mass 
spectrum of isoform 1 of RPL11 observed in spot 25 with an acetylation (refer to 
Fig 3.40). This protein isoform was not fully alkylated and was also observed in 
the HPLC fraction analysis 
 
 
Figure 3.40 MS/MS spectrum identified as the acetylated N-terminal end of 








Figure 3.41 Theoretical (top panel) and experimental (bottom panel) mass 
spectrum of RPL11 isoform 2 and the corresponding PTMs identified by 







Figure 3.42 Precursor ion (z =2+) spectrum identified as the acetylated N-
terminal end of RPL11 isoform 2 found in spot 26B compared with the 





Figure 3.43 MS/MS spectrum identified as the acetylated N-terminal end of 
RPL11 isoform 2 found in spot 26B.  This peptide was only observed with a 








Figure 3.44 MS/MS spectrum identified as lysine acetylated peptide of RPL11 






Figure 3.45 Sequence coverage of RPL11 isoforms aligned. Underlined residues 
indicate a modification was observed.  Both isoforms of RPL11 were observed 
(isoform 1 in spot 25 and isoform 2 in spot 26B; distinguished by residue 3 in 
sequence).  Observed acetylations have been noted in the literature
109; 110; 111
 
previously (A2, K52, K67 & K85) except N-terminal acetylation of isoform 2. 







Two altered spots were identified in the gel arrays as isoforms of RPL23A and 
labeled as spots #26A and #26C (see Fig 3.23 and 3.29). Sequence annotation of this 
protein notes loss of the initiator methionine and this was consistent with molecular 
mass measurements observed (the peptide corresponding with the N-terminal end 
however was not detected).  The most abundant molecular mass noted for spot #26A 
is shown in Figure 3.46 and was 17638.14Da.  Based on the theoretical mass of the 
protein and observations made with the in-gel digestion, this experimental mass 
corresponds with the addition of an acetylation (or trimethylation) and 2 methionine 
oxidations, all of which were discovered in the digestion data.  The MS/MS spectrum 
corresponding to the acetylation noted for this protein in spot#26A (also observed in 
#26C) is shown in Figure 3.47.  The MXR HPLC fraction mass measurement 
containing RPL23A was also found to contain this isoform (without the 2 oxidations).  
The theoretical and experimental mass of the HPLC fraction isoform corresponding 
to the protein found in spot 26A is shown in Figure 3.48.  The isoform of RPL23A 
discovered in spot#26C was found to be most abundant experimentally at a molecular 
mass of 17718.18Da and is shown in Figure 3.49.  Modifications that support this 
mass change from the theoretical mass include the acetylation determined to be 
present in both isoforms (see Fig 3.47) in addition to a phosphorylation detected in 
the MXR HPLC fraction digestion and two artifactual oxidations (1 methionine and 1 
histidine) detected in the digestion data (detected by both in-gel and HPLC fraction 
trypsin digestion).  As discussed with spot 7 of RPS3, these oxidations are attributed 




Figure 3.50.  The sequence coverage for both RPL23A isoforms is shown in Figure 




Figure 3.46 Theoretical (top panel) and experimental (bottom panel) MS of 
protein observed in spot 26A identified as RPL23A and determined by bottom-






Figure 3.47 MS/MS spectrum of acetylated peptide from RPL23A identified in 




Figure 3.48 Spot #26A RPL23A protein isoform was also observed in the LC 
analysis (both fraction and top-down whole ribosomal proteome) with 
acetylation and without oxidation (therefore oxidation was attributed to sample 





Figure 3.49 Theoretical (top panel) and experimental (bottom panel) molecular 
mass observed for spot 26C identified as RPL23A by bottom-up analysis with 1 












Figure 3.51 RPL23A isoform sequence coverage; underlined residues indicate a 
modification was observed.  Both the S43 phosphorylation and the K70 
acetylation are noted in the Uniprot database as common modifications. 
Artifactual oxidations (resulting from sample handling) were observed on H73 
and M87 
 
The two remaining altered protein spots which were investigated in this study 
were found to be isoforms of RPS10 and labeled as #29 and #39 (see Fig 3.23 and 
3.30).  The most abundant molecular mass observed for spot #29 is seen in Figure 
3.52 and was 18952.91Da.  Examination of the digestion data for RPS10 revealed that 
aside from a 12 residue peptide found on the C-terminal end of the protein, there was 
complete sequence coverage.  A protein modification consistent with the mass change 
from the theoretical mass of the protein was not observed in the digestion data.  Noted 
in the sequence annotation for RPS10 is dimethylation of two arginine residues on the 
C-terminal end (R158 and R160), a modification found as a step in the incorporation 
of RPS10 into the ribosome and for ribosome function as a whole.  It is noted in the 
literature that without the addition of this modification, poor subunit association and 
enhanced proteasomal degradation of RPS10 was reported
112




associated with the addition of these two dimethylations matches the observed mass 
change versus the theoretical mass of RPS10 based on the amino acid sequence.  The 
theoretical mass spectrum of the modified RPS10 is shown with that observed for 
spot #29 in Figure 3.52.  The molecular mass measurement of the MXR HPLC 
fraction containing RPS10 (as determined by trypsin digestion) revealed a highly 
abundant deconvoluted molecular mass which corresponded with the isoform 
observed in spot 29.  The experimental molecular mass observed for this HPLC 
fraction sample is shown in Figure 3.53.  The molecular mass observed for spot #39 
was 16019.49Da and is shown in Figure 3.54.  Bottom-up analysis of this protein spot 
revealed no modifications aside from an oxidation (attributed to sample handling). 
There was a marked lack of observation of peptides found near the C-terminal end.  
Given that the observed mass was notably lower than the theoretical mass, the logical 
first assumption was that the protein was truncated on the C-terminal end.  
Incorporating those peptides observed during the MXR acid digestion with the tryptic 
digestion data for spot #39 indicated that all but the last 28 residues of the protein had 
been observed.  If the protein were truncated at that point, the theoretical mass would 
be 16019.45Da which is only 0.04Da from the observed molecular mass.  An 
oxidized version of this protein was also observed and is shown in Figure 3.55.  The 







Figure 3.52 Theoretical (top panel) and experimental (bottom panel) mass 













Figure 3.53 Theoretical (top panel) and experimental (bottom panel) molecular 
mass observed in the MXR HPLC fraction identified as containing RPS10 which 









Figure 3.54 Theoretical (top panel) and experimental (bottom panel) mass 
measurement observed for spot 39 believed to have a C-terminal truncation of 








Figure 3.55 Theoretical and additional experimental mass measurement 
observed for spot 39 showing the proposed C-terminal truncation based on the 











Figure 3.56 Sequence coverage for the two isoforms of RPS10 is shown above 
with legend. Underlined residue indicates modification (M oxidation) 
 
A summary of the molecular masses of the gel extracted proteins of interest 
along with their modifications are listed in Table 3.11.  As will be discussed later, all 
the post translational modifications (acetylation, phosphorylation, dimethylation) 
which were observed (or proposed in the case of dimethylation) have been noted 
previously in the literature. The molecular mass of all but two of the altered protein 
isoforms (spot 26B and spot 39) were confirmed in MXR HPLC fraction molecular 
mass analysis and/or top-down analysis of the MXR ribosomal proteome.  It is 
believed that these variants were not observed in the LC-ESI-Orbitrap analysis due to 
their abundance in the case of spot 39 or combination of abundance and size in the 









Spot # Peptide Modification 
RPS3 6, 7 M.A
Ac
VISK.K N-terminal acetylation 
RPS3 7 K.DEILPTT
P
PISEQK.P  Phosphorylation (T) 
RPS3 7 K.KPLPDHVSIVEPKDEILPTT
p
PISEQK.P  Phosphorylation (T) 
RPS3 7 K.FVDGLMIHSGDPVNYYDTAVR.H Oxidation (M) 
RPS3 7 K.IMLPWDPTGK.I Oxidation (M) 
RPS3 7 K.GGKPEPPAMPQPVPTA.- Oxidation (M) 
RPL11 25 M.A
Ac








AR.Y Acetylation (K) 
RPL11 26B R.NEK
Ac
IAVHCTVR.G Acetylation (K) 
RPL11 26B K.AEEILEK
Ac
GLK.V Acetylation (K) 
RPL11 26B R.ISKEAMR.W Oxidation (M) 
RPL23A 26C K.IRTS
P
















RPS10 39 K.NVPNLHVMK.A Oxidation (M) 
 
Table 3.10 Modified peptides found in the altered protein isoforms including 
oxidations (oxidations were the result of sample handling and are listed here 
only as a result of the molecular mass being the oxidized version of the protein) 
 































20117.63 N-terminal acetylation 20162.62 20161.61 1.01 
26B 
RPL11 









20425.70 20425.61 0.09 
26A RPL23A 17563.15 
Lysine acetylation, 2 
oxidation (sample 
handling) 
17637.14 17638.14 1.00 
26C RPL23A 17563.15 




17718.11 17719.10 0.99 
29 RPS10 18896.87 2 Arg dimethylations 18952.97 18952.93 0.04 
39 RPS10 18896.87 
28 residue C-terminal 
truncation 
16019.45 16019.49 0.04 
 
Table 3.11 Molecular masses of protein isoforms found in altered abundance 
between the MXR and MXS cell lines as indicated by comparative densitometry 
(spot 7 was used as a reference spot). Incomplete alkylation (by IAA) was 
observed in many of the gel spots.  The most abundant molecular mass was used 





Chapter 4: Discussion 
 The ribosome is not a static organelle. Alteration in the structure of rRNA and 
ribosomal protein composition have been noted in relation to everything from  
inherent traits such as cell type and developmental state (embryo vs. adult) to external 
conditions such as physiological stress on the cell or organism
77; 82; 87; 88; 89; 113; 114; 115
.  
This ribosome heterogeneity has been proposed to impact ribosome function.  As 
previously discussed, the ribosome filter hypothesis proposes that mechanisms 
involving differential mRNA capture allow for the ribosomal subunits to affect the 
translation of particular mRNAs.  A principle behind the ribosome filter hypothesis is 
that heterogeneity in the structure of a ribosomal protein or proteins may impact 
accessibility of binding sites within the ribosome (i.e. the mRNA exit channel)
82; 83
.  
Kondrashov et al found that a mutation in one ribosomal protein (RPL38) influenced 
the recruitment of HOX mRNA (critical in skeletal development) to the ribosome 
during embryonic development
89
.  Mutations in other select ribosomal proteins 
(RPS19, RPS20, RPL29, and RPL24) did not have the same effect on the HOX 
mRNA.  It was concluded from functional and biochemical studies that RPL38 was 
able to exert a well-defined role in translational control of HOX mRNA as a 
constituent of the ribosome.  The location of RPL38 (near expansion segment 27) in 
the eukaryotic ribosome was proposed to exert a conformational change in the 
ribosome where it might influence accessibility to subsets of mRNA.  The specialized 
role RPL38 was found to play in translational control led to Kondrashov and 
colleagues to refer to these ribosomes as “specialized ribosomes”
82; 83; 89




investigation into the role that post translational modifications play in “specialized 
ribosomes”/heterogeneous ribosomes has not yet been published.           
Modifications of ribosomal proteins such as those noted in this study 
(truncation, phosphorylation, acetylation, etc.) have been noted as distinguishing 
features of ribosomal proteins in disease and studies of the cell cycle 
25; 73; 74; 75; 79; 87; 
90
.  Given the role the ribosome plays in the regulation of the cell cycle and the link it 
has to some forms of drug resistance in prokaryotic organisms, the goal of this 
investigation was to compare the ribosomal proteome in chemotherapeutic resistant 
human cell lines with a drug susceptible cell line.  A combination of bottom-up, 
middle-down and top-down approaches was used to characterize the ribosomal 
proteins found in the MXR and MXS cell lines.   
 
Comparison of methods 
Number of ribosomal proteins 
Bottom-up vs. middle-down characterization of the MXR ribosome 
 In a bottom-up proteomic strategy, the proteins of interest are first digested 
using enzymatic or chemical cleavage.  These peptides are then analyzed by one of 
several mass spectrometric platforms.  One of the most common approaches 
traditionally first involves the separation of the protein mixture (in this case the 
ribosomal proteome) by 2-D gel electrophoresis followed by individual gel spots 
being subjected to tryptic digestion and analyzed by tandem mass spectrometry.  
Another common workflow requires digestion of the entire protein mixture, 




tandem mass spectrometry.  Each of these methods produces MS/MS spectra, which 
can then be searched against a given database
52; 57
.  Both of these approaches were 
used; the first, as described, was used to compare the two cell lines to identify 
proteins with altered abundances. The second method was used, with a slight 
variation, in that the ribosomal proteome was first fractionated with RP-HPLC prior 
to digestion with trypsin of each fraction and tandem mass spectrometry. 
 The 2-D gel arrays produced in this study were optimized through the use of 
cup-loading in the first dimension.  Cup-loading is widely recommended for basic 
proteins in 2DGE
93; 99; 100
.  Previous research in this laboratory involved the 2DGE of 
the MXR ribosomal proteome and the annotated gels from that study were used for 
comparison and spot identification
1
.  All of the spots selected from the gel in this 
study; those identified as being in altered abundance and the spots used for reference 
and method validation, were cross-referenced with the gels produced from the 
previous study (refer to Fig 3.23).  Proteins identified by digestion in the 23 gel spots 
evaluated in the current investigation all correlated with identifications made in the 
previous study with the exception of  one protein spot, spot 43.  Given that more than 
one protein can be present in a protein spot, it is very likely that the identification 
made in the earlier study is valid. Two additional proteins were identified with the 
bottom-up analyses of these 23 gel spots; RPL23A and RPS7.  In total, the combined 
2-D gel array studies allowed for the annotation of 50 ribosomal proteins and 2 













2 RPL3 45978 10.19 
3 RPL6 32597 10.59 
4 RPL5 34231 9.73 
5 RPS3A 29814 9.75 
6 RPS3 26557 9.68 
7 RPS3 26557 9.68 
8 RPS3 26557 9.68 






























































































































































































































Table 4.1 Proteins identified by gel array in the current study and previous 
study
1
 using the bottom-up approach.  There was agreement between the two 
studies on all but one protein spot *43; identified as RPS10 in the previous study 
and RPS15A in the current investigation 
   
 Bottom-up analysis using fractionation at the protein level by RP-HPLC 
followed by trypsin digestion and tandem  mass spectrometry via LC-ESI-LTQ-
Orbitrap of the fractions identified a larger number of proteins than the 2D-gel arrays.  
Of the 79 human ribosomal proteins, 62 proteins were confidently identified by two 
or more unique peptides and 71 were confidently identified by one peptide.  There 
was however differences between the proteins identified in these two methods as 
shown in Figure 4.1.  A comparison of the proteins identified by bottom-up analysis 
using 2-D gel arrays and in-gel digestion with the RP-HPLC fractionation of the 
ribosomal protein mixture followed by digestion of the fractions revealed that 4 
unique proteins were identified by bottom-up analysis in the 2-D gel arrays and 25 
unique proteins were identified in the HPLC fractions when proteins identified by one 




were examined, there were 18 unique proteins identified by the HPLC fraction 
digestion analysis versus 6 identified by the gel.  These differences could possibly be 
attributed to the limitations set on the proteins in the first dimension of the 2-D gel 
electrophoresis as they are enriched for a selected pI range; IPG strips in the range of 
7-11 were used.    
 
 Middle-down analysis was another approach used to identify the proteins in 
the MXR ribosomal proteome. The middle-down approach typically takes advantage 
of enzymatic or chemical cleavage with selectivity for a single amino acid residue.  
The resulting proteolytic products produced from the proteins of interest are large, 





25 4 46 
Figure 4.1 Venn diagram comparing the protein identifications 
made with bottom-up analysis by 2-D gel array and in-gel digestion 
vs. RP-HPLC fractionation of the proteins followed by in-solution 




polypeptides have been observed to fractionate with improved resolution by HPLC.  
These peptides can be analyzed using a variety of mass spectrometric platforms, often 
through a combination of methods used in top-down and bottom-up proteomics based 
on the nature and complexity of the sample being investigated.  The approach used in 
this investigation involved microwave accelerated acid digestion of the MXR 
ribosomal proteome which cleaves on either side of aspartic acid residues as 
discussed previously by this laboratory
64
.  This was followed by fractionation of the 
peptides via nanoLC interfaced with a Thermo LTQ-Orbitrap, for high resolution 
(survey scans acquired at 30K resolution) tandem mass spectrometry of both 
precursor and product ions.  Large polypeptides carry a higher number of charges 
when electrosprayed which enhances CID.  The middle-down approach is especially 
favored in the investigation of proteins containing multiple PTMs or proteomes which 
contain multiple protein isoforms such as the current study
2; 62; 63; 64; 65; 66
. 
 Middle-down analysis with the acid digestion products of the MXR ribosomal 
proteome allowed for the confident identification of 62 of the 79 human ribosomal 
proteins by two or more unique peptides (70 proteins were confidently identified by 
one peptide).  When compared with the bottom-up methods, the proteins identified 
again differ between the methods.  This is demonstrated in the Venn diagrams seen in 
Figure 4.2 and 4.3.  Based on these results, it would appear that an equal number of 
proteins could be identified with samples collected by HPLC fractionation and trypsin 
digestion versus a sample of the entire MXR ribosomal proteome cleaved with 
microwave accelerated acid digestion.  A combination of 2-D gel array in-gel 




identification of a total of 76 of the 79 ribosomal proteins.  As can be seen in the 
Venn diagrams and Table 4.1, if only one of these methods could be employed, the 
number of proteins identified by the middle-down approach is very comparable to the 
HPLC fractionation- in-solution trypsin digestion and provides a more rapid sample 
preparation time.  The main disadvantage of using the middle-down approach as will 
be discussed with regards to sequence coverage is the fact that protein isoforms are 
more difficult to distinguish using this method. 














Figure 4.2 Venn diagram illustrating overlap/differences between the 
protein identifications made by bottom-up methods and a middle-down 
analysis of microwave accelerated acid digestion products.  These are 





Sequence coverage of the ribosomal proteins and their modifications 
 Optimal sequence coverage of the ribosomal proteins was achieved in this 
investigation by a combination of the results from three digestion methods; in-
solution trypsin digestion of HPLC fractions, in-gel digestion of the MXR protein 
isoforms in the 2-D gel arrays and microwave accelerated acid digestion of the entire 
MXR proteome.  For bottom-up analysis based around HPLC fractionation of the 
ribosomal proteome, the average sequence coverage for the 71 proteins identified was 













Figure 4.3 Venn diagram illustrating overlap/differences between the 
protein identifications made by bottom-up methods and a middle-down 
analysis of microwave accelerated acid digestion products.  These are 




23 protein spots which were chosen for this investigation from the 2-D gel arrays had 
average sequence coverage (solely from the trypsin digestion) of 62% with a range of 
peptide coverage for individual proteins from 25% to 92%.  When the sequence 
coverage observed from the previous study of the in-gel digestion of ribosomal 
proteins is taken into account (50 ribosomal proteins identified in total), the average 
sequence coverage becomes 65% with a peptide coverage range for individual 
proteins that remains from 25% to 92%
1
.  The average sequence coverage of the 70 
ribosomal proteins observed using acid digestion was 52% with a peptide coverage 
range for individual proteins from 6% to 99%
2
.  A comparison of the sequence 
coverage observed for each of the ribosomal proteins based on these three methods 
and based on the isoelectric point of the ribosomal protein is found in Figures 4.4, 4.5 
and 4.6.  Under ideal circumstances, the peptide products from these methods would 
be complimentary (non-redundant).  By combining the peptides identified by the 
different methods for a given protein the average individual ribosomal protein 
sequence coverage was increased to 75% of the 76 ribosomal proteins identified by a 
minimum of 1 confident peptide identification and 78% for the 72 ribosomal proteins 
with two or more confident peptide identifications.  The peptide sequence coverage 
range for individual proteins was from 8% to 100% for the 76 proteins confidently 
identified by 1 peptide and from 19% to 100% for the 72 proteins confidently 
identified by a minimum of 2 peptides as can be seen in Table 4.2. 
When the digestion methods are examined on their own, the cost and benefit 
of each relates to the goal of the investigation and the desire to localize post 




a given post translational modification is also of significance.  Acid digestion 
provided the majority of protein sequence coverage information on the N-terminal of 
a given protein (perhaps due in part to this area being more readily accessible for 
chemical cleavage).  Many ribosomal proteins lose their N-terminal methionine and 
are subsequently acetylated on the new N-terminal residue
115; 116
 and the use of acid 
digestion allowed for the identification of these N-terminal peptides.  As can be seen 
in Table 4.2, digestion with these three workflows allowed for the identification of 
the N-terminus of 52 proteins (not including protein variants).  The N-terminal 
fragments of an additional 7 proteins were exclusively identified with top-down 
fragmentation of intact proteins (18 proteins total) which will be discussed in a 
subsequent section.  Identifications are noted in Table 4.2 by a letter; G signifies in-
gel digestion, A signifies acid digestion, H signifies HPLC fraction trypsin digestion 
and T signifies top-down fragmentation.  Acid digestion allowed for the identification 
of 39 N-terminal peptides with 18 of these peptides being exclusively observed by 
acid digestion.  By comparison, 19 N-terminal peptides were identified by the in-gel 
digestion workflow (not counting N-terminal peptide variants) with only 5 
observations unique to that method.  Similarly, 17 N-terminal peptides were 
identified with the HPLC fractionation and digestion workflow with 4 exclusive to 
that workflow.  Of the 52 N-terminal peptides identified by these three digestion 
methods, 40 were observed to have lost their N-terminal methionine and 19 were 
acetylated (4 of which were N-acetyl-L-methionine).  Twelve of the 19 N-terminal 
acetylations were observed with acid digestion with 6 of those being unique to acid 




found on the N-terminal end of the protein sequence, the in-gel digestion also allowed 
for the identification of variants of a ribosomal protein produced by alternative 
processing of the N-terminal end of a protein.  This was noted for acid digestion in 
the case of RPS3 where the N-terminal peptide was observed with and without 
acetylation.  For in-gel digestion, two forms of RPS5 were noted, one with the N-
terminal methionine and the second without the N-terminal methionine (the version 
without N-terminal methionine is acetylated).  This variable processing of the RPS5 
N-terminus has been noted in several references listed in the UniProt knowledge 
database entry for this protein
117
.   
Post translational modifications found within the protein (as opposed to on the 
N-terminal end) were best identified using the 2-D gel array and in-gel digestion 
workflow.  A somewhat less superior alternative was in-solution digestion of the 
HPLC fractions.  The modifications identified (listed in Table 4.2) included 
phosphorylation, lysine acetylation and a deamidation (methionine oxidation was also 
identified but was not listed as it is considered the result of sample handling).  In-gel 
digestion identified a phosphorylation site on RPL23 at T64.  This has been noted 
previously by Rigbolt and colleagues in an investigation of human embryonic stem 
cells
118; 119
.   The intact molecular mass noted for RPL23 in the HPLC fraction 
collected at 27 minutes did not account for a phosphorylation leading to the 
conclusion that the phosphorylated form of the protein was less abundant or found in 
another HPLC fraction.  Another example of a modification observed by in-gel 
digestion is the phosphorylation of S54 in RPL10.  This modification has been noted 




(PhosphoSitePlus®) in 4 different human samples which included the Jurkat cell line 
(T-cell leukemia) and the K562 cell line (chronic myelogenous leukemia)
119
.  Four 
search engines supported evidence of a phosphorylation found on T123 of RPS7.  
This phosphorylation has been noted in the PhosphoSitePlus® database for 5 human 
samples and 7 mouse samples
119
.  Human samples in this study with this modification 
were listed as HELA cells (cervical carcinoma), NCI-H3255 (non-small cell lung 
cancer) and MKN-45 (gastric carcinoma)
120
.    
Despite these findings and the fact that the in-gel digestion provided the 
highest average peptide sequence coverage for individual proteins, the preparation of 
the 2-D gel arrays was labor intensive and contamination of the protein spots 
(inadvertently from sample handling, carry-over between LC-MS/MS runs, and the 
presence of more than one protein in a spot) posed concerns.  Additionally, the 
number of proteins identified by the 2-D gel array workflow was impacted in part by 
the restrictions placed on the pI range of the proteins investigated in the first 
dimension (See Fig 4.5).  The PTMs confidently identified using in-solution digestion 
of the HPLC fractions was not as numerous as can be seen in Table 4.2 which may be 
attributed to the average sequence coverage of these proteins being much lower than 
the other two digestion methods (33%).  This would be expected to be improved with 
more concentrated samples and repeated sample injections
121
.  
In the context of this investigation, the largest amount of information about 
the MXR protein isoforms was obtained using 2-D gel arrays and in-gel digestion.  
The contribution of the MXR proteome acid digestion cannot be understated, 




such as the N-terminal regions.  In most cases, the proteins where information was 
lacking from the in-gel digestion regarding the N-terminal end involved proteins with 
a basic residue near the N-terminal end.  An alternative approach to sequencing these 
proteins could have been to use in-gel digestion with another endoproteinase such as 



























RPL10 24473 P27635 10.11 17% 24% 54% 72% 
RPL10a 24700 P62906 9.94 40% 47% 72% 84% 
RPL11 20121 P62913 9.64 23% 19% 92% 92% 
RPL12 17819 P30050 9.48 59% 23% 74% 81% 
RPL13 24130 P26373 11.65 40% 58% 42% 79% 
RPL13A 23446 P40429 10.94 50% 6% 71% 77% 
RPL14 23301 P50914 10.94 28% 39% 43% 67% 
RPL15 24015 P61313 11.62 14% 47% 0% 52% 
RPL17 21266 P18621 10.18 25% 64% 57% 91% 
RPL18 21503 Q07020 11.73 32% 18% 0% 43% 
RPL18A 20762 Q02543 10.72 30% 43% 0% 53% 
RPL19 23466 P84098 11.48 20% 39% 0% 47% 
RPL21 18434 P46778 10.49 22% 61% 77% 94% 
RPL22 14656 P35268 9.22 10% 66% 50% 91% 
RPL23 14865 P62829 10.51 25% 92% 75% 100% 
RPL23A 17564 P62750 10.44 44% 26% 59% 78% 
RPL24 17779 P83731 11.26 0% 59% 66% 87% 
RPL26 17258 P61254 10.55 30% 69% 59% 92% 
RPL27 15667 P61353 10.56 35% 95% 67% 100% 
RPL27A 16430 P46776 11 31% 68% 0% 69% 
RPL28 15616 P46779 12.02 32% 63% 0% 76% 
RPL29 17621 P47914 11.66 32% 37% 0% 54% 
RPL3 45978 P39023 10.19 6% 44% 62% 76% 
RPL30 12653 P62888 9.65 34% 11% 84% 87% 
RPL31 14463 P62899 10.54 32% 44% 66% 77% 




RPL34 13162 P49207 11.48 7% 24% 0% 24% 
RPL35 14420 P42766 11.04 44% 97% 0% 100% 
RPL35A 12538 P18077 11.07 6% 33% 41% 50% 
RPL36 12123 Q9Y3U8 11.59 6% 98% 0% 99% 
RPL36A 12310 P83881 10.56 15% 47% 49% 80% 
RPL37 10947 P61927 11.74 - - - - 
RPL37A 10144 P61513 10.44 29% 0% 82% 82% 
RPL38 8087 P63173 10.1 53% 83% 54% 83% 
RPL39 6275 P62891 12.55 20% 0% 0% 20% 
RPL4 47566 P36578 11.07 37% 42% 0% 58% 
RPL40 6181 P62987 10.32 - - - - 
RPL41 3456 P62945 12.96 - - - - 
RPL5 34231 P46777 9.73 17% 49% 68% 79% 
RPL6 32597 Q02878 10.59 55% 64% 25% 83% 
RPL7 29226 P18124 10.66 43% 24% 72% 90% 
RPL7a 29864 P62424 10.61 38% 85% 59% 97% 
RPL8 27893 P62917 11.04 32% 68% 57% 87% 
RPL9 21863 P32969 9.96 23% 49% 72% 90% 
RPLP0 34274 P05388 5.7 42% 27% 0% 42% 
RPLP1 11383 P05386 4.21 56% 0% 0% 56% 
RPLP2 11665 P05387 4.38 96% 74% 0% 100% 
RPS10 18898 P46783 10.15 41% 73% 78% 93% 
RPS11 18300 P62280 10.31 46% 78% 76% 96% 
RPS12 14384 P25398 7.01 34% 62% 0% 72% 
RPS13 17091 P62277 10.53 69% 98% 83% 99% 
RPS14 16142 P62263 10.08 0% 50% 46% 68% 
RPS15 16909 P62841 10.39 12% 58% 64% 76% 
RPS15A 14708 P62244 10.14 0% 88% 62% 98% 
RPS16 16314 P62249 10.21 49% 84% 60% 97% 
RPS17 15419 P08708 9.85 0% 44% 85% 97% 
RPS18 17587 P62269 10.99 52% 39% 69% 76% 
RPS19 15929 P39019 10.31 48% 52% 65% 82% 
RPS2 31193 P15880 10.25 34% 33% 55% 79% 
RPS20 16006 P60866 9.4 29% 40% 88% 79% 
RPS21 9111 P63220 8.68 8% 52% 0% 60% 
RPS23 15676 P62266 10.5 24% 38% 0% 55% 
RPS24 15423 P62847 10.79 9% 55% 0% 55% 
RPS25 13742 P62851 10.12 66% 58% 52% 78% 
RPS26 12884 P62854 11.01 21% 70% 0% 72% 
RPS27 9330 P42677 9.58 0% 32% 0% 32% 




RPS28 7841 P62857 10.7 33% 99% 0% 100% 
RPS29 6546 P62273 10.17 34% 0% 87% 91% 
RPS3 26557 P23396 9.68 46% 30% 91% 98% 
RPS30 6648 P62861 12.15 19% 0% 0% 19% 
RPS3A 29814 P61247 9.75 33% 53% 47% 76% 
RPS4X 29467 P62701 10.16 19% 73% 72% 94% 
RPS5 22876 P46782 9.73 40% 12% 70% 92% 
RPS6 28681 P62753 10.85 27% 16% 60% 61% 
RPS7 22127 P62081 10.09 62% 52% 65% 81% 
RPS8 24074 P62241 10.32 14% 44% 59% 72% 
RPS9 22460 P46781 10.66 65% 43% 87% 94% 
RPSA 32723 P08865 4.79 42% 68% 0% 80% 
 
Table 4.2 A list of the 79 human ribosomal proteins along with their average 
molecular weight (as determined by Expasy), their theoretical pI (also 
determined by Expasy) and sequence coverage observed for each of three 
methods; HPLC-fractionation and in-solution trypsin digestion, microwave 
accelerated acid digestion
2
 and in-gel digestion of 2-D gel arrays and the 
sequence coverage observed when these observations were combined.  Those in-
gel digestion values reported in RED were determined from in-gel digestion 
analysis previously reported from this laboratory
1; 2
.  Those values underlined 
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Figure 4.6 Sequence coverage of the ribosomal proteins as determined by their 















- Met N-term Acetyl + Phos Deam K Acetyl 
RPL10 A; G A; G   G     
RPL10a G G       H 
RPL11 G; H G; H G; H   G G; H 
RPL13 A A         
RPL13A G G G       
RPL14 A A         
RPL15 A A         
RPL17 G G         
RPL19 A A A       
RPL21 G; A           
RPL22 A A         
RPL23 A A A G     
RPL23A -     G   G 
RPL24 G; A           
RPL26 A           
RPL27 A; T A; T         
RPL28 A; T A; T A; T       
RPL3 A; G A; G         
RPL30 T T         
RPL32 A; T A; T         
RPL35 A A         
RPL35A A; T A; T A; T       
RPL36 A A         
RPL36A A A         
RPL37A T T         
RPL38 A; T A; T         
RPL4 H; A H; A H; A       
RPL5 A A         
RPL6 H; G H; G         
RPL7 G           
RPL7a A A         
RPL8 A A         
RPL9 A           
RPLP0 H   H       
RPLP1 H H H       
RPLP2 A; T          H 




RPS11 T; A; G; H T; A; G; H T; A; G; H       
RPS13 A; G A; G         
RPS15 A; H A; H A; H       
RPS15A T T         
RPS16 T; A; G; H T; A; G; H         
RPS17 A A         
RPS18 A; H A; H A; H       
RPS19 T; A; H T; A; H         
RPS2 H           
RPS20 T; A; G T; A; G T; A; G       
RPS21 T; H   T; H       
RPS23 T T         
RPS24 T   T       
RPS27 T T T       
RPS28 A; T   A; T       
RPS29 G; H G; H         
RPS3 A; H; G A; H; G A; H; G G     
RPS3A G G         
RPS4X/Y A A         
RPS5 H; G H; G H; G       
RPS6 A; H     H     
RPS7 A   A G     
RPSA H H H       
 
Table 4.3 Protein name and modification identified (by method); G = in-gel 




Intact mass measurements and top-down characterization of the MXR ribosome 
 Intact mass measurements and top-down mass spectrometry was used to 
characterize the MXR ribosomal proteome.  The top-down approach uses mass 
spectrometry to weigh intact protein ions and multi-stage tandem mass spectrometry 
to produce sequence tags from large protein fragments.  The entire MXR ribosomal 
proteome was injected for LC-ESI-LTQ-Orbitrap MS/MS analysis.  Of one MXR 




alternative approach involves only the acquisition of the molecular ion using a high 
resolution instrument (the LTQ-Orbitrap again in this case) to determine the intact 
protein mass.  Molecular mass measurements were acquired with aliquots of the 
HPLC protein fractions a well as gel extracted ribosomal proteins.  
 The ribosomal proteins identified with top-down fragmentation are listed in 
Table 3.3.  Additional structural information such as the retention /loss of the N-
terminal methionine and acetylation of N-terminus was obtained on all of these 
proteins except for three proteins; RPL32 (loss of 14.12Da), RPL35A (gain of 
18.08Da) and RPLP2 (gain of 162.16Da).  According to the Uniprot database alone, 
RPLP2 contains as many as 6 phosphorylation sites and two acetylation sites.  The 
lysine acetylation site which was observed on K98 of RPLP2 in the HPLC fraction 
digest is noted as a frequent site of ubiquitination in both multiple myeloma cells and 
mouse embryonic stem cells.  A link between sites of lysine acetylation and 
ubiquitination has been proposed by numerous researchers
122; 123; 124
.    
Molecular mass measurements are not stand-alone measurements. In other 
words, additional data is required in order to draw conclusions regarding the identity 
of the protein in question and any modifications that protein may possess.  Without 
detailed information relating the protein being weighed and PTMs found on the 
protein in question, the wrong conclusions can be made about a particular protein.  
For example the protein isoform found in spot 39 was identified as being RPS10 and 
because of the information regarding the sequence coverage observed, the C-terminal 
truncation found in that isoform was able to be correctly identified.  Looking as the 




ribosomal protein with a lower theoretical mass was present in that spot could have 
easily been made. 
 Despite the shortcomings of molecular mass measurements described in the 
paragraph above, bottom-up analysis on its own can sometimes provide information 
about a modification which could be attributed to either an artifact of sample 
processing or a significant biological event.  In such circumstances, it is often only 
with molecular mass values that conclusions can be drawn regarding modifications or 




Rapid assessment of the ribosomal proteome 
The most efficient stand-alone method to rapidly assess the ribosomal 
proteome would be to employ a middle-down approach such as the microwave 
accelerated acid digestion used in this investigation.  A more informative approach 
however would be to use this technique in conjunction with a top-down approach.  As 
discussed above, a drawback of the middle-down approach is the inability to detect 
certain PTMs and to easily distinguish protein isoforms (without matching top-down 
measurements).  To offset this loss, the results of this study would suggest a good 
complementary/alternative method would be to visualize the ribosomal proteome 
using 2-D gel electrophoresis with in-gel digestion using either trypsin or Lys-C to 
determine proteins with altered abundance prior to a top-down/molecular mass 




to visually compare and evaluate the proteome in a gel format allows for selectivity of 
proteins of interest and molecular mass measurements of extracted gel proteins allows 
for confidence in the identification of PTMs/alteration in protein primary structure.   
This provided a larger number of peptide identifications with a very small time 
commitment.  Digesting the entire ribosomal proteome though fast and able to be 
conducted with relative ease, did not allow for peptides to be used to discern between 
protein isoforms.  In addition, certain post translational modifications such as 
phosphorylation are easily hydrolyzed during microwave accelerated acid digestion, 
thus losing the ability to identify this PTM with confidence. 
       
Comparison with previous proteomic studies of ribosomal proteins 
 Every approach applied in this investigation (top-down, bottom-up and 
middle-down) had been previously utilized in proteomic studies to characterize 
ribosomal proteins.  A common conclusion of many proteomic investigations 
attempting to characterize a ribosomal proteome is that ribosomal proteins are as the 
laboratory of David Lubman stated “notoriously difficult to assess”
125
.  Despite the 
assumption that all ribosomal proteins should be in equimolar concentration and thus 
the dynamic range of the investigation should be 1, there exist to my knowledge no 
investigations that have successfully characterized all the ribosomal proteins expected 
for a given sample.  The most elaborate characterizations of ribosomal proteomes 
conducted by the Reilly laboratory and Carroll and colleagues detected all but one of 
the expected ribosomal proteins in their respective investigations (53 of 54 in the case 
of Reilly and 79 of 80 in the case of Carroll)
72; 107




characteristics of these proteins (their basic isoelectric point) are considered to 
contribute to this problem.  For example, one of the 3 proteins that were not detected 
using any of the methods employed in this investigation is RPL41 (refer to Table 4.2).  
This is the most basic of the ribosomal proteins with a theoretical pI of 12.96 in the 
human ribosome (calculated at over 13 in the rat ribosome).  In addition it is one of 
the smallest of the ribosomal proteins with a molecular mass expected around 
3456Da.  The ribosomal protein isolation techniques utilized for the 2DGE aspect of 




 The average sequence coverage observed from a combination of the three 
approaches (bottom-up, middle-down, and top-down) was found to be 76% for the 76 
ribosomal proteins detected.  There was 75% sequence coverage for the 44 ribosomal 
proteins observed from the large subunit and 76% for the 32 ribosomal proteins of the 
small subunit.  This surpasses the sequence coverage of many of the other reported 
proteomic studies of the ribosomal proteome.  The study by the Natalie Ahn 
laboratory of the rat-1 fibroblast small subunit ribosomal proteins observed an 
average sequence coverage of 59%
73
.  The tryptic peptide mass maps of the 53 (of 54 
total) Caulobacter crescentus ribosomal proteins detected by the Reilly laboratory 
were reported with an average sequence coverage of 62%
72
.  The Leary laboratory 
reported observing 31 of the 32 small subunit proteins with 97% coverage however 
the sequence coverage of each protein was not reported in the publication for 
comparison to our results
74




Effect on ribosome function  
 Earlier investigations in this laboratory on the capacity of these MXR 
ribosomes to function looked at two properties of the MXR cells and ribosomes; the 
number of ribosomes in the cells as compared with the MXS cells and the 
translational efficiency of each ribosomal type using methionine incorporation study. 
 
Met incorporation study 
 Given that there were differences detected in the ribosomal protein 
composition between the 2 cell lines, an investigation was conducted by Alexey 
Petrov and Jaclyn Wolff in the laboratory of Professor Jonathan Dinman to determine 
if differences existed between the rates at which these 2 types of ribosomes processed 
mRNA.  The results of this experiment can be seen in Figure 4.7.  Over the 9 hours 
period, the methionine incorporation measurements demonstrated that the MXR 

































Figure 4.7 The result of the methionine incorporation study illustrated that 
ribosomal activity in the MXR ribosomes decreased by about 25% over 9 hours 
when compared with the MXS ribosomes 
 
Ribosome abundance 
 Given that differences were observed in the ribosomal activity between the 
two cell lines, it is reasonable to assume that there may be differences in the number 
of ribosomes in the cells causing this discrepancy.  An experiment comparing the 
number of ribosomes in the cells between the two cell lines was conducted in an 
earlier investigation as described
1
.  This investigation illustrated that in fact there is 
no significant difference in the number of ribosomes between the MXR and MXS cell 
lines as seen in Figure 4.8.  Based on this information, it is clear that a physical 









































































Drug Resistant:22000 ± 3000
Ribosome Abundance is Unchanged
 
Figure 4.8 Over replicate harvests, an earlier investigation
1
 has shown no 
significant differences in the number of ribosomes between the two cell lines 
Technical replicates; N = 8 for ribosome count, N = 2 for cell count 
 
Implications 
The implications of these two experiments is that there is a physical difference 
between the ribosome found in the MXR cell line versus the ribosome found in the 
MXS cell line, the result of which leads to a decrease in translational efficiency in the 
MXR cell line.  As was surmised based on the proteomic evaluation of these 
ribosomes, the primary protein composition is altered between the two cell types.  
The investigations illustrated in Figures 4.7 and 4.8 suggest that the alteration in the 
primary structure of these ribosomal proteins is leading to or contributing to the 
change in translational efficiency.  
 
     MXS cell line                              MXR cell line 




The connection between treatment with a chemotherapeutic agent and the ribosome 
 The effect that treatment with chemotherapeutic drugs including mitoxantrone 
has on the ribosome is rooted in ribosome biogenesis.  In a study of 36 
chemotherapeutic drugs on 2fTGH (a human fibrosarcoma cell line) using in vivo 
labeling of RNA and rRNA analysis and western blotting, Burger and colleagues 
determined that clinically relevant concentrations of most of these drugs led to a loss 
of nucleolar integrity and interruption of rRNA synthesis.  In the case of 
mitoxantrone, exposure of the cells to a concentration below that used for clinical 
treatment led to a fast decrease in the appearance of 47S (35S in yeast) rRNA.  This 
was interpreted as a causal relationship between treatment with mitoxantrone and an 
interruption in the transcription of 47S rRNA
36
.   
A recent publication from Lee et al demonstrated that mitoxantrone binds to 
nucleolar and coiled body phosphoprotein 1 (NOLC1) also known as Nopp140 or 
hNopp140 (human Nopp140)
127
.  The transcription of 47S rRNA is likely affected by 
the interaction that mitoxantrone has with the C-terminal end of Nopp140 (NOLC1).  
Nopp140 has been shown to bind to RNA polymerase I in a coimmunoprecipitation 
study and a double immunofluorescence investigation illustrated that it colocalizes 
with RNA polymerase I at the rDNA (rRNA genes) transcription active foci in the 
nucleolus. Cells which were transfected with only the amino terminal portion of 
hNopp140 or induced for overexpression of hNopp140 resulted in mislocalization of 
RNA polymerase I and altered nucleolar phenotypes such as that observed when cells 
are treated with actinomycin D, a known inhibitor of rRNA synthesis
36; 128
.  The 




Nopp140 with protein kinase CK2 (casein kinase 2).  Protein kinase CK2 plays a role 
in the control of cell growth, the regulation of rDNA transcription and apoptosis.  The 
interaction CK2 has with Nopp140, which is controlled by the phosphorylation state 
of Nopp140, suppresses the catalytic activity of CK2
127
.  As mentioned above, 
mitoxantrone acts as a positive effector of the interaction between these two proteins 
thus ensuring the suppression of the catalytic activity of CK2.  Since elevated CK2 
activity has been linked to many cancers, the suppression of this activity by the 
interactions CK2 has with Nopp140 and mitoxantrone might assist in cancer 
treatment
127
.   
The cause of the interruption in transcription of 47S rRNA is likely 
multifactorial given the fact that there is more than one binding partner of 
mitoxantrone and they participate in multiple functions in the cell.  Gopinath et al 
published a study in 2005 that showed that mitoxantrone binds to specific vault RNAs 
(vRNAs) known as hvg-1 and hvg-2, components of vault cytoplasmic 
ribonucleoprotein particles (eukaryotic organelle three times the size of ribosomes 
found in higher eukaryotes whose function is still not well understood).  It was 
suggested from this work that this may contribute to multidrug resistance due to the 
fact that vRNAs are (1) observed to be overexpressed in cells treated with cytotoxic 
compounds such as mitoxantrone, (2) that they are involved in nucleo-cytoplasmic 
transport and (3) that the compound that the cell is exposed to is found within the 
vRNA complex allowing for the export of the toxic compounds for intracellular 




interactions in the cell, does not explain the relationship between the effect of 
mitoxantrone treatment and alterations found in the ribosomal proteins
38
.    
      
Factors linking acquired mitoxantrone resistance to altered ribosomal proteins 
This investigation has focused on 4 proteins determined to be in altered 
abundance between the MXR and MXS ribosome: RPL11, RPL23A, RPS3, and 
RPS10.  On further examination, the interactions that these proteins have in the cell; 
in conditions of ribosomal stress, in the fully functional ribosome of a healthy cell 
and in ribosome biogenesis help explain why they would be altered in a drug resistant 
cell.  
 Ribosomal protein RPL11 has numerous interacting partners, among them 
p53, MDM2, and c-myc.  Numerous studies have shown that under circumstances of 
cellular stress, RPL11 can act in concert with other ribosomal proteins (RPL5 and 
RPL23) and 5S rRNA to inhibit the activity of MDM2 (an E3 ubiquitin ligase that 
targets p53 for degradation) thus resulting in the activation of the p53 pathway
129
.  
The Myc protein is reputed to bind to and hypothetically control the transcription of 
at least 15% of the eukaryotic genome.  Myc is known to enhance RNA polymerase I 
and III rRNA catalyzed synthesis.  It also participates in coordinating the processing 
of genes of proteins that contribute to rRNA processing, ribosome assembly as well 
as nuclear-cytoplasmic transport of mature ribosomal subunits. Myc participates in 
the RNA polymerase II-dependent transcription of ribosomal protein genes and 
increases the transcription of many of these genes (RPL11 is an example of a 
transcription target)
76




mammalian cells with a drug that inhibits transcription of 47S rRNA (actinomycin D; 
a member of the same class of drugs as mitoxantrone) has shown that cytoplasmic 
RPL11 acts as a first responder to the stress placed on the cell, recruiting miR-24 
loaded miRISC Ago2 (microRNA silencing complex argonaute 2) to the c-myc 
mRNA for mRNA decay and silencing
130
.  In this respect, RPL11 and Myc 
participate in a negative feedback loop which under normal circumstances would 
prevent cell growth and ribosome biogenesis during times of ribosomal stress.  The 
fact that we observe altered abundance and a new protein isoform of RPL11 in a 
chemotherapeutic resistant suggests a possible connection to the role it plays in the 
cell.  These pathways have been altered in the resistant cell line in order for the cells 
to survive continued exposure to mitoxantrone.  This could imply one of three things.  
Either (1) these RPL11 proteins are altered as an effect of a previous interaction with 
their binding partners (bearing in mind that most of the communication involved in 
these pathways involves the presence of certain PTMs), (2) the altered isoforms are a 
result of changes in these cellular pathways that did not directly involve the protein 
itself or (3) the protein becomes altered in the context of the mature ribosome while 
interacting with either an mRNA or a protein involved in these pathways.  Options 2 
and 3 are not exclusive of one another.  Only additional investigations could further 
clarify which of these possibilities has occurred. 
 The ribosomal protein RPL23A (referred to as RPL25 in yeast) also interacts 
with proteins that contribute to ribosomal biogenesis and cell signaling.  Unlike 
RPL11, there is no question as to whether the contribution/interaction of RPL23A is 




found that RPL23A binds to mTORC2 to promote the co-translational stabilization 
and phosphorylation of nascent Akt polypeptide
131
.  A study by Zinzalla et al found 
that ribosomes exposed to protein translation inhibitors are capable of facilitating 
mTORC2 signaling independent of protein synthesis, suggesting that it is the physical 
structure of the 80S ribosome and not the activity that mediate mTORC2 activity.  
Their investigation found that the 80S ribosome was in fact required for mTORC2 
activity
132
.  The mTOR protein, mammalian target of rapamycin, is a serine threonine 
kinase known to be correlated with cell growth, cell survival, rRNA transcription, and 
protein synthesis.  It is associated with two different protein complexes; mTORC1 
and mTORC2. The complex studied by Oh and colleagues which associates with 
RPL23A in actively translating ribosomes consists of mTOR, rictor, SIN1and mLST8 
and is known for its role in cell survival and actin cytoskeletal reorganization.  As 
part of the role it plays in promoting cell survival, mTORC2 has been found to 
mediate the phosphorylation of several members of the AGC antiapoptotic kinase 
family of proteins such as Akt, PKB and SGK which in turn activate these kinases 
towards substrates such as Fox03a and NDRG1.  The phosphorylation event on the 
carboxyterminal tail turn motif associated with the Akt nascent polypeptide is 
required for proper Akt folding and maturation.  Without co-translational 
phosphorylation, ubiquitination of Akt occurs during translation leading to its 
destruction
131; 133
.  Phosphorylated Akt is known to feed into the pathway that signals 
to Myc to transcribe rRNA
134
.   A connection between acquired chemotherapeutic 
drug resistance in attached cells treated with an inhibitor of mTOR and PI3K showed 




pro-survival proteins.  The proteins whose expression was increased varied among 
cell lines (often times the apoptosis regulating protein Bcl-2 was observed) but the 
end result was always the same; increased cap-independent translation and FOXO 
transcription
135
.  Changes in the structure of the ribosomal protein, RPL23A, that 
interacts with a key component of this process, mTORC2 could possibly either 
influence the MXR cells ability to maintain an interaction with the mTORC2 complex 
(even in the face of protein signals that would drive the cell towards apoptosis) or if 
the interaction with mTORC2 was altered, drive the pathways that would lead to an 
increase in cap-independent translation and FOXO transcription.   
 The ribosomal protein RPS3 is not only an important participant in the 
ribosome in translation but it is also known to play a role in DNA repair, apoptosis, 
ribosome biogenesis and cell cycle regulation.  It is a substrate of multiple protein 
kinases (PKCδ, Akt, ERK, Cdk1) resulting in cell signaling phosphorylation which 
many argue determine the localization and function of the protein in the cell at that 
time
136; 137; 138; 139
.  An investigation of yeast ribosome biogenesis revealed that the 
phosphorylation of RPS3 and subsequent dephosphorylation was required for the 
RPS3 to be stably integrated into the pre-40S ribosome for proper 40S formation and 
export from the nucleus
140
.  It has been suggested that under certain conditions, RPS3 
may be capable of leaving the ribosome in the same manner as RPL11
136
.  The 
environment of the cell and stage of the cell cycle determine whether RPS3 will be 
phosphorylated, what kinase will phosphorylate it and on which residue(s) it will be 
phosphorylated.  It should be noted that in our investigation, both cell lines were 




with equal abundance.  This is the only isoform of RPS3 we observed with a 
phosphorylation.  Yoon et al in 2011 has shown that T221 is phosphorylated by Cdk1 
(if both S6 and T221 are phosphorylated, this implicates the PKCδ kinase).  
Experiments with cell cycle inhibitors suggested that phosphorylation of RPS3 on 
T221 by Cdk1 is for the purposes of targeting RPS3 for nuclear transport during the 
cell cycle (particularly at the G2/M phase of the cell cycle)
141
.  It is not entirely clear 
the function served by T221 phosphorylation in RPS3 in both cell lines in the current 
investigation.  The relation of this phosphorylation event to cell cycle events is 
undeniable.  Whether the phosphorylation event precedes the departure of RPS3 from 
the ribosome or signals some other function that RPS3 plays in the ribosomal 
machine is unclear at this time however due to the fact that it is detected in equal 
abundance in both cell lines, it does not directly factor as a structural difference 
between the MXR and MXS ribosomes.  
 Perhaps even more crucial to the primary structure of RPS3 is its interaction 
with the protein RACK1 (Receptor for Activated C Kinase 1) in mature ribosomes.  
RACK1 is often times referred to as a ribosomal protein of the small subunit since it 
is commonly found in association with the 40S ribosome.  In fact, the chemical 
associations that RACK1 has with the ribosomal proteins and rRNA are so strong that 
after studying the crystal structure of the eukaryotic 40S subunit it was concluded that 
free RACK1 would be observed as a result of RACK1 up-regulation as opposed to its 
dissociation/release from the ribosome.  RACK1 has been described as the “central 
cellular signaling hub” of the ribosome
142
.  It directly interacts with several ribosomal 




The C-terminal end of RPS3 in particular interacts with RACK1.  RACK1 is known 
to promote translation by recruiting PKC and eIF6 to the small subunit for the PKC-
driven phosphorylation of eIF6 to stimulate subunit association.  After 80S formation, 
RACK1 is known to recruit signaling molecules to the ribosome.  It has been 
proposed that in addition to the recruitment of signaling molecules, RACK1 recruits 
ribosomes to different cellular sites and to stimulate the translation of specific 
mRNAs
142; 143
.  RPS3 not only interacts directly with RACK1 but also with many of 
the neighbors of RACK1 in addition to a direct interaction with RPS17.  This is 
illustrated in Figure 4.9.  It goes without saying that any alteration in the structure of 
RPS3 could have a domino effect on RACK1 and the interactions it has with the 40S 
and 80S ribosome as well as any proteins it recruits.  Any alterations in these 
pathways could provide an explanation for the change in the MXR ribosomal proteins 
however how this is advantageous to drug resistant cells would require further 
investigation.   
 
 
Figure 4.9 RACK1 shown in red, interacts with RPS16, RPS17 and the C-






                     
 Ribosomal protein RPS10 is an example of one of the proteins that interacts 
with RPS3 in the small subunit.  As a result, a change in the structure of RPS10, 
particularly a C-terminal truncation such as that observed in the protein isoform found 
in spot 39 would be expected to affect ribosomal structure.  The effect of RPS10 on 
ribosomal structure goes beyond its interaction with RPS3.  Ren et al found that 
RPS10 is a substrate for protein arginine methyltransferase 5 (PRMT5) which results 
in the dimethylation of R158 and R160.  Without dimethylation at both of these sites 
they found that the contribution of RPS10 to ribosome biogenesis both in terms of 
being incorporated into the ribosome and contributing to 18S rRNA maturation was 
less than optimal leading to an imbalance in the number of 40S subunits to 60S 
subunits.  In addition, the RPS10 which was not dimethylated was not as effectively 
incorporated into the ribosome and free RPS10 was subject to proteosomal 
degradation
112
.  A recent study in the laboratory of Marc Wilkins found that arginine 
dimethylation can in fact be related to the age of a protein.  When a protein is found 
to be dimethylated, the lifespan of the protein is significantly longer
145
.  The 
implication exists that the metabolism of the ribosomal proteins in the MXR cells is 
possibly different.  The truncated form of RPS10 observed in this investigation would 
alter the interactions in these pathways and would no longer (if it ever did) possess 
the dimethylarginines found in the C-terminal end of the protein.  Given this 
information, it is hard to predict what advantage or purpose this might serve in the 
MXR ribosome.  It is possible that the truncation is a product of proteosomal 




isoform is not likely behind the cause of the resistance but more the result of an effect 
of a pathway that has been disturbed.       
 Protein isoforms and their location in the ribosome 
 This investigation has established that at least 4 proteins have altered 
abundance between the MXR and MXS ribosome; RPS3, RPS10, RPL23A, and 
RPL11.   The modifications we have identified on these ribosomal proteins as well as 
the other ribosomal proteins/ribosomal associated proteins that they interact with in 
the context of the ribosomal machine may play a role in the function of these 
ribosomes.  The crystal structure of the eukaryotic ribosome was published in the last 





Ribosomal protein RPL11 
 There is ribosomal movement during the translocation of mRNA and tRNA 
frequently referred to as ratcheting.  The coordination of the small and large subunit 
in Saccharomyces cerevisiae was published by Ben-Shem et al
147
.  Though protein 
sequences are not identical between yeast and humans, the interactions between most 
proteins and overall ribosomal structure is expected to be very similar.  A key protein 
involved in the interactions between the 60S and 40S subunit is RPL11, referred to as 
the central protuberance protein.  Coordinated with RPL11 are the small subunit 
proteins RPS18 and RPS15 (refer to Figure 4.10).  Based on the 3.0 Angstrom 
resolution crystal structure of 80S ribosome from yeast, at one point in the subunit 
interaction, the RPL11 K85 residue is coordinated with RPS15 F42 residue
146; 147




should be noted again that the yeast sequence for RPL11 is not identical to the human 
sequence (a Blast search reveals that fission yeast and human RPL11 share 74% 
identity
117
),  If the interactions are the same in humans, RPL11 K85 is acetylated in 
the MXR cell line, changing the chemistry of the interaction between the two 
residues.  RPL11 was described along with the other proteins in the central 
protuberance, to undergo considerable rearrangements and a shift in position of all 
regions of the RPL11 sequence except for the N-terminal end.  It was suggested that 
this structural rearrangement is the possible reason for a separate5S rRNA which 
interacts with these proteins.  Based on its role in subunit interaction and the observed 
PTMs found in RPL11 in the MXR cell line, it is not surprising that alterations in 
PTMs might affect the movement of mRNA through the mRNA tunnel.  Based on 
investigations of the mRNA tunnel with a structural translation inhibitor called Stm1 
(a homologous protein in humans is unknown), the path through the mRNA tunnel of 
the Stm1 protein is believed to contact nine different ribosomal proteins indicating the 
presence of these proteins in the tunnel opening.  RPL11 is the only 60S subunit 
protein that is believed to come into direct contact with Stm1 suggesting RPL11 
interacts with mRNA as it passes through the processing tunnel.  This would make 
any alterations in the primary structure of RPL11 relevant to the accessibility of the 
tunnel in the ribosome for mRNA translation
146; 147







Figure 4.10 The ratcheted eukaryotic ribosome illustrating the interaction 
between RPL11, the 40S subunit with the small subunit proteins RPS15 and 




Ribosomal protein RPL23A 
  RPL23A is found near the exit tunnel in the eukaryotic ribosome (refer to 
Figure 4.11).  As previously mentioned, it is capable of interacting with protein 
factors in actively translating ribosomes such as the mTORC2 complex discussed 
above.  One of the most important interactions RPL23A has is as a member of the 
nascent polypeptide associated complex, otherwise known as the NAC, and the signal 
recognition particle, otherwise known as the SRP.  The nascent chain of an emerging 
polypeptide must come into contact with a large variety of factors in the eukaryotic 
cell including protein chaperones, methionine aminopeptidases, N-acetyltransferases, 
the NAC, the ribosome associated membrane proteinERj1p, the SRP, the translocon 




and β-subunit found in abundance in higher eukaryotes.  Altered intracellular levels 
of NAC subunits have been linked with numerous disease processes including 
Alzheimer’s disease, Down syndrome and malignant brain tumors
148
.  Although NAC 
deletion only causes minor growth defects in yeast it has been linked with embryonic 
lethality in mice, flies and nematodes.  With limited space around the exit tunnel of 
the ribosome, certain ribosomal proteins are used in a functional capacity for the 
NAC.  Numerous ribosomal proteins at the site of the exit tunnel including RPL23A 
have been identified as the docking site for both the NAC and the SRP with the 
binding being determined by protein sequence.  In the case of hydrophobic stretches 
of residues, recent studies have suggested that even before they emerge from the 
ribosome, the SRP is recruited by changing conformation of the ribosome.  It has also 
been suggested that the NAC is a modulator for the specificity of the SRP.  
Regardless, both of these so called CLIPS (chaperones linked to protein synthesis), 
have been found to directly interact with RPL23A
148; 149
.   It is interesting to note that 
the interactions that RPL23A has with mTORC2 in monitoring that Akt is modified 
correctly so that it may fold in the proper conformation and avoid ubiquitination  is 
not unlike the role that it plays in the NAC and the SRP.  Since ribosomal 
conformations are noted as changing to acquiesce to the need of the NAC and SRP 
for access to certain nascent polypeptides, if structural changes interfere with this 
ability, this would influence which proteins are successfully folded and modified for 
their role in the cell.  The SRP has been shown to display particular specificity 
towards hydrophobic sequences and transmembrane regions of proteins with the 




endoplasmic reticulum or the plasma membrane.  The SRP has been noted for altering 
the configuration of the ribosome upon binding due to these hydrophobic stretches of 
sequence so it is possible that these proteins would be more affected were the 
structure of the ribosome to be altered 
149
.    Regardless, if the structure of RPL23A is 
altered as in the case of the MXR cells, then it is reasonable to expect that this would 
influence its interactions with the NAC and SRP.   
 
Figure 4.11 RPL23A found with extension running through the exit tunnel of the 




Ribosomal protein RPS3 
 The interaction of ribosomal protein RPS3 with RACK1 is critical not only to 
cell signaling events but also to the structure of the 80S ribosome.  The C-terminal 
end of RPS3 is involved in at least two salt bridges with RACK1 according to 
structural studies of the 40S ribosome conducted by Rabl et al.  Their studies 
indicated that RPS3 spans much of the distance of the mRNA tunnel and interacts 
with RACK1, RPS17, RPS10, RPS20, RPS29 and RPS2 in the small subunit alone
142
.  
An illustration of RPS3 in the mRNA tunnel is shown in Figure 4.12.  Deviations 




would impact much of the interactions between the proteins in the ribosome.  The 
structural change between the RPS3 isoform observed in spot 6 and spot 8 is minimal 
with the N-terminal acetylation being the only difference.  The significance of this 
difference could either come from the chemistry of the change (interactions and size) 
or it could be rooted in the message that this acetylation gives the cell; preservation of 
the protein and destination in the cell
150
.  It is interesting to note that although the 
phosphorylation was common feature of an isoform seen in both cell lines, the 
location of that phosphorylation is on the C-terminal end which would affect whether 
or how RACK1 can interact with it and if RACK1 is not able to interact/continue 
interacting with the ribosome
142
.  Under these circumstances this could be the 
possible reason why certain proteins signal that RPS3 should relocate to the 
nucleus
139
.  One could even posit further that the proteins that then interact with the 
ribosome and set proteins like RPS3 on its course are determined by the state of the 
cell (DNA repair, pathogen response, undergoing a change in the cell cycle, etc.).       
 









Ribosomal protein RPS10 
 In the small subunit ribosomal protein RPS10 interacts with RPS3 as well as 
RPS12, RPS20 and RPS29.  The incorporation of RPS10 and successful interaction in 
the ribosome requires the full length protein with dimethyl arginine modifications 
found on R158 and R160.  The MXR ribosome contained a novel RPS10 isoform 
with a truncation of the last 28 residues from the C-terminal end.  With this truncation 
(from K137 to Q165), the dimethylarginine modification would obviously not be 
present and the interactions of this protein with other ribosomal proteins would be 
dramatically altered
112
.  It is suspected that this isoform is the result of proteosomal 
degradation, either of the RPS10 prior to its incorporation into the ribosome or as a 
result of the C-terminal end being vulnerable to proteases in the cell even in the 
context of the ribosomal machine.  In either case, the shift in ribosomal structure 
would impact the efficiency with which these ribosomes translate mRNA and could at 
least provide an explanation for the 25% decrease in ribosomal activity as determined 
by the methionine incorporation study.     
 
Summary and Prospectus 
This investigation has found that the acquired resistance after treatment of 
MCF7 breast cancer cells with mitoxantrone, a known inhibitor of ribosome 
biogenesis
36
 and binding partner of hNopp140
127
 (a phosphoprotein necessary for the 
localization of RNA polymerase I and binding partner of protein kinase CK2), leads 




ribosomes of the drug resistant cells were found to have altered abundance between 
the MXR and MXS ribosomes of isoforms of RPS3, RPL11, RPL23A and RPS10 and 
novel isoforms of RPS3and RPL11.  Investigations of the methionine incorporation of 
the drug resistant ribosomes found that it was 25% lower than the activity found in 
their drug susceptible counterparts.  This could not be explained by a change in the 
number of ribosomes between the two cell lines.   
Based on our findings and knowledge of the interacting partners of the 
different ribosomal protein isoforms, we would propose that the impact of the altered 
ribosomal proteins within the ribosomal machine extends to the access to ribosomal 
mRNA binding sites.  By altering the access the mRNA binding sites, this could 
allow for differential selective translational activity of the MXR ribosome.  Looking 
at the possible impact that exposure to mitoxantrone may have on the cell (increased 
levels of ROS in the cellular environment), a need for cell survival proteins exists.  
The concept behind differential selective translation is that cell survival proteins 
would be produced during times of cellular stress, such as that which occurs during 
exposure to a chemotherapeutic drug.  Hand in hand with the concept of differential 
selective translation is the ability of the ribosome to utilize cap-independent 
translation (IRES)
151
.  This is supported by the interacting partners of RPL23A, 
namely mTOR. 
Further characterization of these ribosomes is needed in terms of the 
modifications such as phosphorylation (RPS3 T221), in the proteins linked with their 
role in the ribosome (RACK1, Myc, mTOR, NAC, etc.) and in additional proteins 




RPL10, RPL5).  A proteomic approach is most practical.  In certain cases these 
proteins can be investigated using immunological techniques as evidenced by the 
large number of antibodies available for modifications like phosphorylation and for 






























RPSA D VLQMKEEDVLKFLAAGTHLGGTNL D 1.56E-24 
RPSA D VLKFLAAGTHLGGTNL D 1.33E-26 
RPSA D VLKFLAAGTHLGGTNLDFQMEQYIYKRKS D 2.12E-08 















RPS2 D KEWMPVTKLGRLVKD M 6.79E-07 
RPS2 D MKIKSLEEIYLFSLPIKESEIID F 0.000351 




RPS2 D HLVKTHTRVSVQRTQAPAVATT - 8.42E-09 
RPS3 M AVQISKKRKFVA D 7.77E-20 
RPS3 D GIFKAELNEFLTRELAE D 5.37E-22 
RPS3 D TAVRHVLLRQGVLGIKVKIMLPW D 9.57E-11 




RPS3A D VKAPAMFNIRNIGKTLVTRTQGTKIAS D 2.53E-19 
RPS3A D GLKGRVFEVSLA D 1.52E-08 
RPS3A D LQNDEVAFRKFKLITE D 3.33E-09 
RPS3A D EVAFRKFKLITE D 0.000023
3 
RPS3A D VQGKNCLTNFHGM D 2.2E-14 
RPS3A D LKEVVNKLIPD S 5.14E-10 
RPS3A D LKEVVNKLIPDSIGK D 1.54E-14 
RPS3A D SIGKDIEKACQSIYPLH D 6.74E-25 
RPS3A D IEKACQSIYPLH D 1.26E-10 












RPS4X D LETGKITDFIKF D 0.000043
2 











RPS5 D STRIGRAGTVRRQAVD V 0.000178 
RPS6 - MKLNISFPATGCQKLIEV D 9.85E-13 
RPS6 D ANLSVLNLVIVKKGEKD I 5.19E-13 
RPS6 D ANLSVLNLVIVKKGEKDIPGLT D 4.78E-07 
RPS7 - MFSSSAKIVKPNGEKPD E 1.01E-09 
RPS7 - MFSSSAKIVKPNGEKPDEFESGISQALLELEMNS D 3.39E-20 
RPS7 D AILEDLVFPSEIVGKRIRVKL D 3.29E-16 
RPS7 D LVFPSEIVGKRIRVKLD G 0.000515 
RPS7 D GSRLIKVHL D 7.25E-10 




RPS7 D VNFEFPEFQL - 1.23E-15 




RPS8 D GYVLEGKELEFYLRKIKARKGK - 3.27E-20 
RPS9 D PRRLFEGNALLRRLVRIGVLD E 0.000090
2 
RPS9 D PRRLFEGNALLRRLVRIGVLDEGKMKL D 0.000307 



























RPS11 D YLHYIRKYNRFEKRHKNMSVHLSPCFRD V 0.000014
6 




RPS11 D IVTVGECRPLSKTVRFNVLKVTKAAGTKKQFQKF - 1.77E-25 
RPS12 D VNTALQEVLKTALIH D 1.85E-26 
RPS12 D GLARGIREAAKAL D 3.2E-07 
RPS12 D EPMYVKLVEALCAEHQINLIKV D 0.000011
5 
RPS12 D NKKLGEWVGLCKI D 1.62E-08 
RPS12 D YGKESQAKDVIEEYFKCKK - 7.55E-16 
RPS12 D VIEEYFKCKK - 0.000015
3 
RPS13 M GRMHAPGKGLSQSALPYRRSVPTWLKLTSD D 3.3E-09 
RPS13 D DVKEQIYKLAKKGLTPSQIGVILR D 4.03E-24 




RPS13 D LPEDLYHLIKKAVAVRKHLERNRKD K 2.1E-07 




RPS14 D TFVHVTDLSGKETICRVTGGMKVKA D 9.98E-15 




RPS15 M AEVEQKKKRTFRKFTYRGVD L 1.15E-06 
















RPS16 D IRVRVKGGGHVAQIYAIRQSISKALVAYYQKYVD E 6.74E-12 
RPS16 D PRRCESKKFGGPGARARYQKSYR - 1.04E-10 
RPS17 M GRVRTKTVKKAARVIIEKYYTRLGND F 1.83E-08 
RPS17 D TKEMLKLLD F 2.38E-09 
RPS17 D TKEMLKLLDFGSLSNLQVTQPTVGMNFKTPRGPV - 3.58E-16 




RPS18 M SLVIPEKFQHILRVLNTNID G 4.88E-14 
RPS18 D GRRKIAFAITAIKGVGRRYAHVVLRKAD I 1.04E-06 








RPS19 D TVKLAKHKELAPYD E 4.65E-10 
RPS19 D GGRKLTPQGQRDLDRIAGQVAAANKKH - 0.000009
4 
RPS19 D LDRIAGQVAAANKKH - 6.7E-09 
RPS20 M AFKDTGKTPVEPEVAIHRIRITLTSRNVKSLEKVCA D 3.24E-06 
RPS20 D RFQMRIHKRLID L 8.67E-06 
RPS21 D LYVPRKCSASNRIIGAKD H 3.95E-06 
RPS21 D KVTGRFNGQFKTYAICGAIRRMGES D 7.38E-07 
RPS23 D GCLNFIEENDEVLVAGFGRKGHAVG D 1.95E-19 
RPS23 D EVLVAGFGRKGHAVGD I 0.000421 
RPS23 D IPGVRFKVVKVANVSLLALYKGKKERPRS - 8.38E-37 
RPS24 D TVTIRTRKFMTNRLLQRKQMVID V 1.17E-06 




RPS24 D VIFVFGFRTHFGGGKTTGFGMIY D 7.51E-16 










RPS26 D KAIKKFVIRNIVEAAAVRD I 5.23E-29 
RPS26 D KAIKKFVIRNIVEAAAVRDISEASVF D 8.09E-09 
RPS26 D AYVLPKLYVKLHYCVSCAIHSKVVRNRSREARKD R 0.000036
3 
RPS26 D RTPPPRFRPAGAAPRPPPKPM - 1.47E-11 




RPS28 D TSRVQPIKLARVTKVLGRTGSQGQCTQVRVEFM D 1.58E-14 
RPS28 D TSRSIIRNVKGPVREGD V 2.26E-07 
RPS28 D TSRSIIRNVKGPVREGDVLTLLESEREARRLR - 4.22E-27 
RPS28 D VLTLLESEREARRLR - 1.52E-17 
RPL3 M SHRKFSAPRHGSLGFLPRKRSSRHRGKVKSFPK D 3.74E-14 










RPL3 D TTSKFGHGRFQTMEEKKAFMGPLKK D 3.09E-24 
RPL3 D TTSKFGHGRFQTMEEKKAFMGPLKKDRIAKEEGA - 1.96E-20 
RPL4 M ACARPLISVYSEKGESSGKNVTLPAVFKAPIRPD I 9.28E-26 
















RPL5 M GFVKVVKNKAYFKRYQVKFRRRREGKTD Y 1.57E-08 
RPL5 D KNKYNTPKYRMIVRVTNR D 2.68E-06 
RPL5 D AGLARTTTGNKVFGALKGAVD G 3.55E-22 
RPL5 D GGLSIPHSTKRFPGY D 1.97E-10 
RPL5 D SESKEFNAEVHRKHIMGQNVA D 0.000132 
RPL5 D YMRYLMEE D 9.83E-10 
RPL5 D AYKKQFSQYIKNSVTPD M 0.00023 
RPL5 D RVAQKKASFLRAQERAAES - 3.47E-12 





RPL6 D ISNVKIPKHLTD A 9.97E-20 
RPL6 D ISNVKIPKHLTDAYFKKKKLRKPRHQEGEIF D 4.23E-13 
RPL6 D AYFKKKKLRKPRHQEGEIF D 6.23E-13 
RPL6 D AYFKKKKLRKPRHQEGEIFDTEKEKYEITEQRKI D 2.97E-24 
RPL6 D TEKEKYEITEQRKID Q 1.04E-11 
RPL6 D SQILPKIKAIPQLQGYLRSVFALTNGIYPHKLVF - 7.04E-23 





















RPL7A D VPTKRPPVLRAGVNTVTTLVENKKAQLVVIAHD V 8.6E-28 




RPL7A D KGALAKLVEAIRTNYND R 8.99E-09 
RPL7A D KGALAKLVEAIRTNYNDRY D 1.38E-12 




RPL8 D FAERHGYIKGIVKD I 6.02E-12 
RPL8 D FAERHGYIKGIVKDIIHD P 2.58E-24 











RPL9 D IPENVDITLKGRTVIVKGPRGTLRR D 0.000017
6 
RPL9 D ITLKGRTVIVKGPRGTLRR D 9.72E-15 
RPL9 D FNHINVELSLLGKKKKRLRVD K 3.74E-07 
RPL9 D IELVSNSAALIQQATTVKNK D 7.6E-15 
RPL9 D IELVSNSAALIQQATTVKNKDIRKFL D 0.000081 
RPL9 D GIYVSEKGTVQQA D 1.63E-10 
RPL10 M GRRPARCYRYCKNKPYPKSRFCRGVPD A 0.000539 
RPL10 D AKIRIFDLGRKKAKVD E 3.79E-15 
RPL10 D MVAEKRLIP D 2.35E-06 
RPL10A D TLYEAVREVLHGNQRKRRKFLETVELQISLKNY D 1.07E-12 
RPL10A D IPHMDIEALKKLNKNKKLVKKLAKKY D 3.4E-12 




RPL11 D TGNFGFGIQEHID L 5.91E-16 
RPL11 D PSIGIYGL D 6.28E-10 
















RPL14 M VFRRFVEVGRVAYVSFGPHAGKLVAIVD V 1.62E-09 




RPL14 D FILKFPHSAHQKYVRQAWQKAD I 0.000028
5 
RPL14 D INTKWAATRWAKKIEARERKAKMTD F 0.000047
7 
RPL15 M GAYKYIQELWRKKQSD V 1.38E-08 
RPL15 D STYKFFEVILI D 4.77E-13 












RPL18 D VRVQEVPKLKVCALRVTSRARSRILRAGGKILTF D 1.9E-07 




RPL18A D SKIKFPLPHRVLRRQHKPRFTTKRPNTFF - 2.71E-12 
RPL19 M SMLRLQKRLASSVLRCGKKKVWLD P 1.69E-07 
RPL19 D PNETNEIANANSRQQIRKLIKD G 9.52E-07 















RPL23 M SKRGRGGSSGAKFRISLGLPVGAVINCA D 7.77E-14 
RPL23 D NTGAKNLYIISVKGIKGRLNRLPAAGVG D 7.59E-21 
RPL23 D MVMATVKKGKPELRKKVHPAVVIRQRKSYRRKD G 1.41E-09 
RPL23 D NAGVIVNNKGEMKGSAITGPVAKECA D 1.64E-27 
RPL23 D LWPRIASNAGSIA - 2.88E-10 
RPL23A D VKANKHQIKQAVKKLY D 8.2E-16 
RPL23A D VKANKHQIKQAVKKLYDI D 0.00068 
RPL23A D IDVAKVNTLIRP D 0.000012
5 
RPL23A D ALDVANKIGII - 2.52E-21 
RPL23A D VANKIGII - 2.76E-20 









RPL26 D RKKILERKAKSRQVGKEKGKYKEETIEKMQE - 8.23E-17 
RPL27 M GKFMKPGKVVLVLAGRYSGRKAVIVKNID D 4.45E-17 










RPL27 D IPLDKTVVNKDVFR D 3.18E-19 
RPL27 D PALKRKARREAKVKFEERYKTGKNKWFFQKLRF - 4.25E-21 
RPL27A D KYHPGYFGKVGMKHYHLKRNQSFCPTVNL D 5.55E-09 













RPL30 D IIRSMPEQTGEK - 8.84E-16 
RPL31 D TRLNKAVWAKGIRNVPYRIRVRLSRKRNE D 0.000080
4 
RPL31 D SPNKLYTLVTYVPVTTFKNLQTVNVD E 4.47E-15 
RPL32 M AALRPLVKPKIVKKRTKKFIRHQSD R 2.19E-18 
RPL32 D RYVKIKRNWRKPRGI D 0.000455 
RPL34 D RIKRAFLIEEQKIVVKVLKAQAQSQKAK - 2.17E-38 
RPL35 M AKIKARDLRGKKKEELLKQL D 2.69E-11 


























RPL36A D KKRKGQVIQF - 0.000113 




RPL38 D KEKAEKLKQSLPPGLAVKELK - 1.01E-23 




RPLP0 D YTFPLAEKVKAFLA D 3.32E-25 
RPLP2 - MRYVASYLLAALGGNSSPSAK D 2.44E-25 
RPLP2 - MRYVASYLLAALGGNSSPSAKDIKKIL D 3.99E-14 








 Appendix Table 1: Acid Digestion peptide identifications and their 

























1. Hays, F. A. (2006). Mass Spectrometric Analysis of Cytoplasmic Ribosomal 
Proteins in Drug Resistant and Drug Susceptible Human Cell Lines. Doctor of 
Philosophy, University of Maryland. 
2. Cannon, J., Lohnes, K., Wynne, C., Wang, Y., Edwards, N. & Fenselau, C. 
(2010). High-Throughput Middle-Down Analysis Using an Orbitrap. Journal 
of Proteome Research 9, 3886-3890. 
3. Nobelprize.org. (2009). The Nobel Prize in Chemistry 2009. 
4. Spirin, A. S. (2002). Ribosome as a Molecular Machine. FEBS Letters Protein 
Biosynthesis 514, 2-10. 
5. Perry, R. (2005). The Architecture of Mammalian Ribosomal Protein 
Promoters. BMC Evolutionary Biology 5, 15. 
6. Perry, R. P. (2007). Balanced Production of Ribosomal Proteins. Gene 401, 1-
3. 
7. Warner, J. R. (1977). In the Absence of Ribosomal RNA Synthesis, the 
Ribosomal Proteins of HeLa Cells are Synthesized Normally and Degraded 
Rapidly. Journal of Molecular Biology 115, 315-333. 
8. Lam, Y. W., Lamond, A. I., Mann, M. & Andersen, J. S. (2007). Analysis of 
Nucleolar Protein Dynamics Reveals the Nuclear Degradation of Ribosomal 
Proteins. Current biology : CB 17, 749-760. 
9. Cech, T. R. (2000). The Ribosome Is a Ribozyme. Science 289, 878-879. 
10. Matragkou, C. N., Eleni T. Papachristou, Sotirios S. Tezias, Asterios S. 
Tsiftsoglou, Theodora Choli-Papadopoulou, Ioannis S. Vizirianakis,. (2008). 
The Potential Role of Ribosomal Protein S5 on Cell Cycle Arrest and 
Initiation of Murine Erythroleukemia Cell Differentiation. Journal of Cellular 
Biochemistry 104, 1477-1490. 
11. Worbs, M., Wahl, M. C., Lindahl, L. & Zengel, J. M. (2002). Comparative 
Anatomy of a Regulatory Ribosomal Protein. Biochimie 84, 731-743. 
12. Lafontaine, D. L. J. & Tollervey, D. (2001). The Function and Synthesis of 
Ribosomes. Nat Rev Mol Cell Biol 2, 514-520. 
13. Steitz, T. A. (2008). A Structural Understanding of the Dynamic Ribosome 
Machine. Nat Rev Mol Cell Biol 9, 242-253. 
14. Chandramouli, P., Topf, M., Ménétret, J.-F., Eswar, N., Cannone, J. J., Gutell, 
Robin R., Sali, A. & Akey, C. W. (2008). Structure of the Mammalian 80S 
Ribosome at 8.7 Å Resolution. Structure 16, 535-548. 
15. Kenmochi, N., Kawaguchi, T., Rozen, S., Davis, E., Goodman, N., Hudson, T. 
J., Tanaka, T. & Page, D. C. (1998). A Map of 75 Human Ribosomal 
Protein Genes. Genome Res. 8, 509-523. 
16. Lewis, J. D. & Tollervey, D. (2000). Like Attracts Like: Getting RNA 
Processing Together in the Nucleus. Science 288, 1385-1389. 
17. Lecompte, O., Ripp, R., Thierry, J.-C., Moras, D. & Poch, O. (2002). 




Example of Reductive Evolution at the Domain Scale. Nucl. Acids Res. 30, 
5382-5390. 
18. Wilson, D. N. & Nierhaus, K. H. (2005). Ribosomal Proteins in the Spotlight. 
Critical Reviews in Biochemistry and Molecular Biology 40, 243 - 267. 
19. Henras, A., Soudet, J., GÃcrus, M., Lebaron, S., Caizergues-Ferrer, M., 
Mougin, A. & Henry, Y. (2008). The Post-transcriptional Steps of Eukaryotic 
Ribosome Biogenesis. Cellular and Molecular Life Sciences (CMLS) 65, 
2334-2359. 
20. Nakao, A., Yoshihama, M. & Kenmochi, N. (2004). RPG: the Ribosomal 
Protein Gene database. Nucl. Acids Res. 32, D168-170. 
21. Nazar, R. N. (1980). A 5.8 S rRNA-like Sequence in Prokaryotic 23 S rRNA. 
FEBS Letters 119, 212-214. 
22. Wool, I. G., Yuen-Ling Chan, and Anton Glück. (1995). Structure and 
Evolution of Mammalian Ribosomal Proteins. Biochem. Cell Biol. 73, 933-
947. 
23. Xaplanteri, M. A., Papadopoulos, G., Leontiadou, F., Choli-Papadopoulou, T. 
& Kalpaxis, D. L. (2007). The Contribution of the Zinc-Finger Motif to the 
Function of Thermus thermophilus Ribosomal Protein S14. Journal of 
Molecular Biology 369, 489-497. 
24. Dresios, J., Chan, Y.-L. & Wool, I. G. (2002). The Role of the Zinc Finger 
Motif and of the Residues at the Amino Terminus in the Function of Yeast 
Ribosomal Protein YL37a. Journal of Molecular Biology 316, 475-488. 
25. Mazumder, B., Sampath, P., Seshadri, V., Maitra, R. K., DiCorleto, P. E. & 
Fox, P. L. (2003). Regulated Release of L13a from the 60S Ribosomal 
Subunit as A Mechanism of Transcript-Specific Translational Control. Cell 
115, 187-198. 
26. Hemmerich, P., Stefan Bosbach, Anna Mikecz, Ulrich Krawinkel,. (1997). 
Human Ribosomal Protein L7 Binds RNA with an alpha-Helical Arginine-
Rich and Lysine-Rich Domain. European Journal of Biochemistry 245, 549-
556. 
27. Baxter-Roshek, J. L., Petrov, A. N. & Dinman, J. D. (2007). Optimization of 
Ribosome Structure and Function by rRNA Base Modification. PLoS ONE 2, 
e174. 
28. Jack, K., Bellodi, C., Landry, Dori M., Niederer, Rachel O., Meskauskas, A., 
Musalgaonkar, S., Kopmar, N., Krasnykh, O., Dean, Alison M., Thompson, 
Sunnie R., Ruggero, D. & Dinman, Jonathan D. (2011). rRNA 
Pseudouridylation Defects Affect Ribosomal Ligand Binding and 
Translational Fidelity from Yeast to Human Cells. Molecular Cell 44, 660-
666. 
29. Acker, M. G. & Lorsch, J. R. (2008). Mechanism of Ribosomal Subunit 
Joining During Eukaryotic Translation Initiation. Biochemical Society 
Transactions 036, 653-657. 
30. Gebauer, F. & Hentze, M. W. (2004). Molecular Mechanisms of Translational 
Control. Nat Rev Mol Cell Biol 5, 827-835. 
31. Kapp, L. D. & Lorsch, J. R. (2004). The Molecular Mechanics of Eukaryotic 




32. Lee, T.-H., Blanchard, S. C., Kim, H. D., Puglisi, J. D. & Chu, S. (2007). The 
Role of Fluctuations in tRNA Selection by the Ribosome. Proceedings of the 
National Academy of Sciences 104, 13661-13665. 
33. Budkevich, T. V., El'skaya, A. V. & Nierhaus, K. H. (2008). Features of 80S 
Mammalian Ribosome and its Subunits. Nucl. Acids Res. 36, 4736-4744. 
34. Pisarev, A. V., Hellen, C. U. T. & Pestova, T. V. (2007). Recycling of 
Eukaryotic Posttermination Ribosomal Complexes. Cell 131, 286-299. 
35. Nakagawa, M., Schneider, E., Dixon, K. H., Horton, J., Kelley, K., Morrow, 
C. & Cowan, K. H. (1992). Reduced Intracellular Drug Accumulation in the 
Absence of P-glycoprotein (mdr1) Overexpression in Mitoxantrone-Resistant 
Human MCF-7 Breast Cancer Cells. Cancer Res 52, 6175-81. 
36. Burger, K., Mühl, B., Harasim, T., Rohrmoser, M., Malamoussi, A., Orban, 
M., Kellner, M., Gruber-Eber, A., Kremmer, E., Hölzel, M. & Eick, D. 
(2010). Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various 
Levels. Journal of Biological Chemistry 285, 12416-12425. 
37. Mewes, K., Blanz, J., Ehninger, G., Gebhardt, R. & Zeller, K.-P. (1993). 
Cytochrome P-450-induced Cytotoxicity of Mitoxantrone by Formation of 
Electrophilic Intermediates. Cancer Research 53, 5135-5142. 
38. Gopinath, S. C. B., Matsugami, A., Katahira, M. & Kumar, P. K. R. (2005). 
Human Vault-Associated Non-Coding RNAs Bind to Mitoxantrone, a 
Chemotherapeutic Compound. Nucleic Acids Research 33, 4874-4881. 
39. Gopinath, S. C. B., Wadhwa, R. & Kumar, P. K. R. (2010). Expression of 
Noncoding Vault RNA in Human Malignant Cells and Its Importance in 
Mitoxantrone Resistance. Molecular Cancer Research 8, 1536-1546. 
40. Meskauskas, A. & Dinman, J. D. (2007). Ribosomal Protein L3: Gatekeeper 
to the A Site. Molecular Cell 25, 877-888. 
41. Meskauskas, A., Russ, J. R. & Dinman, J. D. (2008). Structure/Function 
Analysis of Yeast Ribosomal Protein L2. Nucl. Acids Res. 36, 1826-1835. 
42. Kawai, S., Murao, S., Mochizuki, M., Shibuya, I., Yano, K. & Takagi, M. 
(1992). Drastic Alteration of Cycloheximide Sensitivity by Substitution of 
One Amino Acid in the L41 Ribosomal Protein of Yeasts. J. Bacteriol. 174, 
254-262. 
43. Wilcox, S. K., Cavey, G. S. & Pearson, J. D. (2001). Single Ribosomal 
Protein Mutations in Antibiotic-Resistant Bacteria Analyzed by Mass 
Spectrometry. Antimicrob. Agents Chemother. 45, 3046-3055. 
44. Carr, J. F., Gregory, S. T. & Dahlberg, A. E. (2005). Severity of the 
Streptomycin Resistance and Streptomycin Dependence Phenotypes of 
Ribosomal Protein S12 of Thermus thermophilus Depends on the Identity of 
Highly Conserved Amino Acid Residues. Journal of Bacteriology 187, 3548-
3550. 
45. Carr, J. F., Hamburg, D.-M., Gregory, S. T., Limbach, P. A. & Dahlberg, A. 
E. (2006). Effects of Streptomycin Resistance Mutations on Posttranslational 
Modification of Ribosomal Protein S12. J. Bacteriol. 188, 2020-2023. 
46. Warner, J. R. & McIntosh, K. B. (2009). How Common Are Extraribosomal 




47. Shi, Y., Zhai, H., Wang, X., Han, Z., Liu, C., Lan, M., Du, J., Guo, C., Zhang, 
Y., Wu, K. & Fan, D. (2004). Ribosomal Proteins S13 and L23 Promote 
Multidrug Resistance in Gastric Cancer Cells by Suppressing Drug-Induced 
Apoptosis. Experimental Cell Research 296, 337-346. 
48. Gottesman, M. M., Fojo, T. & Bates, S. E. (2002). Multidrug Resistance in 
Cancer: Role of ATP-Dependent Transporters. Nat Rev Cancer 2, 48-58. 
49. Wasinger, V. C., Stuart J. Cordwell, Anne Cerpa-Poljak, Jun X. Yan, Andrew 
A. Gooley, Marc R. Wilkins, Mark W. Duncan, Ray Harris, Keith L. 
Williams, Ian Humphery-Smith. (1995). Progress with Gene-Product Mapping 
of the Mollicutes: Mycoplasma genitalium. Electrophoresis 16, 1090-1094. 
50. Wilkins, M. R. S., Jean-Charles; Gooley, Andrew A.; Appel, Ron D.; 
Humphery-Smith, Ian; Hochstrasser, Denis F.; Williams, Keith L. (1996). 
Progress with Proteome Projects: Why all Proteins Expressed by a Genome 
Should be Identified and How to Do It. Biotechnology & Genetic Engineering 
Reviews 13, 19-50. 
51. Anderson, N. L., Norman G. Anderson. (1998). Proteome and Proteomics: 
New Technologies, New Concepts, and New Words. Electrophoresis 19, 
1853-1861. 
52. Dass, C. (2007). Fundamentals of Contemporary Mass Spectrometry, John 
Wiley and Sons Ltd. 
53. Consortium, T. U. (2011). Ongoing and Future Developments At the 
Universal Protein Resource. Nucleic acids research 39, D214-D219. 
54. Hayden, E. C. (2011). Cells May Stray From 'Central Dogma'; The Ability to 
Edit RNA to Produce 'New' Protein-Coding Sequences Could be Widespread 
in Human Cells. Nature doi: doi:10.1038/news.2011.304  
55. Lei, T., He, Q.-Y., Wang, Y.-L., Si, L.-S. & Chiu, J.-F. (2008). Heparin 
Chromatography to Deplete High-Abundance Proteins for Serum Proteomics. 
Clinica Chimica Acta 388, 173-178. 
56. Simpson, R. J. (2003). Proteins and Proteomics : a Laboratory Manual, Cold 
Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 
57. Eng, J. K., McCormack, A. L. & Yates, J. R. (1994). An Approach to 
Correlate Tandem Mass Spectral Data of Peptides with Amino Acid 
Sequences in a Protein Database. Journal of the American Society for Mass 
Spectrometry 5, 976-989. 
58. Siuti, N. & Kelleher, N. L. (2007). Decoding Protein Modifications Using 
Top-Down Mass Spectrometry. Nature Methods 4, 817-821. 
59. Pesavento, J. J., Mizzen, C. A. & Kelleher, N. L. (2006). Quantitative 
Analysis of Modified Proteins and Their Positional Isomers by Tandem Mass 
Spectrometry: Human Histone H4. Anal. Chem. 78, 4271-4280. 
60. Pesavento, J. J., Kim, Y.-B., Taylor, G. K. & Kelleher, N. L. (2004). Shotgun 
Annotation of Histone Modifications: A New Approach for Streamlined 
Characterization of Proteins by Top Down Mass Spectrometry. J. Am. Chem. 
Soc. 126, 3386-3387. 
61. Doerr, A. (2008). Top-Down Mass Spectrometry. Nature Methods 5, 24. 
62. Zee BM, Young NL & BA, G. (2011). Quantitative Proteomic Approaches to 




63. Mann, M. & Kelleher, N. L. (2008). Precision Proteomics: The Case for High 
Resolution and High Mass Accuracy. Proceedings of the National Academy of 
Sciences 105, 18132-18138. 
64. Swatkoski, S., Gutierrez, P., Wynne, C., Petrov, A., Dinman, J., Edwards, N. 
& Fenselau, C. (2008). Evaluation of Microwave-Accelerated Residue-
Specific Acid Cleavage for Proteomic Applications. J. Proteome Res. 7, 579-
586. 
65. Hauser, N. J., Han, H., McLuckey, S. A. & Basile, F. (2008). Electron 
Transfer Dissociation of Peptides Generated by Microwave D-Cleavage 
Digestion of Proteins. Journal of Proteome Research 7, 1867-1872. 
66. Wu, S.-L., Hühmer, A. F. R., Hao, Z. & Karger, B. L. (2007). On-Line 
LC−MS Approach Combining Collision-Induced Dissociation (CID), 
Electron-Transfer Dissociation (ETD), and CID of an Isolated Charge-
Reduced Species for the Trace-Level Characterization of Proteins with Post-
Translational Modifications. Journal of Proteome Research 6, 4230-4244. 
67. Lee, S.-W., Berger, S. J., Martinović, S., Paša-Tolić, L., Anderson, G. A., 
Shen, Y., Zhao, R. & Smith, R. D. (2002). Direct Mass Spectrometric 
Analysis of Intact Proteins of the Yeast Large Ribosomal Subunit Using 
Capillary LC/FTICR. Proceedings of the National Academy of Sciences 99, 
5942-5947. 
68. Vladimirov, S. N., Anton V. Ivanov, Galina G. Karpova, Alekxander K. 
Musolyamov, Tsezi A. Egorov, Bernd Thiede, Brigitte Wittmann-Liebold & 
Albrecht Otto. (1996). Characterization of the Human Small-Ribosomal-
Subunit Proteins by N-Terminal and Internal Sequencing, and Mass 
Spectrometry. European Journal of Biochemistry 239, 144-149. 
69. Link, A. J., Eng, J., Schieltz, D. M., Carmack, E., Mize, G. J., Morris, D. R., 
Garvik, B. M. & Yates, J. R. (1999). Direct Analysis of Protein Complexes 
Using Mass Spectrometry. Nat Biotech 17, 676-682. 
70. Forbes, A. J., Patrie, S. M., Taylor, G. K., Kim, Y.-B., Jiang, L. & Kelleher, 
N. L. (2004). Targeted Analysis and Discovery of Posttranslational 
Modifications in Proteins from Methanogenic Archaea by Top-Down MS. 
Proceedings of the National Academy of Sciences of the United States of 
America 101, 2678-2683. 
71. Strader, M. B., VerBerkmoes, N. C., Tabb, D. L., Connelly, H. M., Barton, J. 
W., Bruce, B. D., Pelletier, D. A., Davison, B. H., Hettich, R. L., Larimer, F. 
W. & Hurst, G. B. (2004). Characterization of the 70S Ribosome from 
Rhodopseudomonas palustris Using an Integrated "Top-Down" and "Bottom-
Up" Mass Spectrometric Approach. J. Proteome Res. 3, 965-978. 
72. Running, W. E., Ravipaty, S., Karty, J. A. & Reilly, J. P. (2007). A Top-
Down/Bottom-Up Study of the Ribosomal Proteins of Caulobacter crescentus. 
J. Proteome Res. 6, 337-347. 
73. Louie, D. F., Resing, K. A., Lewis, T. S. & Ahn, N. G. (1996). Mass 
Spectrometric Analysis of 40 S Ribosomal Proteins from Rat-1 Fibroblasts. J. 




74. Yu, Y., Ji, H., Doudna, J. A. & Leary, J. A. (2005). Mass Spectrometric 
Analysis of the Human 40S Ribosomal Subunit: Native and HCV IRES-
Bound Complexes. Protein Sci 14, 1438-1446. 
75. Carroll, A. J., Heazlewood, J. L., Ito, J. & Millar, A. H. (2008). Analysis of 
the Arabidopsis Cytosolic Ribosome Proteome Provides Detailed Insights into 
Its Components and Their Post-translational Modification. Mol Cell 
Proteomics 7, 347-369. 
76. van Riggelen, J., Yetil, A. & Felsher, D. W. (2010). MYC as a Regulator of 
Ribosome Biogenesis and Protein Synthesis. Nat Rev Cancer 10, 301-309. 
77. Bykhovskaya, Y., Mengesha, E. & Fischel-Ghodsian, N. (2009). Phenotypic 
Expression of Maternally Inherited Deafness is Affected by RNA 
Modification and Cytoplasmic Ribosomal Proteins. Molecular Genetics and 
Metabolism 97, 297-304. 
78. Mao-De, L. & Jing, X. (2007). Ribosomal Proteins and Colorectal Cancer. 
Current Genomics 8, 43-49. 
79. Dai, M.-S. & Lu, H. (2008). Crosstalk Between c-Myc and Ribosome in 
Ribosomal Biogenesis and Cancer. Journal of Cellular Biochemistry 105, 
670-677. 
80. Ellis, S. R. & Massey, A. T. (2006). Diamond Blackfan Anemia: A Paradigm 
for a Ribosome-Based Disease. Medical hypotheses 66, 643-648. 
81. Zhang, Y. & Lu, H. (2009). Signaling to p53: Ribosomal Proteins Find Their 
Way. Cancer Cell 16, 369-377. 
82. Mauro, V. P. & Edelman, G. M. (2007). The Ribosome Filter Redux. Cell 
Cycle 6, 2246-2251. 
83. Mauro, V. P. & Edelman, G. M. (2002). The Ribosome Filter Hypothesis. 
Proceedings of the National Academy of Sciences of the United States of 
America 99, 12031-12036. 
84. Haselbacher, G. K., Humbel, R. E. & Thomas, G. (1979). Insulin-Like 
Growth Factor: Insulin or Serum Increase Phosphorylation of Ribosomal 
Protein S6 During Transition of Stationary Chick Embryo Fibroblasts into 
Early G1 Phase of the Cell Cycle. FEBS Letters 100, 185-190. 
85. Spence, J., Gali, R. R., Dittmar, G., Sherman, F., Karin, M. & Finley, D. 
(2000). Cell Cycle-Regulated Modification of the Ribosome by a Variant 
Multiubiquitin Chain. Cell 102, 67-76. 
86. Porras-Yakushi, T., Whitelegge, J. & Clarke, S. (2006). A Novel SET Domain 
Methyltransferase in Yeast: Rkm2-Dependent Trimethylation of Ribosomal 
Protein L12ab at Lysine 10. The Journal of biological chemistry 281, 35835 - 
35845. 
87. Komili, S., Farny, N. G., Roth, F. P. & Silver, P. A. (2007). Functional 
Specificity among Ribosomal Proteins Regulates Gene Expression. Cell 131, 
557-571. 
88. Bellodi, C., Krasnykh, O., Haynes, N., Theodoropoulou, M., Peng, G., 
Montanaro, L. & Ruggero, D. (2010). Loss of Function of the Tumor 
Suppressor DKC1 Perturbs p27 Translation Control and Contributes to 




89. Kondrashov, N., Pusic, A., Stumpf, C. R., Shimizu, K., Hsieh, Andrew C., 
Xue, S., Ishijima, J., Shiroishi, T. & Barna, M. (2011). Ribosome-Mediated 
Specificity in Hox mRNA Translation and Vertebrate Tissue Patterning. Cell 
145, 383-397. 
90. Kasai, H., Nadano, D., Hidaka, E., Higuchi, K., Kawakubo, M., Sato, T.-A. & 
Nakayama, J. (2003). Differential Expression of Ribosomal Proteins in 
Human Normal and Neoplastic Colorectum. J. Histochem. Cytochem. 51, 567-
574. 
91. Hardy SJ, K. C., Voynow P, Mora G. (1969). The Ribosomal Proteins of 
Escherichia coli. I. Purification of the 30S Ribosomal Proteins. Biochemistry. 
8, 2897-905. 
92. Barritault, D., Expert-BezanÇOn, A., GuÉRin, M.-F. & Hayes, D. (1976). The 
Use of Acetone Precipitation in the Isolation of Ribosomal Proteins. European 
Journal of Biochemistry 63, 131-135. 
93. Görg, A., Obermaier, C., Boguth, G., Csordas, A., Diaz, J.-J. & Madjar, J.-J. 
(1997). Very Alkaline Immobilized pH Gradients for Two-Dimensional 
Electrophoresis of Ribosomal and Nuclear Proteins. Electrophoresis 18, 328-
337. 
94. Görg, A., Weiss, W. & Dunn, M. J. (2004). Current Two-Dimensional 
Electrophoresis Technology for Proteomics. Proteomics 4, 3665-3685. 
95. Kane, L. A., Yung, C. K., Agnetti, G., Neverova, I. & Van Eyk, J. E. (2006). 
Optimization of Paper Bridge Loading for 2-DE Analysis in the Basic pH 
Region: Application to the Mitochondrial Subproteome. Proteomics 6, 5683-
5687. 
96. Lamberti, C., Pessione, E., Giuffrida, M. G., Mazzoli, R., Barello, C., Conti, 
A. & Giunta, C. (2007). Combined cup loading, bis(2-hydroxyethyl) disulfide, 
and protein precipitation protocols to improve the alkaline proteome of 
Lactobacillus hilgardii. Electrophoresis 28, 1633-1638. 
97. Görg, A., Drews, O., Lück, C., Weiland, F. & Weiss, W. (2009). 2-DE with 
IPGs. Electrophoresis 30, S122-S132. 
98. Bartkowiak, K., Wieczorek, M., Buck, F., Harder, S. n., Moldenhauer, J., 
Effenberger, K. E., Pantel, K., Peter-Katalinic, J. & Brandt, B. H. (2009). 
Two-Dimensional Differential Gel Electrophoresis of a Cell Line Derived 
from a Breast Cancer Micrometastasis Revealed a Stem/Progenitor Cell 
Protein Profile. Journal of Proteome Research 8, 2004-2014. 
99. Gorg, A., Klaus, A., Luck, C., Welland, F. & Weiss, W. (2007). Two-
dimensional Electrophoresis with Immobilized pH Gradients for Proteome 
Analysis. In A Laboratory Manual 3 edit., pp. 166. Technical University of 
Munich, Freising-Weihenstephan, Germany. 
100. Li, X.-M., Patel, B. B., Blagoi, E. L., Patterson, M. D., Seeholzer, S. H., 
Zhang, T., Damle, S., Gao, Z., Boman, B. & Yeung, A. T. (2004). Analyzing 
Alkaline Proteins in Human Colon Crypt Proteome. Journal of Proteome 
Research 3, 821-833. 
101. Shevchenko, A., Tomas, H., Havlis, J., Olsen, J. V. & Mann, M. (2007). In-
Gel Digestion for Mass Spectrometric Characterization of Proteins and 




102. Mirza, U. A., Liu, Y.-H., Tang, J. T., Porter, F., Bondoc, L., Chen, G., 
Pramanik, B. N. & Nagabhushan, T. L. (2000). Extraction and 
Characterization of Adenovirus Proteins from Sodium Dodecylsulfate 
Polyacrylamide Gel Electrophoresis by Matrix-Assisted Laser 
Desorption/Ionization Mass Spectrometry. Journal of the American Society 
for Mass Spectrometry 11, 356-361. 
103. Edwards, N., Wu, X. & Tseng, C.-W. (2009). An Unsupervised, Model-Free, 
Machine-Learning Combiner for Peptide Identifications from Tandem Mass 
Spectra. Clinical Proteomics 5, 23-36. 
104. Wynne, C., Fenselau, C., Demirev, P. A. & Edwards, N. (2009). Top-Down 
Identification of Protein Biomarkers in Bacteria with Unsequenced Genomes. 
Analytical Chemistry 81, 9633-9642. 
105. Kamp, R. M. & Wittmann-Liebold, B. (1984). Purification of Escherichia coli 
50 S Ribosomal Proteins by High Performance Liquid Chromatography. 
FEBS Letters 167, 59-63. 
106. Cooperman, B. S., Weitzmann, C. J. & Buck, M. A. (1988). Reversed-Phase 
High-Performance Liquid Chromatography of Ribosomal Proteins. In 
Methods in Enzymology (Harry F. Noller, J. K. M., ed.), Vol. Volume 164, pp. 
523-532. Academic Press. 
107. Carroll, A., Heazlewood, J., Ito, J. & Millar, A. (2008). Analysis of the 
Arabidopsis Cytosolic Ribosome Proteome Provides Detailed Insights Into Its 
Components and Their Post-Translational Modification. Mol Cell Proteomics 
7, 347 - 369. 
108. Gilar, M., Bouvier, E. S. P. & Compton, B. J. (2001). Advances in Sample 
Preparation in Electromigration, Chromatographic and Mass Spectrometric 
Separation Methods. Journal of Chromatography A 909, 111-135. 
109. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. 
C., Olsen, J. V. & Mann, M. (2009). Lysine Acetylation Targets Protein 
Complexes and Co-Regulates Major Cellular Functions. Science 325, 834-
840. 
110. Schwer, B., Eckersdorff, M., Li, Y., Silva, J. C., Fermin, D., Kurtev, M. V., 
Giallourakis, C., Comb, M. J., Alt, F. W. & Lombard, D. B. (2009). Calorie 
Restriction Alters Mitochondrial Protein Acetylation. Aging Cell 8, 604-606. 
111. Odintsova, T. I., Müller, E.-C., Ivanov, A. V., Egorov, T. A., Bienert, R., 
Vladimirov, S. N., Kostka, S., Otto, A., Wittmann-Liebold, B. & Karpova, G. 
G. (2003). Characterization and Analysis of Posttranslational Modifications of 
the Human Large Cytoplasmic Ribosomal Subunit Proteins by Mass 
Spectrometry and Edman Sequencing. Journal of Protein Chemistry 22, 249-
258. 
112. Ren, J., Wang, Y., Liang, Y., Zhang, Y., Bao, S. & Xu, Z. (2010). 
Methylation of Ribosomal Protein S10 by Protein-arginine Methyltransferase 
5 Regulates Ribosome Biogenesis. Journal of Biological Chemistry 285, 
12695-12705. 
113. Dez, C. & Tollervey, D. (2004). Ribosome Synthesis Meets the Cell Cycle. 




114. Di, R., Blechl, A., Dill-Macky, R., Tortora, A. & Tumer, N. E. (2010). 
Expression of a Truncated Form of Yeast Ribosomal Protein L3 in Transgenic 
Wheat Improves Resistance to Fusarium Head Blight. Plant Science 178, 374-
380. 
115. Kamita, M., Kimura, Y., Ino, Y., Kamp, R. M., Polevoda, B., Sherman, F. & 
Hirano, H. (2011). Nα-Acetylation of Yeast Ribosomal Proteins and its Effect 
on Protein Synthesis. Journal of Proteomics 74, 431-441. 
116. Bommer, U.-A. & Stahl, J. (2001). Ribosomal Proteins in Eukaryotes. In eLS. 
John Wiley & Sons, Ltd. 
117. Consortium, T. U. (2012). Reorganizing the protein space at the Universal 
Protein Resource (UniProt). Nucleic acids research 40, D71-D75. 
118. Rigbolt, K. T. G., Prokhorova, T. A., Akimov, V., Henningsen, J., Johansen, 
P. T., Kratchmarova, I., Kassem, M., Mann, M., Olsen, J. V. & Blagoev, B. 
(2011). System-Wide Temporal Characterization of the Proteome and 
Phosphoproteome of Human Embryonic Stem Cell Differentiation. Sci. 
Signal. 4, rs3-. 
119. Hornbeck, P. V., Chabra, I., Kornhauser, J. M., Skrzypek, E. & Zhang, B. 
(2004). PhosphoSite: A Bioinformatics Resource Dedicated to Physiological 
Protein Phosphorylation. Proteomics 4, 1551-1561. 
120. Moritz, A., Li, Y., Guo, A., Villen, J., Wang, Y., MacNeill, J., Kornhauser, J., 
Sprott, K., Zhou, J., Possemato, A., Ren, J. M., Hornbeck, P., Cantley, L. C., 
Gygi, S. P., Rush, J. & Comb, M. J. (2010). Akt-RSK-S6 Kinase Signaling 
Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci. Signal. 3, 
ra64-. 
121. Liu, H., Sadygov, R. G. & Yates, J. R. (2004). A Model for Random Sampling 
and Estimation of Relative Protein Abundance in Shotgun Proteomics. 
Analytical Chemistry 76, 4193-4201. 
122. Sadoul, K., Boyault, C., Pabion, M. & Khochbin, S. (2008). Regulation of 
Protein Turnover by Acetyltransferases and Deacetylases. Biochimie 90, 306-
312. 
123. Caron, C., Boyault, C. & Khochbin, S. (2005). Regulatory Cross-Talk 
Between Lysine Acetylation and Ubiquitination: Role in the Control of 
Protein Stability. BioEssays 27, 408-415. 
124. Yang, X.-J. & Seto, E. (2008). Lysine Acetylation: Codified Crosstalk with 
Other Posttranslational Modifications. Molecular Cell 31, 449-461. 
125. Kreunin, P., Yoo, C., Urquidi, V., Lubman, D. M. & Goodison, S. (2007). 
Differential Expression of Ribosomal Proteins in a Human Metastasis Model 
Identified by Coupling 2-D Liquid Chromatography and Mass Spectrometry. 
Cancer Genomics - Proteomics 4, 329-339. 
126. Suh, M.-J. (2004). Investigation of methods suitable for the matrix-assisted 
laser desorption/ionization mass spectrometric analysis of proteins from 
ribonucleoprotein complexes. European mass spectrometry 10, 89-99. 
127. Lee, W.-K., Lee, S.-Y., Na, J.-H., Jang, S., Park, C. R., Kim, S.-Y., Lee, S.-
H., Han, K.-H. & Yu, Y. G. (2012). Mitoxantrone Enhances the Interaction 




Unstructured Protein, and Modulate its Interaction with Protein Kinase CK2. 
Bulletin of the Korean Chemical Society 33, 2005-2011. 
128. Chen, H.-K., Pai, C.-Y., Huang, J.-Y. & Yeh, N.-H. (1999). Human Nopp140, 
Which Interacts with RNA Polymerase I: Implications for rRNA Gene 
Transcription and Nucleolar Structural Organization. Molecular and cellular 
biology 19, 8536-8546. 
129. Deisenroth, C. & Zhang, Y. (2010). Ribosome Biogenesis Surveillance: 
Probing the Ribosomal Protein-Mdm2-p53 Pathway. Oncogene 29, 4253-
4260. 
130. Challagundla, K. B., Sun, X.-X., Zhang, X., DeVine, T., Zhang, Q., Sears, R. 
C. & Dai, M.-S. (2011). Ribosomal Protein L11 Recruits miR-24/miRISC To 
Repress c-Myc Expression in Response to Ribosomal Stress. Molecular and 
cellular biology 31, 4007-4021. 
131. Oh, W. J., Wu, C. c., Kim, S. J., Facchinetti, V., Julien, L. A., Finlan, M., 
Roux, P. P., Su, B. & Jacinto, E. (2010). mTORC2 Can Associate with 
Ribosomes to Promote Cotranslational Phosphorylation and Stability of 
Nascent Akt Polypeptide. EMBO J 29, 3939-3951. 
132. Zinzalla, V., Stracka, D., Oppliger, W. & Hall, Michael N. (2011). Activation 
of mTORC2 by Association with the Ribosome. Cell 144, 757-768. 
133. Mayer, C. & Grummt, I. (2006). Ribosome biogenesis and cell growth: mTOR 
coordinates transcription by all three classes of nuclear RNA polymerases. 
Oncogene 25, 6384-6391. 
134. Montanaro, L., Treré, D. & Derenzini, M. (2012). Changes in Ribosome 
Biogenesis May Induce Cancer by Down-Regulating the Cell Tumor 
Suppressor Potential. Biochimica et Biophysica Acta (BBA) - Reviews on 
Cancer 1825, 101-110. 
135. Muranen, T., Selfors, Laura M., Worster, Devin T., Iwanicki, Marcin P., 
Song, L., Morales, Fabiana C., Gao, S., Mills, Gordon B. & Brugge, Joan S. 
(2012). Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-
Attached Cancer Cells. Cancer Cell 21, 227-239. 
136. Kim, T.-S., Kim, H. D. & Kim, J. (2009). PKCδ-dependent functional switch 
of rpS3 between translation and DNA repair. Biochimica et Biophysica Acta 
(BBA) - Molecular Cell Research 1793, 395-405. 
137. Kim, T.-S., Kim, H. D., Shin, H.-S. & Kim, J. (2009). Phosphorylation Status 
of Nuclear Ribosomal Protein S3 Is Reciprocally Regulated by Protein Kinase 
Cδ and Protein Phosphatase 2A. Journal of Biological Chemistry 284, 21201-
21208. 
138. Kim, H. D., Lee, J. Y. & Kim, J. (2005). Erk Phosphorylates Threonine 42 
Residue of Ribosomal Protein S3. Biochemical and Biophysical Research 
Communications 333, 110-115. 
139. Gao, X. & Hardwidge, P. R. (2011). Ribosomal Protein S3: A Multifunctional 
Target of Attaching/Effacing Bacterial Pathogens. Fronteirs in Microbiology 
2011, 1-6. 
140. Schäfer, T., Maco, B., Petfalski, E., Tollervey, D., Böttcher, B., Aebi, U. & 
Hurt, E. (2006). Hrr25-Dependent Phosphorylation State Regulates 




141. Yoon, I.-S., Chung, J. H., Hahm, S.-H., Park, M. J., Lee, Y. R., Ko, S. I., 
Kang, L.-W., Kim, T.-S., Kim, J. & Han, Y. S. (2011). Ribosomal Protein S3 
is Phosphorylated by Cdk1/cdc2 During G2/M Phase. BMB Reports 44, 529-
534. 
142. Rabl, J., Leibundgut, M., Ataide, S. F., Haag, A. & Ban, N. (2011). Crystal 
Structure of the Eukaryotic 40S Ribosomal Subunit in Complex with Initiation 
Factor 1. Science 331, 730-736. 
143. Sengupta, J., Nilsson, J., Gursky, R., Spahn, C. M. T., Nissen, P. & Frank, J. 
(2004). Identification of the Versatile Scaffold Protein RACK1 on the 
Eukaryotic Ribosome by Cryo-EM. Nat Struct Mol Biol 11, 957-962. 
144. Schrodinger, LLC. (2010). The PyMOL Molecular Graphics System, Version 
1.3r1. 
145. Pang, C., Gasteiger, E. & Wilkins, M. (2010). Identification of Arginine- and 
Lysine-Methylation in the Proteome of Saccharomyces cerevisiae and Its 
Functional Implications. BMC Genomics 11, 92. 
146. Ben-Shem, A., Jenner, L., Yusupova, G. & Yusupov, M. (2010). Crystal 
Structure of the Eukaryotic Ribosome. Science 330, 1203-1209. 
147. Ben-Shem, A., Garreau de Loubresse, N., Melnikov, S., Jenner, L., Yusupova, 
G. & Yusupov, M. (2011). The Structure of the Eukaryotic Ribosome at 3.0 Å 
Resolution. Science 334, 1524-1529. 
148. Pech, M., Spreter, T., Beckmann, R. & Beatrix, B. (2010). Dual Binding 
Mode of the Nascent Polypeptide-associated Complex Reveals a Novel 
Universal Adapter Site on the Ribosome. Journal of Biological Chemistry 
285, 19679-19687. 
149. Alamo, M. d., Hogan, D. J., Pechmann, S., Albanese, V., Brown, P. O. & 
Frydman, J. (2011). Defining the Specificity of Cotranslationally Acting 
Chaperones by Systematic Analysis of mRNAs Associated with Ribosome-
Nascent Chain Complexes. PLoS Biol 9, e1001100. 
150. Arnesen, T. (2011). Towards a Functional Understanding of Protein N-
Terminal Acetylation. PLoS Biol 9, e1001074. 
151. Holcik, M. & Sonenberg, N. (2005). Translational Control in Stress and 
Apoptosis. Nat Rev Mol Cell Biol 6, 318-327. 
 
 
